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ABSTRACT

PART I. THE DEVELOPMENT OF NON-SECOSTEROIDAL VITAMIN D RECEPTOR
MODULATORS
by
Kelly A. Teske
The University of Wisconsin-Milwaukee, 2015
Under the Supervision of Professor Alexander (Leggy) Arnold
The vitamin D receptor is a nuclear hormone receptor that regulates cell proliferation, cell
differentiation, calcium homeostasis and immunomodulation. The receptor is activated by the
vitamin D metabolite, 1,25-dihydroxyvitamin D3, which induces a cascade of events including the
recruitment of coactivators that activate transcription of specific VDR target genes. Thousands
of VDR agonists have been synthesized based on the secosteroid scaffold of 1,25dihydroxyvitamin D3. However, most of these ligands are metabolically unstable, have suboptimal drug-like properties, and induce hypercalcemia in vivo. The limited numbers of VDR
antagonists reported bear the same secosteroid scaffold and thus exhibit similar problems
encountered by VDR agonists. VDR has been implicated with many diseases including cancer,
allergies, sarcoidosis and autoimmune diseases like Crohn’s disease. Therefore, the synthesis
and biochemical evaluation of novel, non-secosteroidal modulators for VDR were developed and
reported herein.
First, VDR inhibitors were rationally designed to directly target the interactions between
VDR and coactivator SRC2. A fluorescence polarization-based assay evaluated the binding of
these molecules. Next, a high throughput screening campaign with the NIH chemical and
genomics center (NCGC) identified GW0742 as a novel VDR anatagonist. Originally developed by
ii

GlaxoSmithKline as a selective PPARδ agonist, GW0742 was used as a scaffold for the synthesis
of VDR inhibitors with decoupled activity towards PPARδ. Biochemical, cell-based, solubility and
permeability assays determined drug-like properties of over 100 GW0742 analogs. Finally,
secondary bile acids, which are known to bind VDR and modulate transcription without inducing
hypercalcemia, lead to a study of phase 1 and phase 2 metabolites of lithocholic acid. In addition
to biochemical and cell-based assays, a semi-quantitative real time polymerase chain reaction
was used to confirm the ability of lithocholic acid derivatives to induce the transcription of VDR
target genes.
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ABSTRACT

PART II. THE DEVELOPMENT OF A UNIVERSAL GTPase ASSAY
by
Kelly A. Teske
The University of Wisconsin-Milwaukee, 2015
Under the Supervision of Professor Alexander (Leggy) Arnold
GTPases act as a molecular switches in which their “on” and “off” functions are triggered
by the binding and hydrolysis of GTP. Due to their relationship to many diseases, numerous
GTPase targeting drugs have been developed. One third of all drugs targeting proteins are either
interacting with kinases (22% of drugs) or GTPases (15% of drugs). The growing interest in GTPase
targeting drugs has promoted the development of assays that can efficiently test these
compounds in a high throughput and inexpensive way. AviMed Pharmaceuticals, LLC, a local
company founded by Dr. Daniel Sem, pursued the development of a universal kinase/GTPase
assay kit that would be affordable and commercially available for industry and research labs to
test potential drug candidates. The assay designed was based on previous research conducted
by the founder and relies on a beta thiol substituted ATP (GTP for GTPases) that would be
enzymatically hydrolyzed to produce ADP (GDP). The exposure of the thiol makes it nucleophilic
and reactive towards thiol-sensitive fluorescent or calorimetric reagents such as Thiofluor 623.
Herein, we report the synthesis of the assay reagents and the preliminary development of a
universal, inexpensive, sensitive GTPase assay kit that directly detects the GTPβ-S hydrolysis
product, GDPβ-Se.
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PART I. THE DEVELOPMENT OF NON-SECOSTEROIDAL VITAMIN D
RECEPTOR MODULATORS

1

CHAPTER 1: INTRODUCTION
1.1 The History of Vitamin D
Prior to the twentieth century, vitamins and pre-vitamins were largely unknown although
evidence existed that certain foods can prevent diseases such as Scurvy and Beri-Beri.12 In 1910,
Drs. Hopkins and Funk separately demonstrated that diets of purified carbohydrates, proteins,
fats and salts were unable to support growth in animals thus concluding that “vital amines” or
vitamins were present in natural foods and therefore providing sustenance for life.13, 14 In 1914,
McCollum et al. isolated a fat-soluble, non-saponifiable factor from butter fat that was necessary
for normal growth and prevention of the eye disease xerophthalmia in young rats. This substance
became known as “fat soluble factor A” or vitamin A.15 This quickly led to McCollum’s discovery
of the

water soluble vitamin, vitamin B, that deemed necessary for the prevention of

polyneuritis.16 During this time, the skeletal disease rickets was becoming an epidemic in
England. This was mainly brought on by the sudden urbanization of rural areas during the
“Industrial Revolution” that caused a large production of pollutants in the atmosphere blocking
the sun. Thinking the disease was caused by a deficiency in vitamin A, people were given cod
liver oil, a substance known to contain vitamin A, for the treatment of rickets. Although this
treatment worked, McCollum questioned whether vitamin A was responsible. In 1922, he
conducted a pivotal experiment where he heated and bubbled oxygen through cod liver oil to
destroy the vitamin A activity and found that this preparation was incapable of treating vitamin
A deficiencies (i.e. xerophthalmia) but still retained its ability to cure rickets. This surprising result
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prompted McCollum to conclude that the factor that cures rickets was a new vitamin which they
named vitamin D.17, 18
Around the same time, the German scientist, Huldschinsky, made the important
observation that the health of rachitic children as well as their calcium deposition improved by
being exposed to sunlight or artificial ultraviolet (UV) light.19 This was later confirmed by
Harriette Chick in 1922 while working with severely malnourished children in Vienna. She found
that therapeutic exposure to sunlight provided results that were indistinguishable from those
patients receiving cod liver oil.20 This treatment triggered investigations into the active form of
vitamin D.
Many scientist contributed to the long history of the isolation and identification of vitamin
D analogs in the 1920’s and 1930’s including early vitamin D pioneers H. Steenbock (Wisconsin),
A. F. Hess (New York), O. Rosenheim (London) and A. Windaus (Germany).21 Steenbock found
that by irradiating food with UV light, specifically the non-saponifiable lipid fraction, the vitamin
D content increased and promoted growth and bone-calcifying properties in rachitic rats.22 He
concluded that an inactive lipid in the diet and skin could be converted by UV light into an active
antirachitic substance.23 This led to tremendous advances in public health by adding vitamin D
to milk and other foods to prevent disease. Hess et al. isolated sitosterol from cottonseed oil and
found that upon irradiation this inactive non-saponifiable sterol was then active against rickets.
He also observed this phenomenon with “pure” cholesterol isolated from rat brains thus allowing
him to hypothesize that the cholesterol in skin can be converted by UV-irradiation and rendered
an active form of vitamin D.24 However, the sample of cholesterol used by Hess was found to be
impure, which led him to collaborate with the chemists Windaus and Rosenheim to purify the
3

sample. Because physical methods such as recrystallization and saponification had proven
incapable of purifying the cholesterol mixtures to begin with, they converted cholesterol into its
dibromide form, recrystallized it and recovered cholesterol upon treatment with sodium
amalgam. The purified cholesterol, after irradiation, no longer possessed antirachitic properties
making it evident that the impurity was the pro-vitamin they were looking for.
Askew et al. were the first to successfully isolate and determine the structure of vitamin
D or ergocalciferol, better known as Vitamin D2, from ergosterol (a fungal steroid from ergot).25
Windaus and Hess also found that the most highly active antirachitic compound upon irradiation
was ergosterol.26 Furthermore it was determined that ergosterol (Figure 1, A) was a provitamin

Figure 1.
Structure of A) ergosterol, B) 7dehydrocholesterol, C) ergocalciferol or Vitamin D2, and
D) cholecalciferol or Vitamin D3.

with its irradiation product being ergocalciferol or vitamin D2 (Figure 1, C) in plants.27 In 1936,
Windaus et al. isolated 7-dehydrocholesterol (Figure 1, B) from hog skin that provided evidence
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that it was the provitamin found in humans for the production of vitamin D3 cholecalciferol
(Figure 1, D).28, 29
In the 1950’s, Egan Kodicek investigated the metabolism of vitamin D2. He used

14C-

labeled vitamin D2 to monitor its activity and metabolism in the body. However, the degree of
labeling was not sufficient to allow the administration of physiological doses of vitamin D2, which

Figure 2. The active Vitamin D metabolites, 25(OH)D3
and 1,25(OH)2D3, determine by Deluca et al. at the
University of Wisconsin.

increased the storage of the vitamin D rather than its metabolism. After a decade he concluded
that vitamin D2 was the active biological compound and that no metabolic change was
required.30, 31 However, we know today that hydroxylation is essential to activate vitamin D,
which was discovered in Wisconsin led by DeLuca et al. in 1967 using radiolabeled Vitamin D3.
Upon administration, detection of metabolites were seen within 1-2 hours and when isolated
and given to vitamin D-deficient animals proved to be more potent and faster acting than vitamin
D3 in supporting calcium transport. This led to the isolation and identification of the active
metabolite, 25-hydroxyvitamin D3 (25(OH)D3), in 1968 (Figure 2).32,

33

However, when

radiolabeled 25(OH)D3 was administered further metabolism occurred. Holick and DeLuca
identified these metabolites by feeding 1,600 Vitamin D-deficient chickens radiolabeled Vitamin
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D3 and isolating Vitamin D metabolites from the intestines. Analysis conducted by mass
spectrometry and derivatization lead finally to the identification of the most active hormonal
form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) (Figure 2).34, 35

1.2 A Brief Overview of the Activating Enzymes of Vitamin D3
Vitamin D3 can either be absorbed from various food sources in the intestine or
synthesized in the skin by a two-step reaction starting with 7-dehydrocholesterol undergoing a
UV-induced, electrocyclic ring opening reaction to make pre-vitamin D3 followed by an
antarafacial sigmatropic [1,7] hydride shift induced by thermal isomerization to make vitamin D3
(Figure 3). Once formed, vitamin D3 and its analogs bind specifically to the vitamin D binding
protein (DBP), which transports these molecules in the blood to cells and organs such as the liver
and kidney.36, 37 DeLuca found that the liver is the primary site of the first enzymatic activation of
vitamin D3 where hydroxylation of the C-25 position to 25(OH)D3 occurs.38 The mitochondrial
enzyme responsible for this process is 25-hydroxylase, a cytochrome P450 mixed-function
oxidase that in humans is encoded by the CYP2R1 gene.39 25(OH)D3 binds tightly to DBP and
enables it transport to the kidneys. Within the kidneys, specifically the renal tubules, 25(OH)D3
is hydroxylated at C-1 by 1α-hydroxylase, a different cytochrome P450 enzyme encoded by the
CYP27B1 gene.40

This enzymatic reaction forms the final hormonal form of vitamin D3,
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1,25(OH)2D3, which is the most potent ligand of the vitamin D receptor (VDR) and is responsible
for the physiological actions of vitamin D throughout the body.

Diet

Figure 3. The activation of vitamin D3 obtained either from the diet or the photocatalyzed reaction of 7-dehydrocholesterol. CYP enzymes catalyze reactions in the liver
and kidneys make the potent VDR hormone, 1,25(OH)2D3, which get distributed to
different target tissues in the body.

1.3 The Vitamin D Receptor: Structure and Function
In 1969, Haussler and Norman first identified VDR in chicken intestinal chromatin extracts
that demonstrated a preferential uptake of 1,25(OH)2D3 through a protein mediated process.
They also showed that this process was saturable at low concentrations.41 Work done by
Brumbaugh and Haussler in 1975 provided substantial evidence that the protein must function
as a nuclear receptor when observing that cytosol-derived VDR could bind to chromatin fractions
in a hormone-sensitive manner.42, 43 VDR was cloned in the late 1980’s and eventually crystallized
at the turn of the century, which gave much insight into the structure and function of this
hormone activated protein.8, 44
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Today we know that VDR is a transcription factor that belongs to a superfamily of nuclear
receptors (NRs). As a transcription factor, VDR functions within the nucleus where it regulates
gene expression through hormone-activation of the receptor. So far 48 identified proteins
belong to this superfamily. They share similarities in structural and functional features in spite of
the wide variation in their ligands.45 All NRs are modular proteins that typically contain six
domains (A-F) based on regions of similar sequence and function (Figure 4). The nonconserved
N-terminal A/B domain that mediates activation by other molecules is followed by the DNA
A/B
H3

+N

C
DNA

D

E
Ligand
Dimerization

AF-1

F
COOAF-2

Figure 4. The functional domains of typical NRs, which consist of a variable N-terminal
region (A/B), a conserved DNA binding domain (C), a variable hinge region (D), a conserved
LBD (E), and a variable C-terminal region (F). VDR does not contain an F domain.

binding domain (DBD, domain C). The D domain or hinge region is a highly flexible region that
links the NR’s DBD to its ligand binding domain (LBD, domain E) making receptor dimerization
possible. The highly conserved LBD region mediates the interaction with ligands and other
proteins, such as co-repressors and co-activators that are important to fine-tune the
transcriptional activity of VDR. Finally, the F domain is extensively variable among NRs and
absent in VDR.46, 47
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The centrally located VDR DBD consists of a 66 residue core in humans and is made up of two
modules each containing zinc-coordinated structures. The zinc atoms are individually
coordinated in a tetrahedral fashion through four cysteine residues that serve to stabilize the
zinc-finger structure (Figure 5).48, 49 Although the two zinc modules appear structurally similar,
they are not related topologically due to the difference in chirality of the residues that coordinate
the zinc in each module. Thus, each module possesses their own unique function. The aminoterminal module directs specific DNA binding in the major grove of the DNA binding site, while

Figure 5. Crystal structure VDR DBD with Zn2+
coordinated with four cysteine residues. (PDB:
1YNW)1-4

the carboxy-terminal module serves as a dimerization interface for interaction with other
proteins.3, 50 An extra string of residues known as the adjacent C-terminal extension (CTE) of the
DBD provides additional dimerization specificity for VDR (Figure 6, B). Although VDR can
occasionally partner with itself, it commonly heterodimerizes with any of the three isoforms of
the 9-cis retinoic acid receptor (RXR). The VDR-RXR complex binds DNA and activates
transcription by recognizing vitamin D-responsive elements (VDREs) on specific VDR target genes.

9

Response elements typically consist of two hexameric half-sites with a spacer of neutral base
pairs (Figure 6, A). Diversity and specificity of binding is dictated largely by variations of the half-

A

B

Figure 6. Cryo electron microscopy (cryo-EM) structure of the heterodimeric complex
of the human RXR and VDR activated by 1,25(OH2)D3 and bound to a consensus DNA
response element forming a direct repeat (DR3). This was done by fitting known
crystal structures of LBDs and DNA bound DBDs with cryo EM maps of the nuclear
receptor complex. No crystal structure of RXR-VDR-DR3 DNA has been reported yet.
A) Side view with 5’ DNA end on the left. The fitted LBD and DBD/DNA heterodimer
parts are shown in their backbone secondary structure. The DNA is shown in blue
with the first half-site of the response element green and the second half-site in red.
B) Top view of complex as seen along the pseudo two-fold axis through the interface
of the RXR and VDR LBDs (indicated by black star). The CTE helix of VDR is protruding
from the DBD and cross the DNA minor groove indicated by the arrow.

sites relative to one another and the number of neutral base pairs separating the half-element
repeats.51, 52 For example, half-sites can be arranged as inverted, everted or direct repeats (DR),
where VDR-RXR requires a direct repeat of typically 5’-AGGTCA-3’ with a three base pair spacer
(DR3) for DNA binding to occur. In addition, VDR occupies the downstream 3’ half-site and the
RXR occupies the upstream 5’ half-site, which influences the target gene selectivity and
ultimately the rate of RNA polymerase II (RNA Pol II) directed transcription.53
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The E domain or LBD, is a multifunctional region that has complete regulatory control over
DNA-binding and transcription-modifying properties of VDR.54 Within the LBD is a highly
structured region known as the ligand-dependent activation function or AF-2 that acts as the
major interface for dimerization with RXR (Figure 6, B), as well as, the interface for co-activators
and co-repressors. AF-2 is only functional through the binding of VDR ligands (Figure 7). The
general fold of NR’s LBD involve a three-layered α-helical sandwich containing twelve α-helices
designated as H1–H12 and three β-sheets.

Upon binding of 1,25(OH)2D3, helix H11 is

repositioned in line with H10 to allow helix H12 to clamp down and seal the binding pocket. Helix
H12, also referred to as the activating domain (AD) of the AF-2 function, stabilizes ligand binding
by contributing to the hydrophobic environment and making, in some cases, additional contacts
with the ligand. When folded back onto the LBD, Helix H12 forms a hydrophobic cleft with
charged surface-exposed residues on each end. The positively charged K246 (H3) and negatively
charged E420 (H12) form the “charged clamp” that accommodate the recruitment of
coregulators (Figure 7, A).55
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A)

AF-2 surface

B)

Water channel

Figure 7. A) Side view of three layered sandwich fold of hVDR LBD in complex with
1,25(OH)2D3 (ribbon model with colors indicating position: front is blue green, middle as
yellow and rear as green). The AF-2 surface, where coactivators bind, is shown in
transparent yellow oval with charge residues, K246 and E420, as red balls. B) Major
interactions of ligand, 1,25(OH2)D3 with the LBD pocket residues. Yellow residues indicate
hydrophobic interactions while the red dotted lines indicate hydrogen bonds.

The crystal structure of 1,25(OH)2D3 with hVDR reveals a ligand-binding pocket that is wider
at H11 site than many other NRs with 1,25(OH)2D3 occupying 56% of the pocket volume.8 Upon
binding, the ligand obtains an extended configuration with the A ring in the β chair conformation
with the 1α-OH in the equatorial position. The side chain is in proximity of H11, while the A ring
extends into the β-turn region. 1,25(OH)2D3 is anchored in the pocket by six hydrogen bond
interactions: the 1α-OH bonds with Ser237 (H3) and Arg274 (H5), the 3β-OH hydrogen bonds
with Tyr143 (loopH1-H2) and Ser278 (H5) and the 25-OH group forms two hydrogen bonds with
His305 (loop H6-H7) and His 397 (H11) when using the hVDR numbering (Figure 7, B).55, 56
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1.4 General Transcription Factors and Coregulators of VDR-mediated
Gene Expression
VDR-mediated transcription is regulated by a series of temporary macromolecular
interactions, which includes both general transcription factors (GTFs) and coregulatory
proteins.57 Coregulators interact directly with the VDR-RXR heterodimer LBDs and can affect
transcription in either a positive or negative fashion. These positive and negative modulators are
known as coactivators and corepressors, respectively. VDR-coactivator interactions are mediated
by 1,25(OH)2D3 binding to VDR-LBD and corepessor binding occurs typically in the absence of
ligand.
The classic and most simplified model of the ligand induced switch between transcription
“off” and transcription “on” using coregulators begins with unliganded VDR loosely associated
with RXR and nonspecifically bound to DNA. At this point, VDR and RXR are in a favorable
conformation for binding corepessors because helix 12 of the AF2 domain is left in an “open”,
inactive position.58 The best characterized corepressors for VDR are the nuclear receptor
corepressor (NCoR1) and the universally expressed silencing mediator for retinoic acid and
thyroid hormone receptors (SMRT or NCoR2). Both possess a LXXH/IIXXXI/L motif (where x is any
amino acid, L is leucine and I is isoleucine) that interacts with the hydrophobic groove of the
heterodimer (Figure 8).59 NCoR and SMRT both associate with enzymes known as histone
deacetylases or HDACs.60 HDACs interfere with gene transcription by removing acetyl groups
from chromatin and allowing for tight compaction of negatively charge DNA with positively
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Figure 8. Amino acid sequence of corepressors NCoR-2 and SMRT-2 and SRC
family of coactivators and DRIP coactivators with each specific NR box motif
indicated. The LXXLL NR box motif is labeled red and the LXXH/IIXXXI/L is labeled
green for coactivators and corepressors, respectively.9

charged histones. In addition to HDACs and corepressors, the inactive VDR complex may also
associate with an activating GTF known as transcription factor IIB (TFIIB) (Figure 9).61 The true
mechanism of TFIIB is not well understood but it might associate with unliganded DNA-bound
VDR and help sequester TFIIB into the vicinity of specific vitamin D-responsive promoter areas.
Once 1,25(OH)2D3 binds to VDR, TFIIB might assemble with preinitiation complex (PIC) to help
facilitate VDR-mediated transcription.62

Figure 9. A generalized cartoon of unliganded VDR-RXR loosely associated
heterodimer including its proposed interactions with corepressor (NCoR or SMRT),
TFIIB and HDACs. The corepressor is bound to VDR when the AF2 domain is in the
open configuration and attracts HDACs to repress chromatin.3, 5
14

The transcriptional machinery required for the VDR-mediated transcription is a very
complex and includes sequential recruitment of many different VDR interacting proteins. This
process is summarized in Figure 10. In the first step, transcription is switched “on” with the
binding of 1,25(OH2)D3 to VDR. During these first activation steps RXR and VDR associate with a
higher affinity, specific VDREs are recognized and the AF2 domains in both VDR-LBD and RXR-LBD
are repositioned (Figure 10, A).3 This conformational change promotes favorable coactivator
binding and the dissociation of corepressor/HDAC complex. Several different coactivators can
be recruited including the p160/steroid receptor coactivator (SRC) family, which consist of SRC-1
(also known as NCoA1), SRC-2 (also known as NCoA2, GRIP-1, and TIF2) and SRC-3 (also known
as NCoA3, p/CIP, RAC3, ACTR, AIB-1, and TRAM-1), and the large vitamin D receptor interacting
protein complex (DRIP or Mediator D complex).63 Important for VDR binding are multiple highly
conserved LXXLL-containing NR boxes where L is leucine and X is any amino acid (Figure 10).64
The coactivator NR box forms an amphipathic α-helix that interacts with VDR’s AF2 domain. The
preference of certain NR boxes for particular NRs have been reported. For example in the case
of SRC-3, VDR has preferential interaction with NR box III.9, 65 SRC coactivators also possess
histone acetyl transferase activity (HAT), that may include the secondary recruitment of CREBbinding protein (CBP)/p300 cointegrator and p300/CBP-associated factor (p/CAF) (Figure 10, A).66
HAT activity remodels the chromatin by covalently adding acetyl groups onto the carboxylterminal lysine residues of histones. This weakens the electrostatic interaction between the DNA
and histone tail thus priming it for the binding and assembly of PIC, which includes TATA binding
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Figure 10. A generalized cartoon for the VDR-RXR-coactivator complex in VDRactivated transcription. A) 1,25(OH)2D3 binds to VDR and the AF2 domains of the RXRVDR heterodimer seals the LBD pocket. Primary (SRC) and secondary coactivators
(pCAF and CBP/p300) provide HAT activity and prime DNA for transcription. B) SRC
and secondary coactivators dissociate and mediator D-complex DRIP205 binds and
stimulates assembly of PIC components such as TAFs and TFIIB and the recruitment
of RNA Pol II to the repressed chromatin.3-5

accessory factors (TAFs) that target TATA box protein and TFIIB (Figure 10, B).67 Furthermore,
the mediator D complex (DRIP) acts as a bridge between VDR and GTFs that promote the
formation and function of PIC with RNA Pol II.57 It is composed of at least ten different proteins
anchored by DRIP205 that interacts directly with the VDR-RXR heterodimer through their second
of two LXXLL motifs.68 Although DRIP may recruit RNA Pol II to the promotor, the polymerase is
16

not tightly bound thus allowing for its release and efficient initiation of transcription (Figure 10,
B).69

1.5 Vitamin D analogs and Their Pharmacological Effects
VDR is expressed in many different cells and has been affiliated with calcium and
phosphate homeostasis as well as differentiation and proliferation of cells. Novel therapies
based on vitamin D receptor ligands are currently developed to treat skin and metabolic
disorders, gastrointestinal diseases, cardiovascular problems, inflammatory diseases, and
notably cancer.70 The major hurdle for VDR ligand-based treatments is tissue selectivity in order
to exert pharmacological activity in a particular tissue. For instance inducing anti-proliferation in
cancer tissue without increasing the calcium concentration in blood or to increase the bone
mineral density without inducing hypercalciuria. More than 2,000 VDR ligands have been
synthesized and characterized during the last decades but only a very limited number of
compounds have been approved for the treatment of human diseases. This section will describe
the pharmacological effects of two drugs eldecalcitrol (osteoporosis) and EB1089 (cancer) and
their modulation of vitamin D receptor function.

1.5.1 Vitamin D and Osteoporosis (Calcium Homeostasis)
Osteoporosis is the dysfunction of bone resorption and bone formation due to aging.
Bone is the primary location for the resorption of Ca2+ and PO43-; a process that is regulated by
osteoblasts and osteoclasts. Osteoblasts control both the formation and breakdown of bone
necessary for bone remodeling.

Osteoblasts also activate osteoclast differentiation and

formation, which is responsible for the resorption of bone.71 Osteoblasts respond to 1,25(OH)2D3
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via the regulation of the receptor activator of NF-ĸB ligand (RANKL) mediated by VDR and
independently to the parathyroid hormone (PTH) (Figure 11).72, 73
The RANKL gene is regulated by VDR thus eldecalcitrol (aka ED-71) and other vitamin D

Figure 11. Summarized cartoon of the metabolism and biological action of vitamin D via VDR
with particular emphasis to calcium and phosphate balance and bone mineralization.3

ligands regulate osteoclastgenesis by inhibiting the maturation of osteoclast progenitor cells or
reducing the activation of osteoclasts via IL-6.71 However, decelerated osteoclastgenensis can
reduce Ca2+ levels, which in turn is sensed by the parathyroid glands, which to restore Ca 2+
balance, rapidly enhances the secretion of PTH. Elevated PTH levels induce Ca2+ resorption from
the bone independent from VDR and stimulates the expression and activity of renal CYP27B1 that
produces 1,25(OH)2D3. This classic negative feedback loop ends by 1,25(OH)2D3 suppressing PTH
synthesis and renal CYP27B1 activity.74 Therefore, vitamin D ligands developed for osteoporosis
should selectively regulate the VDR target genes RANKL and PTH. Furthermore, VDR ligands can
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activate the transcription of genes encoding osteocalcin and osteopontin, two proteins involved
in bone remodeling by osteoblasts.
Osteoblast differentiation is important for bone
mineralization and is mediated by 1,25(OH)2D3, which
initiated the synthesis of Vitamin D3 analogs by organic
chemist and pharmaceutical companies with aim to separate
the calcemic action of 1,25(OH)2D3 from its ability to regulate
cells growth and differentiation.75 ED-71 was among those
analogs introduced by Chugai Pharmaceuticals for the
treatment of osteoporosis (Figure 12).

Figure 12.
Eldecalcitol, also
known as ED-71, is approved
osteoporosis drug.

Patients with

osteoporosis experience low serum levels of 25(OH)D3, which is common in older or
postmenopausal patients partially due to their low intake of vitamin D, decreased sun exposure,
and impaired renal function. In turn this dysfunction decreases intestinal calcium absorption and
reduces VDR activation. Therefore, a successful osteoporosis drug would need to be given within
a small therapeutic window where calcium levels would increase to maintain bone homeostasis
without causing adverse sides effects such as hypercalciuria, urinary tract stones, and
hypercalcemia. Compared to 1,25(OH)2D3, ED-71 has a higher affinity for serum DBP, binds more
weakly to VDR and shows lower potency in suppression of serum PTH. The plasma half-life of
eldecalcitol is also longer than that of 1,25(OH)2D3 probably due to its higher affinity for DBP.76
Preclinical in vivo studies using ovariectomized rat (ovx-rat) models for osteoporosis showed that
ED-71 suppresses osteoclastic bone resorption and increases bone mass density to a greater
extent than alfacalcidiol, a frequently prescribed anti-osteoporosis drug in many countries
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including Japan.77 Furthermore, there is no significant difference in calcium absorption and
serum PTH suppression between ED-71 and alfacalcidol thus suggesting the effect of increasing
bone mass density by ED-71 to be independent of calcium metabolism. Phase III clinical trials
revealed that patients had a lower incidence of vertebral and wrist fractures while taking ED-71
compared to alfacalcidol. Very few adverse effects were observed at this stage which included
an increase of calcium levels found in serum and urine and a small number of patients (0.4%)
developing hypercalcemia when given ED-71.78, 79 As of 2013, this drug is prescribed in Japan
and is awaiting approval in other countries.

1.5.2 Vitamin D and Cancer (Cell Proliferation)
The inhibition of cancer cell growth in the presence of 1,25-(OH)2D3 was first shown in
1979.80, 81 During the last decades many groups have reported similar antiproliferative effects of
VDR ligands in vitro and in vivo. Human clinical
studies with 1,25(OH)2D3 and analogs are doselimited

because

of

hypercalcemia

and

hypercalciurea, which can cause psychosis, bone
calcification of soft tissue, coronary artery disease,
in severe cases, coma and cardiac arrest.82, 83 These

pain,
Figure 13. EB 1089, a VDR agonist
that exhibits anti-tumor and antiproliferative activity with reduced
hypercalcemic effects.

and,
side

effects prompted the synthesis of thousands of 1,25(OH)2D3 analogs to develop VDR ligands with
lower calcemic activity. Two synthetic VDR ligands EB1089 and ILX23-7553 were tested in clinical
trials.84,

85

Seocalcitol (EB1089, Figure 13) has shown to be 50 times more

potent than

1,25(OH)2D3 in vitro and when given orally it dose dependently inhibits growth of nitrosomethyl
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urea (NMU) induced rat mammary tumors and MCF-7 xenografts without increasing serum
calcium.86 In addition, anti-proliferation, apoptosis, and anti-metastases effects of EB1089 have
shown to be enhanced with co-administration with paclitaxel87, retinoic acid88 or radiation89.
VDR-mediated anti-proliferation is facilitated by its’ ability to modulate the cell cycle (Figure 14).
Proliferating cells progress through the cell cycle, which comprises of the G 0/G1 phase
(differentiation and protein synthesis), the S phase in which new DNA is synthesized, and the G2
phase that is followed by mitosis or M phase upon which cells can reenter G0/G1 phase. Breast
cancer cells treated with VDR ligands have been observed to undergo cell cycle arrest in the G0/G1
phase within 48 hours.90 This arrest is associated with upregulation of genes that code for the
cyclin-dependent kinase inhibitors CDKN1A (p21) and CDKN1B (p27) and act as control switches
for the cell cycle. Depending on the cell type, G1 arrest is due to inhibition of cyclic-dependent
kinase (CDK) activity including CDK2-associated histone H1 kinase, cyclin D1/CDK4, and cyclin
A/CDK2.91, 92 In other situations, VDR interacts with protein phosphatases PP1c and PP1Ac to
inactivate the p70 S6 kinase which is essential for G1/S phase transition.93
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Thus, vitamin D

analogs have the potential to inhibit breast cancer cell growth by preventing their entry into the
S phase thus leading to accumulation of these cells in the G1 phase.

Figure 14. The cell cycle: Gap 0 (G0) where cells can leave the cycle
and quit dividing, Gap1 (G1) is where the cell increases in size and
produce RNA, synthesis (S) phase is where DNA replication occurs, in
Gap 2 (G2) the cell continues to grow and produce protein. The cell
growth and production stops at the mitosis (M) phase where the cell
divides into two similar daughter cells.

In addition to anti-proliferative effects, 1,25(OH)2D3 and other vitamin D analogs induce
cell shrinkage, chromatin condensation, and DNA fragmentation characteristic for apoptosis.
Studies have shown that 1,25(OH)2D3 mediated apoptosis affects the relative expression and/or
subcellular localization of the Bcl-2 family and other pro-apoptotic proteins. When MCF-7 cells
are treated with 1,25(OH)2D3 or VDR agonist, EB1089, a redistribution of Bax, a member of the
pro-apoptotic Bcl-2 family, from the cytosol to the mitochondria occurred and induced downregulation of Bcl-2.94, 95 Bax translocation triggers reactive oxygen species (ROS) generation,
dissipation of the mitochondrial membrane potential, and release of cytochrome C into the
cytosol, which are features of mitochondrial apoptosis.96
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Metastasis is the process by which tumor cells invade secondary sites which requires
degradation of the extracellular matrix and is facilitated by angiogenesis or the growth of new
blood vessels connecting the developing tumor. When ER-negative breast cancer cells (i.e.
SUM159PT), which are invasive in vitro and metastatic in vivo, are treated with 1,25(OH)2D3 or
vitamin D analogs invasion of cancer cells is inhibited.97 This effect may be linked to regulation
of extracellular protease such as MMP-9, urokinase-type plasminogen activator (uPA), and tissue
type plasminogen activator (tPA).98

Furthermore, 1,25(OH)2D3-mediated inhibition of

angiogenesis has been observed in the chick embryo chorioallantoic membrane assay and in
tumor-cell induced angiogenesis assays in mice.99

1.6 Inhibition of the VDR-Coactivator Interactions
Many VDR ligands, commonly VDR agonists, have been developed to treat vitamin D
related diseases. Only a limited number of VDR antagonists have been described with the ability
to either directly or allosterically inhibit the interaction between VDR and its coactivators. 100-102
The following VDR ligands will be discussed in this section: direct VDR antagonists (allosteric VDRcoactivator inhibitors) and direct VDR-coactivator inhibitors.
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1.6.2 Direct VDR Antagonists or Allosteric VDR-Coactivator Inhibitors
The synthesis of new synthetic analogs of 1,25(OH)2D3 resulted in the identification of
new VDR ligands that bind VDR but only weakly promote VDR–coactivator interactions. Usually,
the biological effects of these antagonists have been determined in the presence of agonists like
1,25(OH)2D3 giving results similar to the vehicle control. Interestingly, the degree of coactivator
recruitment by VDR depends on the chemical structure of the VDR antagonist. Thus, the quality
of a VDR antagonist can be defined by its
residual agonistic activity. On the molecular
level, this behavior is believed to be caused
by the orientation of helix 12 (Figure 15).
Depending

on

the

structure,

VDR

antagonists may influence the equilibrium of
VDR bound to coactivators, corepressors, or
neither. Crystal structures of all three
possible complexes have been reported for

Figure 15. Possible equilibrium structure of VDR in
the presence of antagonist.

nuclear receptors. However, VDR prefers to
crystallize solely with an agonistic arrangement.
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One example is ZK159222 that exhibited a sub-nanomolar affinity for the VDR in the presence of
1,25(OH)2D3 and inhibited VDR-mediated transcription with an IC50 value of 300 nM (Figure
16).103, 104 SDS-page demonstrated three different conformations of ZK159222 liganded VDR.105
These conformations may be responsible for the dissociation
between liganded VDR and coactivators SRC1, SRC2, SRC3, and
DRIP205.106, 107 The interaction between corepressor NCoR and

VDR

was inhibited as well.103 ZK159222 also inhibited the interaction
between VDR and corepressor SMRT as demonstrated with a
down assay.108 In human fetal osteoblastic cells, ZK159222

pullFigure 16. Structure
of ZK159222.

inhibited the expression of osteocalcin, alkaline phosphatase
activity, and calcium contents, in the presence of 1,25(OH)2D3.109 In osteoblastic ST2 cells,
ZK159222 blocked the activation of mRLD5 region of mRANKL in the presence of 1,25(OH)2D3.110
The calcemic activity of ZK159222 was 0.02% of that of 1,25(OH)2D3 in mice after 5 days of 10
µg/kg/d.111
In respect to anti-proliferation, ZK159222 also inhibited the differentiation of HL60 cells
in the presence of 1,25(OH)2D3 at a concentration of 6 nM.112 The process involves the upregulation of kinase suppressor of ras 2 gene (KRS-2), which was demonstrated to be inhibited
by ZK159222.113 In addition, ZK159222 inhibited the phosphorylation of Raf-1114, 115 and the
expression of pRb and c/EBPβ, two very important cancer genes, in the presence of
1,25(OH)2D3.116 ZK159222 inhibited the phosphorylation of phosphoinositide and Akt mediated
by phosphatidylinositol 3-kinase in the presence of 1,25(OH)2D3.117 Weak induction of calbindinD28K, a cytosolic calcium binding protein, and VDR itself was observed in the presence of
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ZK159222 in choriocarcinom- derived cells (JEG-3). In the presence of 1,25(OH)2D3, ZK159222
exhibited strong antagonist effects in these cells.118

1.6.3 Direct VDR-Coactivator Inhibitors
The identification of the central coactivator LXXLL motif as being essential to mediate nuclear
receptor binding prompted investigations into peptide-based VDR–coactivator inhibitors that
would evaluate the function of this protein-protein interaction. Pioneered by McDonnell et al for
the estrogen receptor, a phage display library of synthetic LXXLL peptides was generated and
screened with two hybrid assays against a panel of nuclear receptors including VDR.119-121
Peptides, C33, D47, EBIP41 and EBIP44, were identified to bind VDR (Figure 17). Importantly
when C33, D47, EBIP41 and EBIP44 peptides were expressed as Gal4 DBD fusions in cells, they
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Figure 17. Sequences of coactivator peptides that inhibit the interaction between VDR and
coactivators.

inhibited the VDR-mediated transcription in a reporter assay under control of an osteocalcin (OC)
promoter.122

In addition, RXR-selective peptide F6 was able to inhibit VDR-mediated

transcription demonstrating transactivation between RXR and VDR. A more exhaustive phage
display library identified three more LXXLL peptides (Figure 17, compounds 3,4, and 5) that not
only bind VDR in a two hybrid assay but also inhibit VDR-mediated transcription when expressed
in cells.106 These peptides exhibited a consensus sequence of (H/F)P(L/M)LXXLL. Importantly, the
binding of these peptides to VDR was more pronounced in the presence of VDR agonists than
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VDR antagonists. However, these peptides possess limitations in their inability to regulate
endogenous VDR target genes.
To overcome limitations in cell-based assays such as inactivity when transfected as a fusion
peptide or limited cell permeability and stability, new peptide-based inhibitors were
generated.123 Misawa et al. introduced stabilized cyclic heptapeptides that were composed of Lleucine residues and a stapled side chain as VDR inhibitors (Figure 18).124, 125 These stapled linkers
consisting of a long hydrocarbon chain have been reported to increase stability and oral
bioavailability. A dramatic IC50 value change from 220 µM to 3.2 µM was observed by changing
the nonfunctional linker (Figure 18, DPI-06) to a functionalized linker (Figure 18, DPI-07).
Rational drug design resulted in the first small molecules that inhibit the VDR–coactivator
interaction in 2010.126 Using a rational design approach, a benzodiazepine scaffold was
substituted with branched hydrophobic groups to mimic the i, i+3, and i+4 position of leucine of
coactivator DRIP205 (Figure 19).127 Docking studies revealed that compound 2 might form

Figure 18. Structures of cyclic peptide-based VDR–coactivator
inhibitors.
Figure 19. Overlay between a crystal structure of VDR and coactivator peptide DRIP205 and
docked conformation of compound 2 and structures of compound 2 and 35.
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hydrogen bonds with rat VDR clamp residues Glu416 and Lys242. The inhibition activity of
compound 2 (IC50= 17 µM) was confirmed in cells with a reporter gene assay. The results
prompted a more exhaustive structure-activity relationship (SAR) study reported in 2013 by the
same group.128 Despite the large number of analogs with various substituents in the 7- and 8position, only marginal improvement (IC50= 14 µM) was observed for compound 35 (Figure 19).
However, the aniline function in the 8-position was confirmed to be important for binding,
probably interacting with Glu417 of VDR.
In 2012, Arnold et al., identified the first irreversible VDR–coactivator inhibitors using high
throughput screening.129 Among 275,000 compounds, 140 inhibitors with cellular activity were
identified, including a group of 3-indolylmethanamines. A comprehensive SAR study around the
3-indolylmethanamine scaffold identified compound 31B as the most active VDR–coactivator
inhibitor in cells (IC50 = 4.2 µM, Figure 20, A). In addition, a linear free energy relationship
between inhibition rates of 3-indolylmethanamines bearing different electronic substituents
A

B

Figure 20. A) Structure of 31B and PS121912; B) Anti-proliferative effects of
PS121912 in a HL-60 xenograft model.

confirmed irreversibility. Due to the unique mode of binding, a high selectivity of 31B toward VDR
in respect to other nuclear receptors was observed. In addition, 31B is selective towards the
interaction between VDR and coregulator peptide SRC2-3 among other LXXLL coregulator
peptides. Importantly, down-regulation of VDR target gene TRPV6 by 31B was observed in the
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presence of 1,25(OH)2D3 for DU145 cancer cells leading to anti-proliferation at higher
concentration. Inhibition of VDR-mediated transcription and anti-proliferation in the presence of
31B was also observed for ovarian cancer cells OVCAR8 and SKOV3 and endometrial cancer cells
ECC-1.130 In cis-platinum resistant SKOV3 cells, other markers of anti-proliferation and apoptosis
were upregulated in the presence of 31B such as activation of caspase 3, phosphorylation of MAP
kinases p38 and SAPN/JNK, upregulation of P21, and cell-cycle arrest. In a cisplatin-resistant
SKOV3 xenograft tumor model, 31B treatment, delivered 5 times a week at a dose of 5 mg/kg,
led to suppressed tumor growth after two weeks. In addition, reduced tumor formation was
partially caused by a compromised de novo production of fatty acids due to lower expression of
fatty acid synthase (FASN) in the tumor. Further SAR studies resulted in a discovery of 3indolylmethanamine PS121912, a VDR–coactivator inhibitor that inhibited VDR-mediated
transcription with an IC50 of 590 nM (Figure 20).131 Similar to 31B, PS121912 is selective towards
VDR and has a preference for the interaction between VDR and coregulator peptide SRC2-3.
Importantly, ChIP studies revealed that in HL60 leukemia cells PS121912 was able to reduce the
DNA occupancy of VDR and binding of SRC2. However, PS121912 promoted the recruitment of
NCoR to the VDR–DNA complex.132 PS121912 reversed the regulation of VDR target genes in the
presence of 1,25(OH)2D3 at a concentration of 500 nM and modulated the transcription of many
genes affiliated with cell cycle control. Elevated levels of P21 protein levels were observed for
the PS121912 in the presence and absence of 1,25(OH)2D3 in HL60 cells as well as increased levels
of pro-apoptotic serine protease HTRA. In a mouse HL60 xenograft model at 3 mg/kg five times
a week, a significant change in tumor volume was observed after three weeks of treatment
(Figure 20, B). The blood calcium levels and animal weight did not differ from the control group.
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CHAPTER 2: THE RATIONAL DESIGN AND SYNTHESIS OF THIAZOLE-BASED
VDR-COACTIVATOR MODULATORS
2.1 Introduction
The rational design of drugs can be defined as the discovery of a lead molecule with
desirable properties determined prior to its actual identification based upon the information
known about a specific target.133

With advancing computer technology and growing

combinatorial libraries, this form of lead identification has become more and more streamlined.
The rational design of a drug is unique from that of other drug discovery processes such a high
throughput screening. High throughput screening can easily become a game of luck depending
on the size and diversity of compound libraries screened and the quality of assay being used.
However, rational drug discovery isn’t without its own drawbacks. To be truly a de novo rational
design, structural and chemical knowledge must be known about the targeted receptor and
compounds that bind to it. From this, a pharmacophore model can be developed in which set
parameters must be met by the compound in order to bind the active site. Without this, the
method must employ empirical information to base its claims thus becoming more of a “semirational” approach. As established in chapter 1, VDR is a well-studied receptor whose crystal
structure with ligands has been solved. Furthermore, the interaction between VDR and many of
its coactivators have been greatly investigated. Therefore, we were able to use a rational
approach to design a novel inhibitor of the interactions between VDR and its coactivator, SRC2.
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In Figure 21, coactivator peptide (stick model), SRC2, makes specific interaction with VDR
(grey/red) through an LXXLL motif. We hypothesized that by replacing the peptide backbone

Figure 21. Molecular Operating Environment (MOE) was used for fragmentbased design to replace the peptide backbone with a small molecule scaffold.6

(shown in green) with a small molecule scaffold while keeping the leucine residues within the
same space orientation as in SRC2, we could mimic this interaction and successfully inhibit a
coactivator from binding. In addition to the leucine residues, the pharmacophore model required
that the small molecule contained an electron donating group, as well as, the ability to H-bond
with glutamic acid while possessing drug-like properties.

A linker database containing

approximately 3,000 different scaffolds was virtually screened against this pharmacophore
developed in the program Molecular Operating Environment (MOE) and yielded a thiazole
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Figure 22. The thiazole molecule found as a suitable scaffold for peptide
replacement.6

scaffold containing two leucine like residues (Figure 22). Research into the synthesis of this
molecule revealed a quick three step route utilizing an efficient multi-component.134
In general, multi-component reactions (MCRs) are defined as any process in which three
or more reactants combine in one pot to form a product that incorporates structural features of
each reagent (Figure 23).135 There are many advantages to
using MCRs including simplicity, greater efficiency, higher
yields, and higher atom economy over conventional chemical
reactions. These convergent reactions involve all atoms
within the chemical process therefore producing little
chemical waste. This makes them a green synthetic method
for pharmaceutical and drug discovery research. In 1850, the
Strecker 3-component reaction (S-3CR) was the first official
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Figure 23. Simplistic model of
how multi-component work.

MCR discovered for the synthesis of α-aminonitriles by the reaction of ammonia, hydrocyanic
acid, and carbonyl compounds.136 Since then, organic chemist have invented numerous MCR
reactions that are now key players in combinatorial chemistry with their ability to quickly produce
large and diverse compound libraries. The reactions have especially grown in popularity in part
due to the arrival and growth of high throughput screening techniques that enable rapid
screening of these compounds.
Reactions involving isocyanides provide additional benefits to the rapidly developing field
of MCRs. As a very reactive functional group, isocyanides are unique in their ability to react with
nucleophiles and electrophiles at the same carbon atom resulting in a stable C-C bond.137 In many
cases, reactions with isocyanides are chemo-, regio- and stereoselective as well as highly effective
and versatile.138 The most important and vastly studied isocyanide-based MCR is the Ugi four
component reaction (U-4CR) developed in 1959 by Ivar Ugi (Figure 24). Advantages of this
reaction includes variable products by changing the amine (ammonia, primary and secondary),

Figure 24. The original U-4CR was used to produce Xylocaine with dimethylamine,
formaldehyde, 2,6-xylylisocyanide, and water.

carbonyl compounds (ketone or aldehyde), and isocyanides without sensitivity to steric bulk.139
Herein, we report the use of a U-4CR to synthesize novel, non-secosteroidal inhibitors of
VDR. These molecules were rationally designed to directly inhibit the interactions between VDR
and its coactivator SRC2.

Biochemical evaluation was conducted using a fluorescence

polarization binding assay.
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2.2 Chemistry
2.2.1 Synthetic Strategy
A U-4CR was used to synthesize the thiazole ring (Scheme 1).139 In one pot, (2,4dimethoxyphenyl)methanamine (2.1) and isovaleraldehyde (2.2) were initially added together to
undergo a condensation reaction to form the corresponding imine as seen in the reaction
mechanism (Figure 25). With the addition of thioacetic acid (2.3) and isocyanoacrylate (2.4), a

Scheme 1. Synthetic scheme used to develop VDR-SRC2-3 modulators. i) MeOH, room
temperature, overnight; ii) TFA, 60oC, 3 hours; iii) a) THF/H2O, LiOH, 0oC, overnight, b)
DCM, 3-isobutylmorpholine, EDCI, HOBt, DIPEA, 0oC; iv) THF, 30% TBD, morpholine, 80oC,
4 hours.

Figure 25. Mechanism for U-4CR reaction. This reaction produces the final thiazole product
in addition to one equivalent of dimethylammonium ion that can go back into the reaction as
an amine source.

proton exchange occurred with thioacetic acid thus activating the imine for nucleophilic addition
of the isocyanoacrylate and formation of a nitrilium ion. Next, a second nucleophilic addition
took place with the thioacetate anion. This was followed by a unique rearrangement termed a
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Figure 26. The dimethylammonium byproduct reaction mechanism.

Mumm rearrangement where the acyl group transfers from the sulfur to the nitrogen followed
by ring closure and production of an amide thiazole ring product (KAT011311) and a
dimethylammonium byproduct. This byproduct was able to participate in the synthesis as a
starting material and produced the dimethylamine thiazole ring product (KAT052711) as seen in
Figure 26. This was not initially evident due to their overlapping spots on the TLC but with the
addition of 1% acetic acid the two compounds could be easily separated. The acetic acid
protonated the dimethylamine and transformed it into a salt that retained longer on the column
than the desired amide product. Because they were easily purified, KAT052711 was used in the
subsequent coupling reactions in addition to the KAT011311. Deprotection of KAT011311 was
carried out using TFA at elevated temperatures to produce compound KAT030711 (Scheme 1).
Wang et al. previously published the successful amidation to the methyl ester position using
morpholine with 30% triazabicyclodecene (TBD), a bicyclic guanidine base, at 80oC for several
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hours.134 This method was successful for the coupling of a morpholine to KAT030711 and
KAT052711 to produce KAT080411 and KAT031312. Unfortunately these conditions were not
suitable when 3-isobutylmorpholine was used. Alternatively, the hydrolysis of the ester to a
carboxylic acid followed by peptide coupling using EDCI, HOBt, and DIPEA yielded the two desired
3-isobutylmorpholine amides, KAT021712 and KAT021112.

2.2.2 Characterization
Commercially available staring materials were used as received. Dry solvents were bought
in sure-seal bottles and handled under dry conditions using syringe technique. All glassware was
dried overnight at 100oC before use. Thin layer chromatography was performed on pre-coated
silicia gel 60 F254 plates (Fisher Scientific). Synthesized compounds were purified by normal
phase flash chromatography (SPI Biotage, silica gel 230-400 mesh) and concentrated under
vacuum. All pure compounds were stored as solids at -20°C. Compound characterization was
performed using a Shimadzu 2020 LC-MS (single quadrupole) instrument or Surveyor & MSQ LCMS (APCI or ESI) with compounds directly injected. NMR spectra were recorded on a Bruker
300MHz instrument with samples diluted in either CDCl3 or DMSO- D6.
General Procedure for 4-CR Ugi Reaction:

Isovaleraldhyde (107.3 μL, 1 mmol), (2,4-

dimethoxyphenyl)methanamine (167 mg, 1 mmol) and dry methanol (2 mL) with 4 Å molecular
sieves were added together at room temperature and stirred for 1 hour. Then (z)-methyl-3(dimethylamino)-2-isocyanoacrylate (154 mg, 1 mmol) and thioacetic acid (71.4 μL, 1 mmol) were
added to the reaction mixture and stirred at room temperature for 24 hours. The mixture was
concentrated by rotary evaporation. To the crude 1 mL of acetic acid was added and mixed
thoroughly before being purified by column chromatography using EtOAc-Hexanes (2-80%
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strong). Two products were obtained, KAT011311 as a yellow oil and KAT052711 as a cream
colored solid.
KAT011311 64 % yield; 1H-NMR (300 MHz) (CDCl3) δ 8.06 (s, 1H),
6.39-6.90 (d, 1H, J=9 Hz), 6.37-6.35 (m, 2H), 5.71-5.67 (t, 1H, J=
6Hz)), 4.49 (s, 2H), 3.91 (s, 3H), 3.77 (s, 3H), 3.78 (s, 3H), 2.16 (s, 3H),
2.06-1.96 (m, 2H), 1.59-1.50 (m, 1H), 0.90-0.86 (m, 6H, J= 13.5Hz,
7.5Hz);

13C-NMR

δ 171.90, 170.96, 161.83, 159.27, 157.58, 145.90, 128.60, 127.50, 117.20,

103.93, 98.48, 64.78, 55.33, 55.05, 41.59, 25.22, 22.68, 22.46. MS APCI (+ve) calcd. m/z for
C21H28N2O5S[(M)] 420, found [(M+H)+] 421.2.
KAT052711 16% yield; 1H-NMR (300 MHz) (CDCl3) δ 8.32 (s, 1H), 4.89-4.85
(dd, 1H, J=9Hz, 3Hz), 3.98 (s, 3H), 2.85 (s, 6H), 1.43-1.26 (m, 3H), 0.97-0.90
(dd, J=15Hz, 6Hz);

13C-NMR

δ. 172.78, 162.05, 146.11, 127.89, 64.72,

52.36, 42.26, 41.60, 25.06, 22.85 (isobutyl CH3), 22.38 (isobutyl CH3). MS APCI (+ve) calcd. m/z
for C12H20N2O2S[(M)] 256.1, found [(M+H)+] 257.1.
General Procedure for Deprotection Reaction: 1 mL of TFA was added to KAT011311 (85 mg,
0.2 mmol) and the mixture was heated to 60oC for 1 hour. Reaction was monitored by TLC (4:1
EtOAc- Hexanes) by taking an aliquot of reaction and working up a fraction with ammonium
chloride to remove acid. Upon complete conversion, the solution was concentrated and purified
by column chromatography using EtOAc and Hexanes with 1% AcOH (2-80% strong). A yellow
solid was obtained.
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KAT030711 66% yield; 1H-NMR (300 MHz) (CDCl3) δ 8.11 (s, 1H), 6.236.22 (d, 1H, J=6Hz), 5.46-5.40 (m, 1H), 3.96 (s, 3H), 2.04 (s, 3H), 1.971.81 (m, 2H), 1.68-1.59 (m, 1H), 1.00-0.96 (dd, 6H, J= 6Hz, 3Hz) ;

13C-

NMR δ 172.72, 169.72, 161.75, 146.70, 127.36, 52.50, 49.34, 44.40, 24.97, 23.16, 22.75, 22.01.
MS APCI (+ve) calcd. m/z for C12H18N2O3S [(M)] 270.1, found [(M+H)+] 271.1.
General Procedure for 3-isobutylmorpholine Coupling: 40 mg, 0.148 mmol of either KAT030711
(amide) or KAT052711 (dimethyl amine) were dissolved in 1 mL of THF, 400 μL of a 0.5M LiOH
solution (1:1 THF: H2O). The solution was stirred overnight under 0°C. Product conversion was
determined by TLC (4:1 EtOAc-Hexanes, Rf= baseline). To the solution, 100 µL 4M HCl Dioxane
was added to neutralize the base and stirred for 20 minutes. The mixture was concentrated by
rotary evaporation to yield an oil of the acid. The prepared acid was diluted with 2 mL of
dichloromethane and to it of EDCI (28.4 mg, 0.148 mmol), HOBt (20.0 mg, 0.148 mmol), DIPEA
(95.5 mg, 0.74 mmol, 128.8 μL) and 3-isobutylmorpholine (26.6 mg, 0.148 mmol) were added at
0°C and warmed to room temperature and stirred overnight. The reaction was monitored by TLC
(3:2 MeOH-EtOAc, 1% acetic acid, Rf= 0.75). Upon conversion, the crude was diluted with
dichloromethane and washed with water, dried over Na2SO4 and evaporated. The crude sample
was purified on silica gel with EtOAc-MeOH (2%-60% strong, with 1% Ac) using normal phase
flash chromatography system.
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KAT021712 3% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.91 (s, 1H), 5.335.28 (m, 1H), 4.01-3.56 (m, 7H, morpholine ring), 2.02(s, 3H), 1.98-1.69
(m, 6H), 1.02-0.97 (dd, 12H, J= 9Hz, 6Hz); MS APCI (+ve) calcd. m/z for
C19H31N3O3S [(M)] 381.5, found [(M+H)+] 382.3.
KAT021112 5% yield; 1H-NMR (300 MHz) (CDCl3) δ 8.00 (s, 1H), 4.56
(m, 1H), 3.99-3.55 (m, 7H, moropholine ring), 2.30 (s, 6H), 1.95-1.50 (m,
6H, isobutyl CH2 and CH), 0.98-0.92 (dd, 12H, J= 10.5Hz, 7.5Hz); MS APCI
(+ve) calcd. m/z for C19H33N3O2S [(M)] 367.3, found [(M+H)+] 368.2.
General Procedure for Morpholine Coupling: 48 mg (0.177 mmol) of either KAT030711 (amide)
or KAT052711 (dimethyl amine) were diluted with 1 ml of dried THF. To the solution 30% TBD
and 0.355 mmol of morpholine were added and stirred at 40°C overnight. Reaction was
monitored by TLC (4:1 EtOAc- Hexanes, Rf= 0.75). After full conversion, the mixture was
concentrated to dryness and purified on silica gel with EtOAc-MeOH (2%-60% strong, with 1%
acetic acid) using normal phase flash chromatography system.
KAT080411 35% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.83 (s, 1H), 6.026.00 (d, 1H, J= 6Hz), 5.44-5.36 (m, 1H), 3.77 (m, 8H, morpholine CH2),
2.06 (s, 3H), 1.94-1.84 (m, 2H), 1.79-1.71 (m, 1H), 1.00-0.97 (dd, 6H, J=
3Hz, 6Hz); 13C-NMR δ 171.57, 169.55, 162.62, 149.76, 124.32, 67.00, 49.51, 44.61, 24.99, 23.23,
22.73, 22.10. MS APCI (+ve) calcd. m/z for C15H23N3O3S [(M)] 325.3, found [(M+ H)+] 326.
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KAT031312 30% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.96 (s, 1H), 4.394.37 (d, 1H, J= 6Hz), 3.99-3.76 (m, 8H, morpholine CH2), 2.30 (s, 1H),
1.79-1.73 (m, 2H), 1.64-1.53 (m, 1H, J= 9Hz, 6Hz); 13C-NMR δ 171.09,
162.78, 149.48, 125.40, 66.98, 64.53, 41.51, 41.13, 29.66, 25.24, 23.10, 22.04. MS APCI (+ve)
calcd. m/z for C15H25N3O2S [(M)] 311.4, found [(M+H)+] 312.2.

2.3 Modulation of VDR-Coactivator Binding with Rationally Designed
Thiazole Derivatives
A fluorescence polarization-based (FP) assay was used to quantify the binding between
VDR and coactivator in the presence of small molecules. Synthesized compounds displaying

Figure 27. Cartoon of the FP-assay used to determine if newly synthesized
molecules are competitive inhibitors of the VDR-coactivator interaction.

agonistic binding induce the interactions between VDR and Alexa Fluor 647-labeled coactivator
peptide through favorable conformational changes of the VDR protein. Therefore, high
fluorescence polarization is observed upon its binding to VDR-LBD. In contrast, low polarization
is observed when the LXXLL mimic molecule competes with the coactivator for binding in the
presence of 1,25(OH)2D3 (Figure 27).
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Potency and efficacy are determined directly from the dose-response curve produced for
each compound. Potency is recorded as a median effective concentration (EC50) or a median
inhibition concentration (IC50) value for agonist and antagonist binding, respectively. The
maximal efficacy reflects the limit of the dose-response relation on the response axis. For
example, a full agonist occupies the ligand binding pocket (LBP) of VDR more efficiently than
partial agonists. This is seen by the lower response produced by the partial agonists compared
to a full agonists (Figure 28). It is important to note that the failure of partial agonists to produce
a maximal response is not due to decrease affinity for VDR. 140 Although partial agonist do not
elicit a maximal therapeutic response it may be beneficial in limiting the drug’s propensity to
cause a toxic effect.

2.3.1 Experimental Procedure
Reagents and Instrumentation: The assay buffer was prepared with 18MΩ water, 25mM PIPES

Figure 28. General dose-response showing example
curves of a partial and full agonist.

(piperazine-N,N′-bis(2-ethanesulfonic acid)) (Sigma), 50mM NaCl (Fisher), and 0.01% NP-40
(Thermo Scientific) a detergent used to reduce any non-specific binding. The pH was adjusted to
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6.75 and filtered to remove any particulates. LG190178
(a VDR agonist) was synthesized following a published
procedure and used as a positive control (Figure 29).141,
142

CBT1 (a VDR-coactivator inhibitor) was used as

second positive control and was synthesized using a

Figure 29. LG190178, a synthetic
agonist for VDR that binds with an Ki=
150 nM

previously published method (Figure 30).143 The expression and purification of VDR-LBD was
performed as described by previous literature.9 SRC2-3 (CKKKENALLRYLLDKDDTKD) was
purchased and labeled with cysteine-reactive Alexa Fluor
647 or Texas Red maleimide. Labeled peptides were
purified by reverse phase quantitative HPLC using a C18
column and stored at -20oC. All fluorescence readings
were performed on a Tecan Infinite M1000 plate reader.

Figure 30. CBT is known to inhibit
the interactions between VDR and its
coactivator.

Small volume transfers were performed on the Tecan Freedom EVO liquid handling system with
a 100 nL pin tool transfer (V&P Scientific). Serial dilutions were done in 96-well polypropylene
plates (Corning, #3365) and assays were conducted in 384- well black polystyrene microplates
(Nunc, #262260).
Fluorescence Polarization-based Binding Assay Protocol: To 30 mL of buffer, 1 μL of the Alexa
Fluor 647-labeled SRC2-3 (7.5 nM final concentration) was added. The optimal concentration of
VDR-LBD (EC90) was determined by serially diluting VDR protein ranging from 35 to 0.017 μM and
combined it with the coactivator containing solution in a 384-black well black plate. To the plate
a solution of LG190178 was transferred using the pin tool at a final concentration of 2 μM. The
calculated EC90 obtained determined was 0.1 μM VDR-LBD. The optimal LG190178 concentration
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was determined by combining a serial diluted LG190178 solution ranging from 20μM-0.1nM to a
solution containing VDR-LBD (0.1μM) and Alexa Fluor 647-labeled SRC2-3 (7.5 nM).

The

calculated EC90 determined was 0.75 μM. 10 mM stock solutions of synthesized compounds made
in DMSO were serially diluted (1:3) in 96-well plates. Four 14 μL aliquots of each compound
concentration was transferred to opaque 384-well plates for storage. 600 nl of each compound
concentration was transferred into 20 µl assay solution resulting in a final maximum
concentration of 300 μM. Agonistic binding was determined in the absence of LG190178 while
antagonistic binding was determine in the presence of LG190187. Fluorescence polarization was
detected after 30 minutes at an emission/excitation wavelength of 635/685 nm (Alexa Fluor 647).
LG190178 and DMSO were used as positive and negative controls in the agonistic binding assay,
respectively. In the antagonist binding assay CBT1 was the positive control while DMSO was used
as a negative control. Controls were measured within each plate to determine the z’ factor
(Equation 1), which assed the quality of the assay and enabled data normalization. Three
independent experiments were carried out in quadruplicate, and data was analyzed using
nonlinear regression with a variable slope (GraphPrism, Equation 2).

Equation 1:

Equation 2:

𝑍′ = 1 − (

3 × (𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒)
|𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒|

𝐵𝑜𝑡𝑡𝑜𝑚+(𝑡𝑜𝑝−𝑏𝑜𝑡𝑡𝑜𝑚)
(1+10(𝑙𝑜𝑔𝐼𝐶50−𝑋)(𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒) )
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)

2.3.2 Results and Discussion
Table 1 summarizes the binding results for the rationally designed thiazole molecules.
Although these compounds showed great promise as VDR-coactivator inhibitors in the initial
molecular modeling they did not exhibit any agonistic or antagonistic effects in the binding
assay.
Table 1. Modulation of VDR-Coactivator binding in the presence of rationally
designed thiazole ligands.
Recruitment of SRC-2-3 Inhibition of SRC2-3 VDR
to VDR
Interaction
Compound
EC50 (µM)
IC50 (µM)
KAT011311
KAT052711
KAT030711
KAT021712
KAT021112
KAT080411
KAT031312

Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive

Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive

The maximum concentration used for this assay was 300 µM of each compound.

2.3.3 Conclusion
Although these initial rationally designed molecules did not bind to VDR and inhibit
coactivator interactions, further computer modeling could aid in the development of active
molecules. Also, these molecules may behave differently within cells and potentially exhibit
transcriptional modifying properties. Further evaluation would be needed to determine this.

44

CHAPTER 3: GW0742
Introduction
High throughput screening (HTS) has quickly
evolved over the last decades to become one of the
main methods for the identification of lead compounds

Target ID &
Validation

Assay Development HTS

in drug discovery. As seen in Figure 31, it includes many

Screening

different stages of the drug discovery process such as

Hit Triage

assay development, screening, hit compound selection,

Hit-to-lead &
ADME/toxicity

and the measurement of

absorption, distribution,
Lead Optimization

metabolism, and excretion (ADME) as well as

toxicity.7

Early drug discovery was simpler and focused more on
the disease than on specific targets. Studies were
carried out in vivo and required large amounts of each
compound. Due to the identification of many new

Preclinical
Development

Clinical Phases
Figure 31. Stages of drug discovery and
development and the involvement of
HTS activities.7

biological targets that mediate various diseases, more economic processes have been developed
that include HTS using miniaturization and automation. The HTS revolution all began in 1951
with the invention of the microwell plate by Dr. Gyula Takatsky that was quickly commercialized
as a plastic microplate later that decade.144 With the development of microplate readers by
Biotek that accepted different microwell plates, the concept really started to increase in
popularity. By the 1990s, many companies were producing microplates and readers with many
different features. In addition, automation was adopted which led to automated instruments,
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automated liquid-handling systems, and automated screening systems that integrated more than
20 different instruments. Furthermore, the increase of publications containing detailed HTS assay
adaptations helped mature HTS automation and detection systems. It was not long before
standardization of microplates was necessary. The Society for Biomolecular Screening (SBS) was
founded in 2002, which established a Microplate Standards Working group with the goal of
introducing HTS standards and distributing knowledge among researchers in this field.
Today, HTS is more than assay development, validation and screening. It is a collective
term that encompasses a range of multidisciplinary activities, ranging from the creation of
specialized cell lines and purified enzymes for screening to compound design using
computational chemistry and novel parallel chemistry approaches and even engineers creating
suitable robots and instrumentation. HTS is constantly advancing with the development of new
technology that increase throughput (i.e. ultraHTS) and decreases costs and waste. 144
Drug target selection is an important starting point for drug discovery. Understanding the
biology and pharmacological aspects of a biological target is essential before beginning a HTS
campaign. There are many things to consider including the “drug-ability” of a target. For
example, is there any evidence to support that a target is amendable to modulation by small
molecules? In our case, nuclear receptors are known to be modulated by small molecules called
hormones. Between 2001-2004, GlaxoSmithKline (GSK) had a 72% success rate of identifying new
lead compounds for nuclear receptors among diverse libraries of small molecules. 145, 146 In
addition, these compounds had ideal, drug-like chemical structures and exhibited a SAR. It is
essential to note that the success of finding a hit compound is dependent upon the diversity of a
compound library. The “chemical space” is quite large with an estimated 1040-10100 compounds.
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When considering that HTS is currently carried out with 0.5-1 million compounds, a selection
process has to occur in order to make this approach successful.147 By taking the structure of
current drugs into account, Lipinski introduced the rule of five for drug-like molecules: 1. No more
than five hydrogen-bond donors; 2. no more than ten hydrogen-bond acceptors; 3. a molecular
mass less than 500 Daltons; 4. an octanol-water partition coefficient logP ≤ 5.148
In a general sense, HTS assays used for the identification of lead compounds are either
biochemical or cell-based assays.

The detection of activity can include fluorescence,

luminescence, radioactive elements, heat of binding, and mass spectrometry.149 Biochemical
assays can include purified proteins such as receptors, enzymes, transporters and many more. 7
They offer the advantage of clear drug-target interactions leading to SAR during hit-to-lead
optimization without being convoluted by other processes that can occur in cell-based assays.
However, by assessing a compound within the environment of a cell, we are able to determine
the quality and biological relevance of a hit compound in addition to any off-target effects it may
have.144
In 2011, we conducted a screening campaign in collaboration with the NIH chemical and
genomics center (NCGC) to identify a potential VDR inhibitor (AID: 504847, pubchem). 150
Approximately 390,000 compounds were screened using a FP assay where an inhibiting
compound would disrupt the interaction between VDR and a fluorescently labeled peptide, SRC23. This primary screen found that 1,938 compounds exhibited IC50 values ≤ 40 μM. Two
alternative FP assays, one with a Texas Red-labeled SRC2-3 and the other with a fluoresceinlabeled SRC2-3, were employed to further validate the primary results. The Texas Red-labeled
SRC2-3 revealed that out of the 1,938 initial hit compounds 69% of the compounds exhibited an
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IC50 value of ≤ 40 μM. 83% of the compounds with the fluorescein-labeled SRC2-3 possessed an
IC50 value of ≤ 40 μM. A good correlation was observed when Texas Red-labeled SRC2-3 and
fluorescein-labeled SRC2-3 assay results were combined with those of the Alexa Fluor 647 assay.
Accordingly, 747 compounds were selected based on diverse scaffold structures and
functionality. To discriminate those compounds that might inhibit coactivator binding by
irreversibly reacting with cysteine residues of the VDR-LBD protein, the VDR-SRC2-3 FP assay was
conducted in the presence of 2-mercaptoethanol (ME).

The idea was that the electrophilic

compounds would react with the excess nucleophilic ME rather than the nucleophilic VDR protein
residues such as cysteine. A significant decrease in the inhibition of VDR-SRC2-3 interaction was
observed in the presence of 100 mM ME in comparison to 1 mM ME (Figure 34) thus suggesting

Figure 32. Inhibition of VDR-SRC2-3 Alexa Fluor 647 interaction by small molecules
(50μM) in the presence of A) 1mM ME and B) 100mM ME.

that a large number of the primary hits may inhibit VDR-coactivator interactions through
modifications of surface cysteine residues. However, a small number of compounds were not
influenced by ME at high concentrations. Among these was GW0742 shown in Figure 33, A.
GW0742 was originally developed by GlaxoSmithKline in 2003 as a selective agonist for
the peroxisome proliferator activated receptor δ (PPARδ) (EC50 = 0.001 μM).151 The biological
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role of PPARδ had remained elusive, in part, due to its broad tissue expression and the lack of
good chemical tools to distinguish the pharmacology between the PPAR isoforms (α, γ, and δ).
Thus, with the development of the selective GW0742 agonist, the function of PPARδ was
investigated in cell-based assays and in vivo to reveal its role in hypertension, diabetes,
inflammation, obesity, and cancer.
In our lab, GW0742 was evaluated in a dose responsive manner with a number of
different assays. FP assays were used to determine the inhibition of VDR-SRC2-3 interaction with
three different probes and IC50 values of 14 μM (Alexa Fluor 647), 25.1 μM (Fluorescein), and
inconclusive (Texas Red) were determined. A cell-based transcription assay showed GW0742
inhibited VDR-mediated transcription with an IC50= 26 μM as well as maximal response of 30% in
the absence of 1,25(OH)2D3. A cytotoxicity assay using HEK293T cells found that GW0742
encouraged 18% cell death at a concentration of 45.8 μM. In addition, a FP-assay using VDR and
a rhodamine-labeled VDR ligand determined that GW0742 was binding the VDR ligand binding
pocket and not the coactivator binding site with an IC50= 8.7 ± 1.7 μM (Figure 33, B).
The selectivity of GW0742 with respect to its ability to inhibit the interaction between

Figure 33. A) Structure of GW0742; B) FP-assay competing GW0742
against rhodamine-labeled VDR ligand.

other NRs and their coactivators was evaluated by using a FP assay with different Alexa Fluor 647
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labeled coactivator peptides. The NR-coactivator pairs investigated included VDR and SRC2-3, the
thyroid hormone receptor β (TRβ) and SRC2-2, PPARγ and DRIP2 (derived from coactivator
DRIP205), and the androgen receptor (AR) and SRC2-3. GW0742 was able to disrupt NRcoactivator interactions from strongest to weakest potency as follows: AR-SRC2-3 (6.6 ± 1.5 μM),
VDR-SRC2-3 (27.2 ± 2.7 μM), TRβ-SRC2-2 (59.9 ± 9.5 μM) and PPARγ-DRIP2 (>86 μM). Other
groups have investigated GW0742 with respect to other nuclear receptors in a variety of assay.151
GlaxoSmithKline used PPARα, PPARγ, and PPARδ cell-based transactivation assays (alkaline
phosphatase as the reporter enzyme) to determine GW0742 agonistic activity EC50= 2.0 ± 1.3 μM
(PPARγ), 1.1 ± 0.109 μM (PPARα) and 0.001 ± 0.002 μM (PPARδ).151
GW0742 was evaluated in an array of nuclear receptor-mediated transcription assays
using HEK293-T cells to confirm the pan nuclear receptor-coactivator inhibition caused by high
concentrations of GW0742 in the FP assay. The nuclear receptors investigated were VDR, PPARα,
PPARγ, PPARδ, AR, RXRα, TRα, TRβ, and ERα in the presence or absence of their endogenous
ligands or synthetic agonists with different concentrations of GW0742. The EC 50 and IC50 values
are summarized in Table 2. As expected GW0742 was able to activate transcription mediate by
PPARα, PPARγ, and PPARδ among the nuclear receptors tested with EC50 values in agreement
with previously reported results. In contrast, inhibition of transcription was found for all NRs
with GW0742 showing significantly lower IC50 values for VDR and AR with 12.1 μM and 14.7 μM,
respectively. In addition, a cytotoxicity assay found that GW0742 at 37.5 μM was nontoxic (93%
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of cells were alive). Interestingly, GW0742 exhibited an agonistic effect at lower concentrations
and an antagonistic effect at higher concentrations. For PPARγ GW0742 exhibited EC 50 values

Table 2. Evaluation of GW0742 in different nuclear receptor reporter assays.
NUCLEAR RECEPTOR

AGONIST EC50 (µM)

ANTAGONIST IC50 (µM)

VDR
PPARα
PPARγ
PPARδ
AR
RXRα
TRα
TRβ
ERα

Inactive
1.3 ± 0.3
2.8 ± 0.7
0.0037 ± 0.0014
Inactive
Inactive
Inactive
Inactive
Inactive

14.7 ± 1.5a
37.4 ± 8.2b
20.2 ± 5.4c
21.6 ± 4.9d
12.1 ± 5.3e
22.9 ± 3.8f
31.4 ± 4.0g
25.8 ± 5.2h
21.3 ± 7.2i

a

1,25(OH)2D3 (10nM), bGW7647 (30nM), cRogsiglitazone (300nM), dGW0742 (50nM), eDHT (10nM),
Bexarotene (200nM), gT3 (10nM), hT3 (10nM), iEstradiol (10nM). Three independent experiments
were conducted in quadruplicate and data were analyzed using nonlinear regression with a variable
slope (Graphpad Prism).
f

between 2.6 μM to 2.8 μM, whereas at concentrations higher than 20 μM GW0742 inhibited
PPARγ-mediated transcriptional. The interaction between PPARγ-LBD and DRIP2 was inhibited at
concentrations higher than 86 μM.
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Together with the NIH NCGC, our goal was to develop novel, non-secosteroidal VDR
modulators based on the GW0742 scaffold that 1) did not influence PPARδ signaling and 2)
inhibited VDR-coactivator interactions. Reducing GW0742’s ability to bind PPARδ might be
accomplished by modulating the interaction with key LBP amino acid residues. Compared to
VDR, PPARδ has a larger LBP that contains three different regions that can make contact with the
ligand. GW0742 occupies this Y-shaped space by making a total of 29 ligand interaction with the
pocket.10 Region I (Figure 34, yellow residues) is mostly polar with residues that line the C-

Figure 34. Stereo view of the binding site of PPARδ-LBD (grey
cartoon) interacting with GW0742 (pink). The ligand makies
interactions with residues belonging to region I (yellow), region
II (green) and region III (orange).10

terminal activation of helix 12. Region II (Figure 34, green residues) and region III (Figure 34,
orange residues) are predominately hydrophobic.

GW0742 hydrophilic carboxylate group

interacts with region I and its hydrophobic tail group containing the thiazole and the fluorine
substituted phenyl ring is positioned mostly in region II. Therefore, it can be assumed that
molecules lacking the ability to bind in this orientation would make poor PPARδ agonists.
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Figure 35 depicts the SAR scheme followed to develop such GW0742 analogs reported
within this chapter. Part 1 discusses changes made in the carboxylate region (blue) of GW0472.
Part 2 includes over 100 analogs that have changes in the phenyl (pink), linker (green), methyl
(light blue), and carboxylate (blue) regions.

Finally, part 3 describes the synthesis and

biochemical effects associated with a thiazole-oxazole switch. All compounds were investigated
using nuclear receptor binding assays, transcription and toxicity assays to evaluate the selectivity
and potency of GW0742 analogs to interact with VDR and PPARδ.

Replace with
oxazole

Thiazole

Methyl

Linkers
Phenyl
Mono, poly, and
heteroaromatic- substitution
of phenyl

Replace S and O with CH2,
N, O or S

Replace CH3 with H

Carboxylate
Replace acid with tetrazole

Figure 35. SAR scheme for the synthesis of GW0742 analogs.

Part 1: Evaluation of Coactivator Recruitment by the Vitamin D Receptor or
the Peroxisome Proliferator-Activated Receptor δ in the Presence of
GW0742 Analogs
3.1 Purpose
As previously discussed, our lab introduced GlaxoSmithKline’s compound, GW0742,151 as
a novel antagonist for VDR.152 In addition, GW501516, another GSK molecule that possesses a
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1000-fold selectivity for PPARδ over other PPAR subtypes was found to inhibit VDR mediated
transcription (IC50= 16.0 ± 3.6 µM).151 The compounds differ in structure by a m-fluorine
substituent.

Within this chapter, GW0742 and GW501516 analogs containing an ester

(compound 2) or alcohol moiety (compound 3) in the carboxylate region were investigated for
agonistic and antagonistic effects towards VDR and PPARδ. We hypothesized that analogs with
appropriate substitution in the carboxylate region could diminish PPARδ binding. Therefore, we
focused on the decrease of hydrogen bond interactions with important residues His413 and
Tyr437 in region I. Virtual docking of compound 3 overlaid with GW0742 in the PPARδ LBP in
Figure 36 visualizes the decrease in hydrogen bonding due to alcohol functionality.
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A

B

Figure 36. Virtual docking with PPARδ co-crystallized with GW0742 (PBD: 3TKM) were used to
visualize the affects carboxylate substitution had on binding. A) GW501516 alcohol analog
(lime green) overlaid GW0742 (pink). Hydrogen bonding is shown in black dashes and hydrogen
pi bonds are shown in yellow. B) A 2D depiction of the interactions GW0742 (red) and
GW501516 alcohol analog (lime green) have with PPARδ LBD.

3.2 Modulation of VDR-Coactivator Binding by GW0742 Analogs
The activities of compounds 1-3 with respect to VDR were determined using a FP assay
employing recombinant VDR-LBD, Alexa Fluor 647 labeled SRC 2-3 peptide, and the synthetic VDR
ligand LG190178.129 The results are presented in Table 3. Compounds 1-3 possess no agonistic
Table 3. Summary of EC50 and IC50 values of compounds 1-3 for VDR determined
by fluorescence polarization.

Compound

R

R1

Agonist EC50 (µM)

Antagonista IC50 (µM)

1 GW0742

F

CH2COOH

Inactive

7.73 ± 1.68

2

H

CH2COOCH3

Inactive

>30

3

H

CH2CH2OH

Inactive

9.03 ± 5.5

a

A VDR-LBD concentration used was 0.1µM. Inhibition of VDR-SRC2-3 interaction in the presence
of LG190178 (0.75 µM). Three independent experiments were conducted in quadruplicate and data
were analyzed using a nonlinear regression with a variable slope (GraphPad Prism).
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activity thus the inability to initiate the interaction between VDR-LBD and coactivator peptide
SRC2-3. The antagonistic behavior of all compounds was determined in the presence of VDR
agonist LG190178.153 Compound 1, GW0742, was the most active inhibitor with an IC50 of 7.73 ±
1.68 µM in the presence of 100 nM VDR-LBD. We observed that higher concentrations of VDRLBD resulted in ligand depletion and therefore higher IC50 values for instance the recently
reported IC50 of 27.2 ± 2.7 µM for GW0742 in the presence of 600 nM VDR-LBD.152 Interestingly,
compound 2 bearing a carboxylic ester functionality instead of the carboxylic acid is significantly
less active. The corresponding alcohol 3 however has a similar inhibitory activity as GW0742 with
an IC50 of 9.03 ± 5.5 µM.

3.3 Modulation of VDR and PPARδ-Mediated Transcription by GW0742
Analogs
Unlike fluorescence polarization-based binding assays, which provide information on
favorable compound binding or inhibition, cell-based assays provide information about
compound cell permeability, biological relevance and overall toxicity of novel compounds. Three
specific assays were conducted using highly transfectable HEK-293T kidney cells: 1) VDR
transcription assay; 2) A PPARδ transcription assay; and 3) a cell viability assay. The VDR
transcription assay applies two plasmids. VDR is overexpressed under control of a
cytomegalovirus promoter (CMV) and the reporter plasmid possesses a luciferase reporter gene
under control of a CYP24A1 promoter (Figure 37). In the presence of an agonist like 1,25(OH)2D3,
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VDR is activated and recognizes the VDRE found on the CYP24A1 promoter region and induces
the transcription of the luciferase reporter gene. A bioluminescent reaction in the presence of

A

B

VDR Coactivator
LBD
Light
VDR
Pol II
DBD
CYP24A1
Luciferase gene

Coactivator

N

VDR
LBD
VDR
DBD
CYP24A1

N
H

No Transcription
Luciferase gene

Figure 37. Cartoon describing luminescence-based transcription assay. A) Activated VDR
transcribes the luciferase gene and produces light. B) In the presence of an inhibitor, VDR
is unable to transcribe the luciferase gene and produce light.

its substrates (i.e. luciferin, ATP, Mg2+ and O2) creates light that is directly proportional to the
amount of expressed enzyme, and thus, the transcriptional activity of VDR (Figure 37, A). An
inhibitor induces a conformational change to VDR that is unfavorable for coactivator binding and
thus transcription of the luciferase gene does not occur (Figure 37, B).
The PPARδ transcription assay is a 2-hybid assay that includes a vector of PPARδ’s ligand
binding domain fused to a GAL4 DNA domain. The reporter plasmid includes a luciferase genes
under control of a UAS. In the presence of an agonist like GW0742, PPARδ is activated and
binding of GAL4 to the UAS induces transcription of the luciferase gene, thus the ability to
produce light. Because we are trying to diminish PPARδ-activated transcription with the GW0742
analogs, a decrease in light production would indicate poor agonistic effects and the desired
discrimination against PPARδ.
The cytotoxicity assay allows for the direct quantification of the ATP present in viable
cells, which is an indicator of metabolically active cells. Because ATP is a necessary substrate for
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luciferase enzyme, living cells producing it will promote a bioluminescent reaction through this
enzyme.

3.3.1 Experimental Procedure
Reagents and Instrumentation: Human embryonic kidney (HEK) 293T cells were purchased
(ATCC) and cultured in 75 cm2 flasks (CellStar) coated in matrigel (BD Bioscience, #354234), a
gelatinous protein secreted by mouse sarcoma that helps cells adhere to the flask. Cells are
grown in DMEM/High Glucose (Hyclone, #SH3024301) media to which non-essential amino acids
(Hyclone, #SH30238.01), 10 mM HEPES (Hyclone, #SH302237.01), 5 x 106 units of penicillin and
streptomycin (Hyclone, #SV30010), and 10% of heat inactivated fetal bovine serum (Gibco,
#10082147) were added. Cells are harvested using 0.05% Trypsin (Hyclone, #SH3023601), which
disrupts the cell monolayer and proteolytically cleaves the bonds between the cells and flask.
The assay is conducted in DMEM/High Modified buffer without phenol red (Hyclone,
#SH30284.01) that contains all the above mentioned additives plus 10 mM sodium pyruvate and
2% percent charcoal treated FBS (Invitrogen, #12676-011) instead of HI FBS. Cell transfection
was conducted by lipid-based methods using LipofectamineTM reagent with PLUSTM reagent (Life
Technologies, #15338020). VDR and PPARδ-mediated transcription was determined using
Bright-Glo™ Luciferase Assay Kit (Promega, Madison, WI).

Controls used with VDR were

1,25(OH)2D3 (10 nM in DMSO, purchased form Endotherm) and DMSO while PPARδ controls were
GW0742 (30 nM in DMSO, purchased from Tocris). Bright-Glo™ contains all substrates (luciferin,
ATP, and Mg2+) necessary for expressed luciferase to produce a light. The cell viability assay was
evaluated using Cell Titer-Glo™ Luminescent Cell Viability Assay Kit (Promega, Madison, WI)
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which contains luciferase and all its substrate but ATP. The controls for the cytotoxicity assay
used were 3-dibutylamino-1-(4-hexyl-phenyl)-propan-1-one (100 μM in DMSO, positive, Figure
38) and DMSO (negative). Cell culture was performed in a Baker Company Class II Biological
Safety Cabinet.

All luminescence readings were

performed on a Tecan Infinite M1000 plate reader.
Small volume transfers were performed on the Tecan

Figure 38. 3-dibutylamino-1-(4-hexylphenyl)-propan-1-one

Freedom EVO liquid handling system with a 100 nL pin
tool transfer (V&P Scientific). Serial dilutions were done in 96-well polypropylene plates
(Corning, #3365) and assays were conducted in 384- well white optical bottom plates (Nunc,
#142762).
Luminescence-Based VDR-Mediated Transcription Assay Protocol: Cell transfection was carried
out with 70-80% confluent HEK 293T cells that had been cultured in 75 cm 2 flasks. For VDR
transfection, 2 mL of untreated DMEM/High Glucose media (without additives) containing 0.7 μg
of VDR-CMV plasmid, 16 μg of a CYP24A1-luciferase reporter gene, LipofectamineTM LTX (75 μl),
and PLUSTM reagent (25 μl) was added to the flask. For PPARδ transfection, 2 mL of untreated
DMEM/High Glucose media (without additives) containing 1.5 μg of PPARδ GALx4 plasmid, 16 μg
of a GALx4RE luciferase reporter gene, LipofectamineTM LTX (75 μl), and PLUSTM reagent (25 μl)
was added to the flask . After 16 hours of incubation at 37 oC with 5% CO2, the cells were
harvested with 3mL of 0.05% Trypsin, added to 10mL of the assay buffer, DMEM/High Modified
buffer without phenol red, and spun down for 2 minutes at 1000 rpm. The media was removed
and cells were resuspended in the DMEM assay media. Prior to adding cells to sterile white,
optical bottom 384-well plates, plates were treated with 20 μL per well of a 0.25% matrigel
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solution. To each well, 20 μL of cells were added to yield a final concentration of 15,000 cells
per well. The plates were then spun down for 2 minutes at 1000 rpm. After 4 hours, plated cells
were treated with 100 nL of small molecules and controls which were added using the pin tool.
In the competitive inhibition assay, 1,25(OH)2D3 (10 nM) was also added to the small molecule
wells. After 16 hours of incubation at 37oC with 5% CO2, 20μL of Bright-Glo™ Luciferase Assay Kit
(transcription assay) or Cell Titer-Glo™ Luminescence Assay Kit (cytotoxicity assay) were added
and luminescence was read. Controls were measured within each plate to determine the z’ factor
(Equation 1) and to enable data normalization. Three independent experiments were performed
in quadruplicate and data was analyzed using nonlinear regression with variable slope
(GraphPrism, Equation 2).

3.3.2 Results and Discussion
To further explore the biological role of compounds 1-3, transcription assays mediated by
VDR and PPARδ were employed using transiently transfected HEK293-T cells.129 The results are
summarized in Table 4.
Table 4. Summary of transcriptional activation and deactivation mediated by VDR and
PPARδ in the presence of GW0742 analogs.
a

R1a

VDR EC50
(µM)
Inactive

Cmpd

R

1
GW0742

F

CH2COOH

2

H

CH2COOCH3

3

H

CH2CH2OH

0.15 ± 0.08
(11%)b
0.12 ± 0.03
(38%)b

VDR
IC50
(µM)
12.7 ±
8.0
0.95 ±
0.30
0.36 ±
0.055

PPARδ
EC50 (nM)

PPARδ
IC50 (µM)

Toxicity
LD50 (µM)

3.5 ± 0.31

3.9 ± 2.4

>50

3.9 ± 0.38
(35%)c
40 ± 19
(13%)c

0.26 ±
0.12
0.63 ±
0.22

5.47 ± 3.3
(70%)d
1.73 ±
0.14

a

For structure see Table 1; b percent partial VDR activation in reference to calcitriol; c Percent partial
PPARδ activation in reference to compound GW0742; d Percent partial toxicity

As expected, GW0742 was inactive as a VDR agonist but could inhibit VDR-mediated transcription
with an IC50 value of 12.7 ± 8.0 µM (Table 4). Furthermore, we confirmed the activation of PPARδ
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at nanomolar concentrations of GW0742 (EC50 3.5 ± 0.31 nM) and inhibition of PPARδ-mediated
transcription at higher concentration (IC50 3.9 ± 2.41 μM).152 Interestingly, compounds 2 and 3,
which were not able to initiate the interaction between VDR-LBD and SRC2-3 peptide (Table 3)
exhibited partial VDR agonistic effects at concentrations between 110-150 nM (Table 4, entries
2 and 3). Compound 3 activated the VDR-mediated transcription with a 38% efficacy in respect
to VDR agonist calcitriol and an affinity of 0.12 ± 0.03 μM (EC50). For the activation of PPARδmediated transcription compound 2 was superior to compound 3 with an EC50 of 3.9 ± 0.38 nM
and an efficacy of 35% in comparison to GW0742. Importantly, compound 2 and 3 inhibited
PPARδ- and VDR-mediated transcription at sub-micromolar concentrations. In addition, the
toxicity of analogs 2 and 3 is more pronounced than that of GW0742. Compound 2 has three-fold
selectivity towards the inhibition of PPARδ-mediated transcription with an IC50 of 0.26 ± 0.12 μM
and compound 3 is two-fold more active to inhibit VDR-mediated transcription with an IC50 of
0.36 ± 0.055 μM.

3.4 Conclusion
Overall, we demonstrated agonistic behaviors of GW0742 and its analogs at lower
concentrations for PPARδ and inhibition of PPARδ-mediated transcription at higher
concentrations. In addition, GW0742 analogs 2 and 3 exhibited a similar behavior for VDR but at
significantly higher concentrations for the partial agonist effect. The toxicity of both compounds
is significant and may play a role in the relatively low inhibition of transcription for the both
receptors.

61

Part 2: A High Throughput Approach to Identify Novel Nuclear
Receptor Ligands Based on the GW0742 Scaffold
3.1 Purpose
In this part, molecules with substitutions made in the phenyl, linker, methyl and
carboxylate regions of GW0742 were synthesized to investigate their effects on PPARδ and VDR
A

B

Figure 39. Virtual screening docking with PPARδ co-crystallized with GW0742 (PBD: 3TKM)
were used to visualize the affects phenyl substitution had on binding. A) GW0742 analog,
NCGC00344919-01, possessing a 1H-indol-4-yl substituent in the phenyl position (lime
green) overlaid GW0742 (pink). Hydrogen bonding is shown in black dashes and hydrogen
pi bonds are shown in yellow. B) A 2D depiction of the interactions GW0742 (red) and
NCGC00344919-01 (lime green) have with PPARδ LBP.

transcription. As before, we wanted to deactivate PPARδ-mediated transcription by creating
unfavorable interactions with its LBD while creating a potent VDR inhibitor. As seen in figure 39,
the addition of a heteroaromatic ring system such as an indole in the phenyl position would
create steric bulk and diminish favorable hydrogen bonding interactions with Tyr437, His413, and
His287.
Furthermore, by adding different electron donating and accepting groups on the phenyl
substituent, itself, may also create the necessary interactions needed for a potent VDR inhibitor.
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The addition of bioisosteric linkers such as nitrogen, oxygen and carbon provided diversity in
bond angles and molecule length that might decrease PPARδ activation. Figure 40 depicts how
a sulfur/oxygen switch changes the orientation of a GW0742 analog caused by increased polar
surface and reduced molecule length.
B

A

Figure 40. Virtual screening docking with PPARδ co-crystallized with GW0742 (PBD: 3TKM)
were used to visualize the affects linker substitution had on binding. A) GW0742 analog
containing an oxygen and carbon linkers (lime green) overlaid GW0742 (pink). Hydrogen
bonding is shown in black dashes and hydrogen pi bonds are shown in yellow. B) A 2D
depiction of the interactions GW0742 (red) and GW0742 with oxygen and carbon linkers (lime
green) have with PPARδ LBP.

3.2 Chemistry
3.2.1 Synthetic Strategy
Synthetic route developed by UWM (Scheme 1): The synthesis of mono-substituted GW0742
analogs included the reduction of ethyl 2-bromo-5-methylthiazole-4-carboxylate to obtain
primary alcohol (KAT051412).154 This compound was coupled with methyl 3-(4hydroxyphenyl)propionate under Mitsunobu reaction conditions yielding thiazole ester
KAT091212.155 Originally a two-step reaction was applied transforming KAT051412 into the
corresponding chloride in the presence of methanesulfonyl chloride followed by the subsequent
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Scheme 2. Synthesis of phenyl ring-subsituted ligands containing oxygen and carbon linkers: i)
NaBH4, EtOH, room temperature, 4 hrs; ii) PPh3, DIAD, DCM, methyl 3-(4-hydroxyphenyl)
propionate, room temperature, 2hrs; iii) a) 4-(trifluoromethyl)boronic acid (KAT031513) or 3(hydroxymethyl)phenyl) boronic acid (KAT050713), PdCl2(PPh3)2, Na2CO3∙H2O, DME/H2O/EtOH,
160oC, 10minutes, MW, b) (3-(hydroxymethyl)phenyl)boronic acid, PdCl2(PPh3)2, Na2CO3∙H2O,
DME/H2O/EtOH, 160oC, 10 min, MW.

reaction with methyl 3-(4-hydroxyphenyl)propionate. However, the overall yield was still lower
than the one step Mitsunobu reaction at 25%. A microwave assisted Suzuki reaction allowed for
the introduction of the third aromatic ring.156 Conveniently, carbon-carbon bond formation and
hydrolysis occurred under microwave conditions to form final carboxylic acids KAT031513 and
KAT050713 with a para-trifluoromethyl or meta-methylene hydroxy substituent, respectively.
Synthetic route developed by NIH: Mono, poly, and heteroaromatic-substituted GW0742
analogs were synthesized according to reaction scheme 3. Similar to our reaction, methyl 2bromo-5-methylthiazole-4-carboxylate was reduced to a primary alcohol. A substitution to
produce a corresponding chloride (compound 3.1) was accomplished with thionyl chloride
followed by the coupling with 4-hydroxy-3methylthiophenol in the presence of cesium
carbonate. Alkylation of the phenol with tert. butyl bromoacetate afforded compound 3.2. A
Suzuki coupling was applied to enable diversity in this position with different boronic acids
utilizing a unique solid supported diphenylphosphine palladium (II) heterogeneous catalyst that
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could be recycled and used again. The resulting esters were hydrolyzed with trifluoroacetic acid
in DCM to afford the final carboxylic acid products.

Scheme 3. Synthesis of mono, poly, and heteroaromatic-substituted ligands: i) NaBH4,
EtOH, room temperature, ii) SOCl2, DCM, rt; iii) a) 4-hydroxy-3methylthiophenol,
Cs2CO3, acetonitrile, room temperature; b) tert. butyl bromoacetate, Cs2CO3,
acetonitrile, room temperature; iv) a) boronic acid Na2CO3, SiliaCat® DPP-Pd, DME,
150°C, MW, 0.5 h; b) TFA, DCM, room temperature, 1h.

Bioisosteric substitution is a common approach in medicinal chemistry to improve
potency, selectivity or toxicity in a drug while maintaining similar physical (i.e. size, shape,
polarity) and chemical properties (i.e. pKa). In our case a tetrazole ring was introduced in place
of the carboxylate as depicted in scheme 4. Therefore, cyano-substituted analogs were treated
with sodium azide to form tetrazoles by a traditional [2+3] cycloaddition.
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Scheme 4. Synthesis of bioisostere-substituted ligands. i) Cs2CO3, CAN,
room temperature, 2 hours; ii) NaN3, NH4Cl, DMF, 100oC, overnight.

3.2.2 Characterization
General Chemistry: Starting reagents such as ethyl 2-bromo-4-methylthiazole-5-carboxylate,
methyl

3-(4-hydroxyphenyl)propionate,

4-(trifluoromethyl)boronic

acid,

and

3-

(hydroxymethyl)phenyl)boronic acid were purchased from Sigma-Aldrich. Anhydrous solvents
were purchased in sure-seal bottles and handled under dry conditions using syringe technique.
All glassware was dried overnight at 100oC before use.

Thin layer chromatography was

performed on pre-coated silica gel 60 F254 plates (Fisher Scientific). Microwave reactions were
performed using a CEM Discover SP instrument. Synthesized compounds were purified by
normal phase flash chromatography (SPI Biotage, silica gel 230-400 mesh) and concentrated
under vacuum. All pure compounds were stored as solids at -20°C. Compound characterization
was performed using a Shimadzu 2020 LC-MS (single quadrupole) instrument or Surveyor & MSQ
LC-MS (APCI or ESI) with compounds directly injected. NMR spectra were recorded on a Bruker
300MHz instrument with samples diluted in either CDCl3 or DMSO- D6.
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KAT051412: 60% yield; To an ice cold solution of ethyl 2-bromo-5methylthiazole-4-carboxylate (2.6g, 15.6 mmol) in ethanol (60mL) and
water (1 mL) a solution of NaBH4 (2.36g, 62.4mmol) and ethanol (50mL)
was added slowly over 40 minutes. Once added, the reaction was warmed to room temperature
and stirred overnight. The reaction was monitored by TLC using EtOAc-hexanes (4:1, v/v). Next,
ethanol was removed using rotary evaporation. The oily residue was resuspended in EtOAc and
carefully washed with saturated NH4Cl. The aqueous layer was then washed with EtOAc three
times, combined, dried over Na2SO4 and concentrated to dryness. The crude product was
purified on silica gel with EtOAc-hexanes (2%-60% strong) using normal phase flash
chromatography system. The pure product was a cream colored solid.

1H-NMR

(300 MHz)

(CDCl3) δ 4.78 (s, 2H), 2.39 (s, 3H); 13C-NMR δ 149.05, 135.73, 134.18, 56.43, 50.47, 14.96. MS
APCI (+ve) calcd. m/z for C5H6BrNOS [(M)] 207.0, found [(M+H)+] 208 and [(M+H+2)+] 211.1.
KAT091212: 25% yield; Methyl 3-(4-hydroxyphenyl)propionate
(87 mg, 0.48 mmol) and triphenylphosphine (164 mg, 0.63
mmol) were added to a solution of (2-bromo-4-methylthiazol-5yl)methanol (100 mg, 0.48 mmol, compound KAT051412) and DCM (5mL) and cooled to 0ºC.
Diisopropyl azodicarboxylate (123.1 μL, 0.63mmol) was added dropwise and allowed to stir for
15 minutes before being warmed to room temperature. The reaction was monitored by TLC
using EtOAc-hexanes (4:1, v/v). Upon completion, the solvent was removed and purification was
conducted with EtOAc-Hexanes (2%-60% strong). Pure fractions were isolated and dried under
high vacuum to obtain a cream colored solid. 1H-NMR (300 MHz) (CDCl3) δ 7.17-7.14 (d, 2H, J=
9Hz), 6.90-6.87 (d, 2H, J= 9Hz), 5.07 (s, 2H), 3.69 (s, 3H), 2.95-2.90 (t, 2H, J= 7.5 Hz), 2.65-2.60 (t,
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2H, J= 7.5Hz), 2.40 (s, 3H); 13C-NMR δ 173.30, 156.32, 150.40, 149.18, 133.89, 129.44, 129.18,
115.04, 61.95, 51.62, 35.87, 30.08, 15.28. MS DUIS calcd. m/z for C15H16BrNO3S [(M)] 369.2,
found [(M+H)+] 370.0 and [(M+H+2)+] 372.0.
General Procedure for Suzuki Coupling Reaction: In a 10 mL microwave reaction vessel methyl
3-(4-((2-bromo-4-methylthiazol-5-yl)methoxy)phenyl)propionate (50 mg, 0.14 mmol, compound
KAT091212), 4-(trifluoromethyl)boronic acid or 3-(hydroxymethyl)phenylboronic acid (0.20
mmol, 1.5 equiv.), Na2CO3∙H2O (25 mg, 1.5 equiv.), bis(triphenylphosphine)palladium(II)
dichloride (1 mg, 0.0014 mmol, 0.01 equiv.) were dissolved in a mixture of DME-H2O-EtOH (7:3:2,
v/v/v). The reaction mixture was treated with nitrogen to remove traces of oxygen and capped.
The reaction was heated in a microwave reactor to 160oC for 10 minutes. TLC using EtOAcHexanes with 1% AcOH (4:1, v/v) was used to confirmed conversion of the starting material
(KAT091212) and appearance of a new product. The crude reaction was dried, resuspended in
saturated NH4Cl and extracted with EtOAc (2x) and DCM (2x). The organic layers were combined,
dried over Na2SO4 and concentrated to dryness. The crude mixture was purified with silica gel
using EtOAc-Hexanes with 1% AcOH (2-80% strong).
KAT031513: 36% yield; 1H-NMR (300 MHz) (DMSOD6) δ 8.14-8.11 (d, 2H, J= 9Hz), 7.86-7.83 (d, 2H, J=
9Hz), 7.19-7.16 (d, 2H, J= 9Hz), 6.98-6.95 (d, 2H, J=
9Hz), 5.31 (s, 2H), 2.79-2.74 (t, 2H, J= 7.5Hz), 2.51-2.50 (t, 2H), 2.47 (s, 3H); 13C-NMR δ 174.21,
163.73, 156.36, 152.01, 144.83, 137.00, 134.27, 129.76, 129.63, 127.06, 126.64, 122.78, 115.36,
62.06, 35.99, 29.92, 15.56; 13CDEPT-135 NMR δ Negative (-), CH2: 62.07, 36.08, 30.02, Positive
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(+): 129.76, 127.05, 126.64, 115.36, 15.55; ESI-MS (+ve and –ve) calcd. m/z for C21H18F3NO3S
[(M)] 421, found [(M+H)+] 422.2 and [(M-H)-] 420.
KAT050713: 33% yield; 1H-NMR (300 MHz) (DMSO-D6) δ
7.88 (s, 1H), 7.77-7.75(1H, d, J= 6Hz), 7.46-7.38 (m, 2H),
7.18-7.15 (d, 2H, J=9Hz), 6.97-6.94 (d, 2H, J= 9Hz), 5.28 (s,
2H), 4.57 (s, 2H), 2.79-2.74 (t, 2H, J= 7.5Hz), 2.51 (m, 2H), 2.44 (s, 3H); 13C-NMR δ 174.29, 165.87,
156.55, 151.71, 144.19, 134.09, 133.25, 129.74, 127.76, 124.73, 124.13, 115.37, 62.91, 62.07,
36.02, 30.00, 15.56; 13CDEPT-135 NMR δ Negative (-), CH2: 62.91, 62.07, 36.02, 30.00, Positive
(+): 129.74, 129.43, 128.62, 124.73, 124.13, 115.38, 15.56; ESI-MS (+ve) calcd. m/z for C21H21NO4S
[(M)] 383, found [(M+H)] 384.

NIH General Chemistry: Preparative purification was run on a Waters semi-preparative HPLC
system using a Phenomenex Luna C18 (5 micron, 30 x 75 mm) at a flow rate of 45 mL/min. A
gradient of 10% to 50% acetonitrile in water over 8 minutes (each containing 0.1% trifluoroacetic
acid) was used as a mobile phase during the purification. Fraction collection was triggered by UV
detection (220 nm).

Analytical analysis was performed on an Agilent LC/MS (Agilent

Technologies, Santa Clara, CA). Method t1: A 7 minute gradient of 4% to 100% Acetonitrile
(containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used
with an 8 minute run time at a flow rate of 1 mL/min. A Phenomenex Luna C18 column (3 micron,
3 x 75 mm) was used at a temperature of 50° C. Method t2: A 3 minute gradient of 4% to 100%
Acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic
acid) was used with a 4.5 minute run time at a flow rate of 1 mL/min. A Phenomenex Gemini
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Phenyl column (3 micron, 3 x 100 mm) was used at a temperature of 50° C. Method t3: Analysis
was performed on an Agilent 1290 Infinity Series HPLC. UHPLC Long Gradient Equivalent 4% to
100% acetonitrile (0.05% trifluoroacetic acid) in water over 3.5 minutes run time of 4 minutes
with a flow rate of 0.8 mL/min. Purity was determined using an Agilent Diode Array Detector for
both Method t1, Method t2 and Method t3. Mass determination was performed using an Agilent
6130 mass spectrometer with electrospray ionization in the positive mode. 1H NMR spectra were
recorded on Varian 400 MHz spectrometer. Chemical shifts are reported in ppm with DMSO at
2.49 ppm as internal standard. High resolution mass spectrometry was recorded on Agilent 6210
Time-of-Flight LC/MS system. Confirmation of molecular formula was accomplished using
electrospray ionization in the positive mode with the Agilent Masshunter software (version B.02).

3.3 Evaluation of GW0742-Based Analogs using Biochemical and Cell-based
Assays
GW0742 analogs were characterized using a PPARδ-mediated transcription assay and
toxicity assay.157 The results are summarized in the following tables: mono-substituted analogs
(Table 5), poly-substituted analogs (Table 6), heteroaromatic-substituted analogs (Table 7),
tetrazole-substituted analogs (Table 8), and linker-substituted analogs (Table 9). PPARδ agonists
with EC50 values greater than 1 µM were summarized into Table 10.
GW0742 analogs with non-substituted phenyl rings like compound NCGC00319174-01
exhibited low PPARδ activation (Table 5). This suggests that the substituents such as p-CF3 and
m-F of the parent compounds encourage favorable interactions with PPARδ LBP. Only three
mono-substituted compounds modulated transcription with high potency.
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They were

NCGC00241455-04 (p-CF3), NCGC00319058-01 (p-OCF3), and NCGC00319066-01 (p-CO2Et) with
EC50 values lower than 15 nM. It was no surprise that compound NCGC00241455-04, also known
as GW501516, was confirmed as a potent PPARδ agonist.158 The other two compounds have not
been reported but exhibit similar electron donating properties and significant hydrophobicity.
Notably, the positioning of substituents around the phenyl ring affected the ligands ability to
activate transcription. A para positioned substituent, in most cases, is a more potent PPARδ
agonist than compounds that bear the same group in the ortho or meta position. This is observed
with a methyl, trifluoromethyl, trifluoromethoxy and cyano substituents.
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Table 5. Evaluation of mono-substituted GW0742 analogs
Entry

R

NCGC00319174-01
NCGC00319046-01
NCGC00319053-01
NCGC00319065-01
NCGC00319061-01
NCGC00319050-01
NCGC00319056-01
NCGC00319063-01
NCGC00319048-01
NCGC00319055-01
NCGC00319064-01
NCGC00319049-01
NCGC00241455-04
(GW501516)
NCGC00319047-01
NCGC00319052-01
NCGC00319051-01
NCGC00319058-01
NCGC00319036-01
NCGC00319057-01
NCGC00319069-01
NCGC00319067-01

H
o-CH3
m-CH3
p-CH3
o-Cl
m-Cl
p-Cl
o-F
m-F
p- F
o-CF3
m-CF3

o-OCH3
m-OCH3
m-OCF3
p-OCF3
m- CN
p-CN
p- N(CH3)2
p-NHCH3

NCGC00319066-01

p- COOCH2CH3

NCGC00319054-01
NCGC00319070-01
NCGC00319071-01
NCGC00319151-01
NCGC00319150-01

m-methylsulfinyl
p-methanesulfonamide
p-NHCOCH3
m-CONH(CH2)3N(CH3)2
p-CONH(CH2)2N(CH3)2
p-(4-methylpiperazinyl)
methanone
p-piperazinyl
Morpholino-methanone

NCGC00319169-01
NCGC00319072-01
NCGC00319068-01

p-CF3

a

PPARδ
EC50 (μM) a,(b)

Toxicity LD50
(µM)c

0.26 ± 0.35 (90)
0.60 ± 0.17 (66)
1.62 ± 0.41 (74)
0.05 ± 0.02 (100)
0.58 ± 0.20 (71)
0.50 ± 0.16 (74)
0.13 ± 0.04 (66)
0.26 ± 0.08 (94)
0.43 ± 0.23 (96)
0.16 ± 0.04 (93)
2.4 ± 0.95 (39)
1.1 ± 0.6 (79)
0.013 ± 0.004
(100)
2.3± 0.70 (27)
2.36 ± 0.67 (96)
0.45 ± 0.15 (100)
0.014 ± 0.007 (49)
3.2 ± 1.0 (74)
0.12 ± 0.42 (100)
0.16 ± 0.02 (100)
0.57 ± 0.24 (100)
0.009 ± 0.002
(100)
6.7 ± 3.2 (59)
>100
3.9 ± 2.3 (100)
2.4 ± 1.3 (70)
2.1 ± 1.4 (65)

>100
>100
>80
>80
>80
28.8 ± 5.0
>100
>80
>100
Non-toxic
>100
>50

6.9 ± 5.53 (70)

Non-toxic

16.8 ± 5.7 (37)
3.8± 1.5 (37)

>80
Non-toxic

>33
>100
>80
>50
>50
>80
>80
>50
Non-toxic
>80
Non-toxic
Non-toxic
>100
Non-toxic
Non-toxic

Two-hybrid assay using a CMV-PPARδ-LBD-GAL4-DBD plasmid and a 6xGal4-luc reporter vector. The
maximum concentration used for this assay was 100 μM of each compound; bEfficacy in PPARδ assay
in respect to full activation with GW0742; cCell-TiterGlo (Promega).
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However, halide substituents (F and Cl) showed no significant difference between ortho,
meta, or para positioning around the ring possibly due to their smaller atomic size or change in
ligand orientation. Para positioned fluorine and chlorine substituents had similar but relative
high EC50 values of around 0.14 µM (compounds NCGC00319055-01 and NCGC00319056-01). The
least active PPARδ agonist was compound NCGC00319070-01 (SO2NH2) introducing high polarity
with the ability to be both a hydrogen-bond donor and acceptor. Depending on its position within
the LBP, the extra hydrogen bonding capability may not be favorable.

Compound

NCGC00319072-01 (piperazine) was another example where hydrogen bonding as a donor and
acceptor may deactivate PPARδ with an EC50= 16.8 ± 5.7.
Interestingly, many compounds possess partial agonistic activity against PPARδ although
no evident trend was observed. Finally, most compounds exhibited LD50 values of higher then 80
μM. An exception was compound NCGC00319050-01 (m-Cl) with an LD50 of 28.8 µM. Polysubstituted phenyl rings found in Table 6 were also capable of activating PPARδ mediated
transcription.
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Table 6. Evaluation of poly-substituted GW0742 analogs.

NCGC00092344-05
(GW0742)
NCGC00319082-01
NCGC00319145-01
NCGC00319172-01
NCGC00344925-01
NCGC00344922-01
NCGC00344921-01
NCGC00319077-01
NCGC00319159-01
NCGC00319154-01
NCGC00319171-01
NCGC00319147-01
NCGC00319168-01
NCGC00344924-01
NCGC00319153-01
NCGC00319148-01
NCGC00319143-01
NCGC00344923-01
NCGC00319075-01
NCGC00319142-01
NCGC00344926-01
NCGC00344927-01
NCGC00319146-01
NCGC00344928-01
NCGC00344929-01
NCGC00344930-01

H

F

CF3

H

H

H
CF3
Cl
H
H
H
H
H
H
H
F
H
H
H
CF3
H
H
H
Cl
H
H
H
Cl
Cl
Cl

CF3
H
H
Cl
Cl
F
OCH3
F
CH3
CF3
F
F
Cl
CN
H
CF3
F
Cl
H
Cl
CF3
Cl
H
Cl
H

H
H
H
H
H
H
H
H
H
H
H
F
H
H
H
H
H
H
H
F
Cl
Cl
H
H
Cl

H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
Cl
H
H

NCGC00319170-01

H

F

CF3
CF3
CF3
CF3
OCF3
OCF3
OCH3
OCH3
OCH2CF3
F
F
F
F
F
Cl
Cl
Cl
Cl
CN
H
H
H
H
H
H
Benzylmorphol
ine

PPARδ
EC50 (μM)a, (b)
0.0035 ± 0.00031
(100)
0.99± 0.42 (46)
0.20± 0.09 (50)
0.028 ± 0.013 (88)
0.007 ± 0.003 (75)
0.009 ± 0.004 (69)
0.020 ± 0.010 (100)
1.06± 0.47 (44)
0.074 ± 0.031 (100)
0.050± 0.028 (100)
0.49± 0.31 (100)
0.042 ± 0.009 (100)
0.046± 0.019 (100)
0.18 ± 0.08 (43)
1.07± 0.59 (100)
0.18± 0.12 (63)
0.22± 0.09 (100)
0.035 ± 0.011 (92)
0.692 ± 0.137 (79)
0.066 ± 0.04 (100)
0.17 ± 0.05 (62)
0.60 ± 0.28 (23)
0.71± 0.27 (78)
6.6 ± 4.8 (84)
0.028 ± 0.017 (78)
1.40 ± 0.74 (75)

H

H

4.3± 1.9 (50)

Entry

R

R1

R2

R3

R4

a

Toxicity
LD50 (µM)d

>100

>50
>50
>50
>50
>33
>50
>50
>100
>100
>50
>50
>80
>100
>50
>100
>50
>50
>50
>50
>100
>50
>33
>50
>100
>100
>80

Two-hybrid assay using a CMV-PPARδ-LBD-GAL4-DBD plasmid and a 6xGal4-luc reporter vector. The
maximum concentration used for this assay was 100 μM of each compound; bEfficacy in PPARδ assay in
respect to full activation with GW0742; cCell-TiterGlo (Promega).
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The least active compound in our series was compound NCGC00344928-01 (o,o’Cl2) with an EC50
of greater than 5 µM, indicating that two groups occupying both ortho positions of the phenyl
ring is not favorable for PPARδ activation. Interestingly, by moving just one chloride to the R-3
position, like in compound NCGC00344929-01, greatly increased activity by 230-folds. The
positioning of groups like CF3, Cl, F and OCF3 on phenyl ring positions gave some insight into
PPARδ affinity. For example, by switching the p-CF3 and m-F substituents on GW0742 to make
compound NCGC00319171-01 (m-CF3, p-F) a 500 fold decrease in potency was observed. When
both those positions were occupied by CF3 groups like in compound NCGC00319082-01, agonistic
activity decreased 1000 fold compared to GW0742. If the CF3 substituent was moved to the
ortho position (compound NCGC00319145-01 (o-CF3, p-CF3)), an increase in potency was
observed. An even more significant increase in activation was observed when the CF3 group was
changed to a chlorine (NCGC00319172-01 (o-Cl, p-CF3) and even more when the chlorine was
moved to the meta position (NCGC00344925-01 (m-Cl, p-CF3) with a 7 nM affinity. With respect
to all fluorine substituents, it appeared that two fluorine substituents were better than one
regardless of their positioning, which was observed for all chlorine substituents as well. The
toxicity of poly-substituted GW0742 analogs was, in general, higher than their mono-substituted
counterparts, however none of them showed pronounced toxicity below 50 μM.
Heteroaromatic substituents were also coupled to the C-2 position of the thiazole ring
and summarized in Table 7. Six compounds were able to activate PPARδ with an EC50 less than
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Table 7. Evaluation of heteroaromatic-substituted GW0742 analogs
Entry

R

NCGC00319037-01
NCGC00319078-01
NCGC00319073-01
NCGC00319074-01

NCGC00319076-01
NCGC00319038-01
NCGC00319039-01
NCGC00319155-01
NCGC00319173-01
NCGC00319059-01
NCGC00319162-01
NCGC00319164-01
NCGC00319149-01

3,5-dimethylisoxazol-4-yl
1H-indazol-4-yl
4-pyridine
2-(benzofuran-2-yl)
2,3-dihydrobenz[1,4]dioxin-6yl
Naphthalene-1-yl
Benzo[1,3]dioxol-5-yl
Benzo[1,2,5]oxadiazol-5-yl
Furan-2-yl
Pyridin-3-yl
Benzothiophen-2-yl
Piperazin-1-yl
Pyrimidin-yl
1H-indazol-6-yl

NCGC00319160-01

Benzothiazol-6-yl

NCGC00319166-01
NCGC00319163-01
NCGC00319167-01
NCGC00319165-01
NCGC00319144-01
NCGC00319157-01
NCGC00319156-01
NCGC00319152-01
NCGC00319158-01
NCGC00344920-01
NCGC00344919-01
NCGC00344918-01

Isoquinolin-4-yl
6-fluoropyridin-3-yl
1-methyl-1H-indazol-6-yl
6-(trifluoromethyl)pyridin-3-yl
1-methyl-1H-indol-6-yl
1H-indol-5-yl
1H-pyrazol-4-yl
2-fluoropyridin-4-yl
1H-indazol-5-yl
Benzothiophen-5-yl
1H-indol-4-yl
1H-indol-2-yl

NCGC00319040-01

PPARδ
EC50 (μM) a,(b)
0.29± 0.12 (100)
0.052± 0.035 (100)
9.1± 3.6 (81)
0.061± 0.028 (97)

Toxicity LD50
(µM) c
>100
>100
>80
>80

0.72± 0.23 (100)

>80

1.69± 0.34 (36)
0.26± 0.12 (52)
0.16± 0.04 (35)
6.0± 2.7 (96)
8.1± 5.6 (87)
0.026± 0.014 (100)
0.57± 0.39 (46)
1.57± 0.62 (51)
3.18± 1.80 (100)
0.0738± 0.053
(100)
0.35± 0.18 (51)
0.192± 0.082 (100)
0.58± 0.34 (100)
0.013 ± 0.006 (91)
0.52± 0.29 (100)
1.31± 0.42 (98)
3.9 ± 1.7 (74)
3.3± 1.9 (100)
1.44 ± 0.66 (64)
0.14 ± 0.08 (95)
>100
0.035 ± 0.015 (100)

>50
>50
>100
>100
>100
>100
>100
Non-toxic
>100
100
Non-toxic
Non-toxic
>100
>100
>100
>100
Non-toxic
Non-toxic
Non-toxic
>50
Non-toxic
>50

a

Two-hybrid assay using a CMV-PPARδ-LBD-GAL4-DBD plasmid and a 6xGal4-luc reporter vector.
The maximum concentration used for this assay was 100 μM of each compound; bEfficacy in PPARδ
assay in respect to full activation with GW0742; cCell-TiterGlo (Promega)

75 nM. Of these six, all but one had a bicyclic aromatic ring structure. This result was unexpected
because of the rigidity and sheer bulkiness of the introduced substituents. However, it suggests
that the LBD of PPARδ is spacious enough to accommodate such ligands, possibly through a
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unique orientation unlike GW0742. From Table 5 we concluded that non-substituted phenyl ring
structures such as compound NCGC00319174-01 made a poor PPARδ agonist. Similarly,
substitution of the phenyl ring with a pyridine, as in compound NCGC319173-01, resulted in a
poor PPARδ ligand. However, when the pyridine ring bears a trifluoromethyl group like
compound NCGC319165-01, a 1600-fold increase in transcriptional activation was observed. This
suggests the importance of the hydrophobic interactions between the trifluoromethyl of
GW0742 with region II of PPARδ’s LBP. The positioning of heterocyclic rings seemed to matter
when comparing compounds NCGC00344918-01 and NCGC00344919-01. Both have an indole
ring attached to C-2 of the thiazole but the 1H-indol-4-yl group (NCGC00344919-01) was nearly
3,000 times less potent than the 1H-indol-2-yl substituent (NCGC00344918-01). It could be
speculated that the 1H-indol-4-yl ring unfavorably reaches into region III unlike GW0742, which
interacts with region II of the Y-shaped PPARδ LBP. Interestingly, when docked in PPARδ LBP with
respect to GW0742, the carboxylic acid region of NCGC00344919 reached out to region III
residues (orange) and interacted with solvent molecules. This allowed for favorable hydrophobic
interactions between region II residues (green) and 1H-indol-4-yl ring but an unfavorable
conformation for a potent PPARδ agonist (Figure 41).
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Figure 41. Overlay of GW0742 (pink) with compound NCGC00344919
(blue) in PPARδ LBP (PBD: 3TKM). Hydrogen bonding is shown in black
dashes and hydrogen pi bonds are shown in yellow. Region I, II, and III are
shown in yellow, green and orange, respectively.

Bioisoteric substitution of the carboxylate group with a tetrazole ring was used for several
analogs to determine its effect on PPARδ-mediated transcription (Table 8). In general, increased
toxicity and decreased potency was observed when compared to their carboxylate counterparts.
Compound NCGC00264097-01 is most like GW0742 and had a 40 fold decrease in potency and a

Table 8. Evaluation of tetrazole-substituted GW0742 analogs
Entry

R1

R2

R3

R4

NCGC00264097-01
NCGC00344870-01
NCGC00344869-01
NCGC00344871-01

H
Cl
H
H

CF3
H
Cl
Cl

F
Cl
H
Cl

H
H
CF3
H

a

PPARδ
EC50 (μM) a, (b)
0.04± 0.018 (29)
0.594 ± 0.435 (29)
0.51 ± 0.18 (51)
0.24 ± 0.11 (26)

Toxicity
LD50 (µM)c
>33
>50
>33
>33

Two-hybrid assay using a CMV-PPARδ-LBD-GAL4-DBD plasmid and a 6xGal4-luc reporter
vector. The maximum concentration used for this assay was 100 μM of each compound;
b
Efficacy in PPARδ assay in respect to full activation with GW0742; cCell-TiterGlo (Promega).
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two fold increase in toxicity. Although similar in acidity, the rigidity of the ring may decrease its
ability to be a good hydrogen bond donor/acceptor with PPARδ. The two oxygens on the
carboxylate group make hydrogen bonds with key residues like His413 (helix 10/11), Try437 (helix
12), His287 (helix 7) of PPARδ LBP and are implicated with maintaining the locked conformation
of helix 12.10 Overall, these compounds had the lowest efficacy ranging from 26-51% compared
to any other series of thiazole compounds making them excellent partial agonist.
The replacement of the sulfur and oxygen linkers of GW0742 allowed investigations into
geometry of successful PPARδ agonists (Table 9). In addition, the role of the methyl group on the

Table 9. Evaluation of linker-substituted GW0742 analogs.
Entry

R1

R2

Y

R

X

NCGC00264098-01
NCGC00264099-01
NCGC00263796-01
NCGC00264094-01
NCGC00264104-01
NCGC00264093-01
KAT-031513
NCGC00264101-01
NCGC00264103-01
NCGC00264102-01
KAT050713

H
F
F
F
F
F
H
F
F
F
CH2OH

CF3
CF3
CF3
CF3
CF3
CF3
CF3
CF3
CF3
CF3
H

S
S
S
O
O
O
O
N
N
N
O

CH3
H
H
CH3
H
H
H
CH3
H
H
H

CH2
-O
O
CH2
S
CH2
O
O
CH2
CH2

PPARδ
EC50 (μM) a,(b)
0.039 ± 0.022 (87)
0.018 ± 0.010 (70)
0.026 ± 0.008 (84)
0.02 ± 0.02 (73)
0.032 ± 0.021 (77)
0.27 ± 0.023 (75)
0.703 ± 0.108 (100)
0.18 ± 0.12 (61)
0.16 ± 0.045 (78)
0.0576± 0.021 (95)
18.2 ± 2.8 (47)

Toxicity
LD50 (µM)c
>100
>100
>100
>100
>100
>100
>100
>100
>80
>80
Non-toxic

a

Two-hybrid assay using a CMV-PPARδ-LBD-GAL4-DBD plasmid and a 6xGal4-luc reporter vector. The
maximum concentration used for this assay was 100 μM of each compound; bEfficacy in PPARδ assay in
respect to full activation with GW0742; cCell-TiterGlo (Promega).

linker was investigated in respect to its role in favorable PPARδ binding. Compound
NCGC00263796-01 was structurally similar to GW0742 except for the removal of the methyl in
the R position. Without the methyl group, this compound had an EC50 that was 10 times less
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potent than GW0742 and surprisingly behaved as a partial agonist (84% in comparison with
GW0742). A large decrease in potency was observed for compound KAT-031513 when Y was
replaced with a smaller oxygen atom and X with a CH2 in the absence of a fluoride and methyl
group in positions R1 and R, respectively. KAT-031513 was ~700 times less potent than GW0742.
When compared to compound NCGC00264104-01 with a fluorine in the R1 position this
difference was only 22 fold less suggesting the necessity of the hydrophobic interactions between
PPARδ LBP and the fluoride. However, if the Y linker was exchanged with a nitrogen, the presence
of a fluoride on position R1 did not benefit the activity of these compounds. Overall, the nitrogen
linker produced compounds that were about 125 times less able to activate PPARδ transcription
compared to GW0742. Only when the X linker is exchanged with a CH2 group does the potency
increase. When comparing NCGC00264101-01 and NCGC00264103-01, the presence or absence
of an R positioned methyl had little effect on activation of transcription thus producing agonists
that were 200 times less potent than GW0742. The least potent compound was KAT-050713 with
the addition of a meta-CH2OH substituent on the phenyl ring where the linkers were the same as
that of KAT-031513. It was approximately 18,000 times less potent than GW0742 suggesting that
hydrogen bond donor and acceptor moieties are not favorable for PPARδ binding.
The SAR study of GW0742 analogs has given us some inside in the structural requirements
for successful GW0742 ligands. In addition, structural elements have been identified that
significantly reduced the ability of ligands to activate PPARδ-mediated transcription. These
ligands are summarized in Table 10 with EC50 values higher than 1 µM.
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Table 10. Compounds that showed an activation of PPARδ greater than
1μM.
Entry
NCGC00319071-05
NCGC00319064-01
NCGC00319047-01
NCGC00319036-01
NCGC00319054-01
NCGC00319151-01
NCGC00319150-01
NCGC00319082-01
NCGC00319077-01
NCGC00319153-01
NCGC00344928-01
NCGC00344930-01
NCGC00319073-01
NCGC00319076-01
NCGC00319068-01
NCGC00319170-01
NCGC00319155-01
NCGC00319173-01
NCGC00319164-01
NCGC00319149-01
NCGC00319157-01
NCGC00319156-01
NCGC00319152-01
NCGC00319158-01
NCGC00344919-01
NCGC00319053-01
NCGC00319049-01
NCGC00319052-01
NCGC00319169-01
NCGC00319072-01
KAT050713

VDR-SRC2-3 interaction
(IC50) μMa
40.11± 9.26
32.27± 5.28
45.18± 5.65
>100
>100
30.28± 4.5
52.03± 12.79
9.088± 0.982
>10
53.53± 15.95
40.28± 8.07
14.47±2.21
43.88± 8.54
20.19± 1.89
>100
68.79± 13.04
>100
>100
>100
57.78± 8.69
15.07± 11.79
>100
>100
51.14± 5.55
28.93± 4.69
47.45± 6.61
24.5± 2.27
48.82± 6.56
>100
>100
inactive

a

VDR transcription
IC50 (μM)b
inactive
31.5± 9.1
31.4± 8.1
25.1± 10.0
>100
inactive
>100
15.0± 4.7
>50
23.7± 4.7
33.0 ± 7.2
>50
inactive
26.3±0 8.3
>100
>50
>50
>100
inactive
inactive
>50
inactive
>100
inactive
inactive
38.2± 8.6
19.0± 6.01
26.3± 6.9
24.5 ± 6.1
inactive
inactive

VDR-LBD concentration used was 0.1µM. Inhibition of VDR-SRC2-3 interaction in the
presence of LG190178 (0.75 µM). The maximum concentration used for this assay was
300 μM of each compound; bTranscription assay using a CMV-VDR plasmid and a
luciferase reporter plasmid under control of a 24-hydroxylase promoter with GW0742
analogs. The maximum concentration used for this assay was 100 μM of each
compound. Data were analyzed using a nonlinear regression with a variable slope
(GraphPad Prism).
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Subsequently, a fluorescence polarization assay employing VDR and an Alexa Fluor 647
labeled SRC2-3 peptide was used to determine the ability of these compound to inhibit the
interaction between VDR and coregulators. Inhibition of VDR-mediated transcription was
evaluated in HEK293T cells in the presence of VDR ligand 1,25(OH)2D3. None of the GW0742
analogs exhibited nanomolar activity in the VDR FP assay or the transcription assay thus
selectivity towards VDR was not achieved. In addition, we found large differences for some
compounds in regards to their activity determined in the biochemical and cell-based assay
indicating the involvement of other mechanism. GW0742 is able inhibit VDR-coregulators
interactions in the FP-assay at 7.73 µM and in the cell-based assays at 12.7 µM. NCGC0031908201 bearing two trifluormethyl groups at the meta and para position of the phenyl ring exhibited
similar activity towards VDR although its ability to activate PPARδ is more than 300-fold less than
GW0742. Thus is seems that region II of PPARδ consisting of V305, V312, and V245 is less
accommodating to larger groups perpendicular to the molecule axis than VDR. Compounds
NCGC00319049-01 and NCGC00319076-01 are similar in this respect bearing a meta positioned
trifluormethyl group and naphthalene group, respectively. As depicted in Figure 42A, the
naphthalene group of NCGC00319076-01 is accommodated in what would be region I of PPARδ.
This conformation is stabilized further by pi bond interactions between His397 and His 305 and
the naphthalene ring. In Figure 42B, the naphthalene ring is forced into region II of PPARδ pocket
thus forcing it into a sterically unfavorable conformation with residues like Val305.
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A

B

Figure 42. Docked in green is compound NCGC00319076. A)
VDR LBP co-crystallized with 1,25(OH)2D3 (pink) (PDB: 1DBI)8.
B) PPARδ LBP co-crystallized with GW0742 (pink) (PDB: 3TKM).
Region I, II, and III are shown in yellow, green and orange,
respectively.
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3.3.3 Conclusion
The synthesis of analogs of GW0742 established a good SAR for the activation of PPARδ.
Substituents such as CF3, OCF3 and CO2CH2CH3 in the para-position of the GW scaffold were
important for high activity suggesting a balance between hydrophobicity and electron density for
successful interaction PPARδ. Additional aromatic substituents had a significant impact on the
activity, with fluorine and chlorine substituents in the meta position being the most favorable.
An attempt to substitute the phenyl ring with other heterocyclic groups did not yield in better
ligands, however the results provided an insight of the size and tolerance of region III of PPARδ.
The screen of the least active PPARδ ligands with VDR did not result in a clear SAR towards VDR
binding. However a weak correlation between PPARδ and VDR binding was observed as depicted
in Figure 43, when log of PPARδ EC50 (µM) was plotted against the log of VDR IC50 (µM). It was
evident that when making a potent VDR inhibitor it often resulted in a potent PPARδ agonist.

PPARδ vs VDR
PPARδ LOG(EC50) (μM)

3
2
1
0
-1

0

0.5

1

1.5

2

-2

-3

VDR LOG(IC50) (μM)

Figure 43. Log PPARδ EC50 (µM) was plotted against Log VDR IC50 (µM) to demonstrate the
selectivity and potency of GW0742 analogs tested. GW0742 is highlighted in pink.
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Unfortunately, most compounds exhibited poor inhibition of VDR, while still activating PPARδ in
the sub-micromolar range or better as seen in the bottom right quadrant of the plot. Overall, we
produced many potent PPARδ agonist that could be evaluated in PPARδ-related diseases such as
obesity. Future experiments are ongoing in collaboration with Prof. Silvaggi here at UWM by
attempting to co-crystallize any of the GW0742 analogs with VDR. With the crystal structure,
computer based rational design could be used to develop a more potent and selective inhibitor
of VDR based on the GW0742 scaffold.

Part 3: Development of Oxazole-Substituted GW0742 Analogs and Their
Effect on Nuclear Receptor Mediated Transcription
3.1. Purpose
To improve the potency and selectivity of the GW0742-based VDRcoactivator inhibitors,
we substituted the thiazole moiety with an oxazole, because GlaxoSmithKline reported that
compound 7f had low activity towards all isoforms of PPAR (Table 11). In addition, our previous

Table 11. Binding data reported by GlaxoSmithKline for compound 7f.

a

Cmpd

PPARα EC50 (µM)a

7f

Inactive

PPARγ EC50 (µM)a

PPARδ EC50 (µM)a

PPARδ IC50 (µM)b

Inactive

5.9 ± 5.5

5.5± 0.28

b

Cell-based transactivation assay and binding assay against human PPAR receptors.

study showed that GW0742 analogs with methoxy substitution such as o-OCH3 (VDR IC50= 31.4 ±
8.11 µM, PPARδ EC50= 2.25± 0.69 µM) and m-OCH3 (VDR IC50= 26.3± 6.93 µM, PPARδ EC50= 2.36±
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0.67 µM) had relatively good VDR activity and poor PPARδ activity. Docking studies with an
oxazole analog containing a m-OCH3 substituted phenyl ring revealed that this shorter and more
ridged molecule was unable to bind His413 and His287 but rather Tyr437 and His287 (Figure 44).
A

B

Figure 44. Virtual docking with PPARδ co-crystallized with GW0742 (PBD: 3TKM) were used
to visualize the affects an oxazole substitution would have on binding. A) GW0742 analog
containing an oxazole (lime green) overlaid GW0742 (pink). Hydrogen bonding is shown in
black dashes and hydrogen pi bonds are shown in yellow. B) A 2D depiction of the interactions
GW0742 (red) and GW0742 oxazole analog (lime green) have with PPARδ LBP.

Furthermore, the molecule did not reach as deeply into the pocket of region III, thus making less
hydrophobic interactions. Within Part 3, we report the synthesis of the ortho and meta methoxy
GW0742 oxazole analogs, which were evaluated using both biochemical and cell-based assays to
determine their affinity and selectivity towards VDR and PPARδ. In addition to the acids, the
corresponding methyl esters of the acids were studied. Furthermore, a solubility assay and a
permeability assay were utilized to characterize both the ester and acid forms of the GW0742
derived oxazoles.
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3.2 Chemistry
3.2.1. Synthetic Strategy
The formation of the oxazole ring was accomplished through a modified Hantzch reaction,
where either 2- or 3-methoxybenzamide was reacted with ethyl 2-chloroacetoacetate (Scheme
5, i).159, 160 The mechanism for the modified Hantzch reaction begins with a nucleophilic attack,

Scheme 5. Synthesis of GW0742-based analogs with an oxazole subsitituion. i)
Ethyl-2-chloro acetoacetate, neat, 120-125oC, 3 days; i) LiAlH4, THF, 0oC to room
temperature, 3 hours; iii) a) SOCl2, DCM, 1-2 hours, b) Cs2CO3, DMF, phenol; iv) a)
THF, 2M NaOH aq., 40-70oC, overnight, b) HCl.

loss of HCl and the formation of an imine. Cyclization occurs with the nitrogen on the imine
attacking the acetyl carbonyl (Figure 45). A loss of water affords the final oxazole product.
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Figure 45. Mechanism for a modified Hantzch reaction.

LiAlH4 was used to produce the corresponding primary alcohols, which were converted
into chlorides using thionyl chloride. Subsequent coupling of different phenols afforded the
corresponding esters, which were hydrolyzed in the presence of NaOH to yield the final carboxylic
acids.

3.2.2 Characterization
All starting materials were purchased either from Sigma-Aldrich or Fisher Scientific
without further purification. Anhydrous solvents were purchased in sure-seal bottles and
handled under dry conditions using syringe technique. All glassware was dried overnight at 100 oC
before use. Thin layer chromatography was performed on pre-coated silica gel 60 F254 plates
(Fisher Scientific). Synthesized compounds were purified by normal phase flash chromatography
(SPI Biotage, silica gel 230-400 mesh) and concentrated under vacuum. All pure compounds were
stored at -20oC. Compound characterization was performed using a Shimadzu 2020 LC-MS (single
quadrupole) instrument with compounds directly injected. NMR spectra were recorded on a
Bruker 300MHz instrument with samples diluted in either CDCl3 or DMSO- D6.
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General Procedure for Hantzsch Reaction: To substituted benzamide (29.6 mmols), ethyl-2chloro acetoacetate (148 mmols, 5 equiv.) was added. The solution was stirred neat at 120-125°C
for 48-72hrs or until the disappearance of the benzamide on TLC using EtOAc-hexanes (4:1, v/v).
To remove any unreacted ethyl-2-chloro acetoacetate, the resulting orange-yellow solution was
subjected to vacuum distillation (60°C, 1.8 mbar) followed by purification on silica gel with EtOAchexanes (2-35% strong) using a normal phase flash chromatography system.
JWB071813 66 % yield; 1H-NMR (300 MHz) (CDCl3) δ 7.76-7.73 (d,
1H, J=9.0 Hz), 7.65 (s, 1H), 7.43-7.38 (t, 1H, J=8 Hz), 7.06 (d, 1H), 4.474.40 (q, 2H, J=7 Hz)), 3.91 (s, 3H), 2.57 (s, 3H), 1.46-1.42 (t, 3H, J=6 Hz); 13C-NMR δ 162.1, 159.8,
158.8, 146.9, 137.4, 130.0, 127.6, 120.3, 118.2, 111.5, 61.1, 55.5, 14.4, 13.51. MS DUIS calcd.
m/z for C14H15NO4 [(M)] 261.3, found [(M+H)+] 262.4 .
JWB080513-1 50% yield; 1H-NMR (300 MHz) (CDCl3) δ 8.04-8.01 (d,
1H, J= 9 Hz), 7.51-7.45 (t, 1H, J= 9 Hz), 7.09-7.03 (t, 2H, J= 9 Hz), 4.454.38 (q, 2H, J=8 Hz), 3.99 (s, 3H), 2.58 (s, 3H), 2.18 (s, 2H), 1.45-1.40 (t,
3H, J= 8 Hz); 13C-NMR δ 161.0, 159.0, 158.2, 146.7, 137.0, 132.9, 130.9, 120.7, 115.4, 112.0, 61.0,
56.2, 14.4, 13.5. MS DUIS calcd. m/z for C14H15NO4 [(M)] 261.3, found [(M+H)+] 262.4.
JWB080513-2 30% yield; 1H-NMR (300 MHz) (CDCl3) δ8.04-8.02 ( d, 1H,
J=), 7.87-7.84 ( d, 1H, 7.71-7.62,

13C-NMR δ160.0, 158.6, 146.6, 138.6,

131.8, 131.7, 131.0, 129.6-128.3 (m, fluorine coupling), 127.0-126.90 (m, fluorine coupling),
125.3, 121.5, 61.2, 14.2, 13.4.
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KAT090513 40% yield; 1H-NMR (300 MHz) (CDCl3) δ 8.10-8.08 (d, 1H,
J= 6 Hz), 7.58-7.56 (d, 1H, J= 6 Hz), 7.42-7.32 (m, 2H), 4.46-4.39 (q, 2H,
J= 7 Hz), 2.73 (s, 3H), 2.58 (s, 3H), 1.46-1.41 (t, 3H, J= 7.5 Hz) ; 13C-NMR δ 162.8, 159.0, 146.68,
138.3, 131.7, 131.6, 129.6, 127.2, 126.1, 125.6, 61.0, 21.9, 14.4, 13.6; MS DUIS (+ve) calcd. m/z
for C14H15NO3 [(M)] 245.3, found [(M+H)+] 246.4.
JWB072413 30% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.96 (s, 1H), 7.957.92 (d, 1H, J=9 Hz), 7.40-7.31 (m, 2H), 4.46-4.39 (q, 2H, J=7 Hz), 2.55
(s, 3H), 2.43 (s, 3H), 1.43-1.41 (t, 3H, J= ;

13C-NMR

128.8, 127.6, 126.2, 124.8, 61.1, 21.3, 14.7, 13.5.

δ 162.9, 158.9, 147.0, 138.7, 137.3, 132.1,
13C-NMR

δ. MS DUIS (+ve) calcd. m/z for

C14H15NO3 [(M)] 245.3, found [(M+H)+] 246.4.
General Procedure for Reduction of Ester: LiAlH4 (22.8 mmol, 2.5 eq) was slowly dissolved in dry
THF (75mL) on ice. The appropriate oxazole ester, 1a or 2a, (9.12 mmol) was dissolved in dry THF
(75mL) and added dropwise to the LiAlH4. After addition was complete, the reaction was warmed
to room temperature and stirred for 2.5 hours or until the disappearance of the starting material.
The reaction was monitored by TLC using Hexanes-EtOAc (4:1, v/v). 3M HCl was added dropwise
(pH= 1-2) to make a cloudy white solution. The solution was diluted in EtOAc and washed with
brine and water, dried over anhydrous MgSO4 and concentrated in vacuo to give a white solid.
No further purification was needed.
JWB072213 100% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.61-7.59 (d, 1H,
J= 6.0 Hz), 7.54 (s, 1H), 7.37-7.32 (t, 1H, J= 7.0 Hz), 7.01-6.89 (d, 1H, J=
6.0 Hz), 4.69 (s, 2H), 3.87 (s, 3H), 2.23 (s, 3H);
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13C-NMR

δ 160.5, 159.9,

145.7, 134.8, 129.9, 128.2, 118.8, 117.2, 110.7, 55.4, 54.2, 11.4; MS DUIS (+ve) calcd. m/z for
C12H13NO3 [(M)] 219.2, found [(M+H)+] 220.4.
JWB082113-2 40% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.84-7.82 (d, 1H,
J= 6 ), 7.36-7.33 (t, 1H, J= 7.5), 6.99-6.94 (m, 2H), 4.60 (s, 2H), 3.88 (s, 3H),
2.13 (s, 3H);

13C-NMR

δ 158.8, 157.4, 145.4, 134.5, 131.6, 130.2, 120.6,

116.4, 111.8, 55.9, 53.9, 11.25; MS DUIS (+ve) calcd. m/z for C12H13NO3 [(M)] 219.2, found
[(M+H)+] 220.4
JWB080713 100% yield; 1H-NMR (300 MHz) (CDCl3) δ 8.01-7.98 (d, 1H, J=9
Hz), 7.83-7.80 (d, 1H, J= 9 Hz), 7.67-7.56 (m, 2H), 4.71 (s, 2H), 2.28 (s, 3H);
13C-NMR

δ 159.1, 147.6, 135.6, 132.6, 132.1, 131.0, 129.3, 128.7, 127.6,

127.5, 54.6, 11.7; MS DUIS (+ve) calcd. m/z for C12H8F3NO3 [(M)] 257.2, found [(M+H)+] 258.4
KAT092613 92% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.98-7.95 (d, 1H, J=
9), 7.35-7.30 (m, 4H), 4.73 (s, 2H), 2.69 (s, 3H), 2.29 (s, 3H);

13C-NMR

δ

161.1, 145.1, 137.3, 134.6, 131.5, 129.9, 128.9, 126.5 125.9, 54.2, 21.8, 11.4; MS DUIS (+ve) calcd.
m/z for C12H11NO3 [(M)] 203.2, found [(M+H)+] 204.4
JWB082113-1 40% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.84 (s, 1H), 7.817.79 (d, 1H, J=6 Hz), 7.35-7.24 (m, 2H), 4.68 (s, 2H), 2.40 (s, 3H), 2.22 (s,
3H);

13C-NMR

δ 160.7, 145.7, 138.5, 134.5, 131.2, 128.6, 127.0, 126.8, 123.4, 53.8, 21.3, 11.2;

MS DUIS (+ve) calcd. m/z for C12H11NO3 [(M)] 203.2, found [(M+H)+] 204.4
General Procedure for Chlorination and Coupling Reaction: The appropriate reduced oxazole
(0.739 mmol) was mixed with thionyl chloride (3.69 mmol, 5 equiv.) in dry DCM (5mL). The
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reaction was stirred at room temperature and monitored by TLC using EtOAc-Hexanes (3:2, v/v)
for an hour or until completion. The reaction vessels were dried under vacuum to remove DCM.
The crude product was used for the next reaction without purification. Phenol (0.738 mmol, 1
equiv.) and Cs2CO3 (1.48 mmol, 2 equiv.) were mixed in dry DMF (5mL) and stirred at room
temperature for 30 minutes. A notable yellow color was observed after 30 minutes. The chloro
oxazole in dry DMF (5mL) was added and the reaction was stirred at room temperature overnight.
The reaction was monitored by TLC using EtOAc-hexanes (3:2, v/v). Once complete, the reaction
was quenched by the slow addition of a saturated NaHCO3 solution until carbon dioxide
formation ceased followed by the extraction with EtOAc. The organic layer was dried over MgSO4
and concentrated in vacuo to obtain a yellow oil. The oil was further purified on silica gel with
hexanes- EtOAc (2-70%, strong) using a normal phase flash chromatography system.
KAT092013-1 57% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.91-7.89 (d,
1H, J= 6 Hz), 7.79-7.76 (d, 1H, J= 9Hz), 7.45-7.35 (m, 2H), 7.12-7.09
(d, 1H, J= 9), 7.04-6.97 (m, 3H), 5.15 (s, 2H), 3.91 (s, 3H), 3.82 (s, 3H),
2.25 (s, 3H); 13C NMR δ 166.6, 159.4, 157.6, 157.5, 141.5, 137.0, 133.3, 131.9, 131.6, 130.3, 121.9,
121.6, 120.5, 116.3, 115.9, 111.81, 61.6, 56.0, 52.1, 11.6; MS DUIS (+ve) calcd. m/z for C20H19NO4
[(M)] 353.2, found [(M+1)+] 354.4.
KAT092313-2 20% yield; 1H-NMR (300 MHz) (CDCl3) δ 8.04-8.01
(d, 2H, J= 9Hz), 7.93-7.91 (d, 1H, J=6 Hz), 7.45-7.39 (t, 1H, J= 7.5
Hz), 7.06-7.00 (t, 4H, J=9 Hz), 5.13 (s, 2H), 3.95 (s, 3H), 3.89 (s,
3H), 2.32 (s, 3H) ; 13C NMR δ 170.1, 166.7, 162.0, 159.7, 157.6, 141.1, 137.2, 131.9, 131.6, 130.4,
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123.2, 120.6, 116.6, 114.5, 111.9, 59.6, 56.0, 51.9, 11.7 ; MS DUIS (+ve) calcd. m/z for C20H19NO4
[(M)] 353.2, found [(M+1)+] 354.4.
KAT092413-3 51% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.93-7.90
(d, 1H, J=9Hz), 7.68 (s, 1H), 7.65 (s, 1H), 7.42-7.31 (m, 2H), 7.197.16 (d, 1H, J= 9Hz), 7.03-6.97 (t, 2H, J= 9Hz), 5.11 (s, 2H), 3.91
(s, 3H), 3.89 (s, 3H), 2.31 (s, 3H).

13C

NMR δ 166.75, 159.6, 158.2, 157.6, 141.31, 137.0, 131.8,

131.5, 130.3, 129.5, 122.7, 120.6, 120.5, 116.3, 115.1, 111.8, 60.4, 59.7, 56.0, 52.2, 11.65; MS
DUIS (+ve) calcd. m/z for C20H19NO4 [(M)] 353.2, found [(M+1)+] 354.4.
KAT092513-4 20% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.94-7.92
(d, 1H, J= 6Hz), 7.46-7.40 (t, 1H, J= 9Hz), 7.25-7.22 (d, 2H, J=
9Hz), 7.07-6.97 (m, 4H), 5.08 (s, 2H), 3.95 (s, 3H), 3.70 (s, 3H),
3.59 (s, 2H), 2.31 (s, 3H); 13C NMR δ 172.3, 159.5, 157.6, 157.5, 141.7, 126.8, 131.8, 131.8, 130.4,
126.9, 120.6, 116.4, 115.2, 111.9, 59.8, 56.1, 52.0, 40.3, 11.7 ; MS DUIS (+ve) calcd. m/z for
C21H21NO5 [(M)] 367.4, found [(M+H)+] 368.5.
KAT092513-5 22% yield; 1H-NMR (300 MHz) (CDCl3) δ 8.14
(d, 1H), 7.46-7.40 (t, 1H, J= 9Hz), 7.17-7.14 (d, 2H, J= 9Hz),
7.07-7.02 (t, 2H, J= 7.5Hz), 6.97-6.94 (d, 2H, J= 9Hz), 5.06
(s, 2H), 3.96 (s, 3H), 3.68 (s, 3H), 2.95-2.90 (t, 2H, J= 7.5Hz), 2.65-2.60 (t, 2H, J= 7.5Hz), 2.31 (s,
3H); 13C NMR δ 173.6, 159.5, 157.6, 156.8, 141.8, 136.7, 133.5, 131.8, 130.4, 129.3, 120.6, 116.4,
115.2, 111.9, 59.8, 56.1, 51.6, 35.9, 30.1, 11.6; MS DUIS (+ve) calcd. m/z for C22H23NO5 [(M)] 381.4,
found [(M+H)+] 382.4.
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JWB091313-1 42% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.83-7.81
(d, 1H, J= 6Hz), 7.65-7.63 (d, 1H, J= 6Hz), 7.57 (s, 1H), 7.52-7.47 (t,
1H, J= 7.5 Hz), 7.40-7.34 (t, 1H, J= 9Hz), 7.14-7.07 (m, 2H), 7.037.00 (d, 2H, J= 9Hz), 5.19 (s, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 2.26 (s, 3H); 13C NMR δ166.6, 160.9,
159.8, 157.5, 141.9, 137.3, 133.4, 131.7, 129.9, 128.4, 122.1, 121.8, 118.8, 117.1, 116.0, 110.8,
61.6, 55.4, 52.1, 36.4, 31.4, 11.5; MS DUIS (+ve) calcd. m/z for C20H19NO5 [(M)] 353.4, found
[(M+H)+] 354.4.
JWB091313-2 66% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.72 (s,
1H), 7.70 (s, 1H), 7.66-7.63 (d, 1H, J= 9Hz), 7.57 (s, 1H), 7.42-7.34
(q, 2H, J= 8Hz), 7.22- 7.19 (d, 1H, J= 9Hz), 7.02-7.00 (d, 1H, J=
6Hz), 5.14 (s, 2H), 3.94 (s, 3H), 3.88 (s, 3H), 2.32 (s, 3H); 13C NMR δ 166.7, 161.0, 159.8, 158.1,
144.8, 137.3, 131.5, 129.8, 129.6, 128.3, 122.8, 120.6, 119.7, 119.4, 117.1, 114.8, 110.8, 59.6,
52.2, 11.6. MS DUIS (+ve) calcd. m/z for C20H19NO5 [(M)] 353.4, found [(M+H)+] 354.4.
JWB091313-3 38% yield; 1H-NMR (300 MHz) (CDCl3) δ 8.078.04 (d, 2H, J= 9Hz), 7,67- 7.64 (d, 1H, J=9Hz), 7.60 (s, 1H),
7.41-7.35 (t, 1H, J= 9Hz), 7.07-7.04 (d, 1H, J= 9Hz), 7.01 (s, 1H),
5.14 (s, 2H), 3.92 (s, 3H), 3.90 (s, 3H), 2.33 (s, 3H); 13C NMR δ 166.7, 161.9, 161.2, 159.9, 141.5,
137.5, 137.5, 131.7, 129.9, 128.3, 123.4, 118.9, 117.3, 114.4, 110.9, 59.5, 55.45, 51.9, 11.64; MS
DUIS (+ve) calcd. m/z for C20H19NO5 [(M)] 353.4, found [(M+H)+] 354.4.
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JWB091313-4 57% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.637.61 (d, 1H, J= 6Hz), 7.56 (s, 1H), 7.35-7.30 (t, 1H, J= 7.5Hz),
7.23- 7.21 (d, 2H, 6Hz), 6.99 (s, 1H), 6.97-6.94 (d, 2H, J= 9Hz),
5.02 (s, 2H), 3.82 (s, 3H), 3.67 (s, 3H), 3.57 (s, 2H) 2.26 (s, 3H);
13C

NMR δ 172.3, 161.0, 159.9, 157.3, 142.2, 137.0, 130.4, 128.3, 127.1, 119.4, 118.9, 117.2,

110.8, 59.6, 55.4, 52.0, 40.3, 36.5, 11.5; MS DUIS (+ve) calcd. m/z for C21H21NO5 [(M)] 367.4, found
[(M+H)+] 468.5.
JWB091313-5 33% yield; 1H-NMR (300 MHz) (CDCl3)

δ

7.65-7.63 (d, 1H, J= 6Hz), 7.58 (s, 1H), 7.39-7.34 (t, 1H, J=
7.5Hz), 7.18-7.15 (d, 2H, J= 9Hz), 7.02-7.00 (d, 1H, J= 6Hz),
6.96-6.93 (d, 2H, J= 9Hz), 5.05 (s, 2H), 3.88 (s, 3H), 3.68 (s,
3H), 2.95-2.90 (t, 2H, J= 7.5Hz), 2.65-2.60 (t, 2H, J= 7.5Hz), 2.29 (s, 3H); MS (ESI+) calcd. m/z for
C22H23NO5 [(M)] 381.4, found [(M+H)+] 382.5.
General Procedure for Saponifcation: The appropriate thiazole ester (0.06mmol) was dissolved
in THF (3mL) and adjusted to pH= 9-10 with 2M NaOH. The reaction was stirred at room
temperature overnight and monitored by TLC using EtOAc-Hexanes with 1% acetic acid (4:1, v/v).
Acids that did not convert at room temperature were heated between 40oC-70oC and stirred for
an additional 12 hours. Once the reaction was complete, THF was removed under reduced
pressure and the left over residue was resuspended in water (5mL) and acidified with 2M HCl
until pH=2. More water (5 mL) was added and the product was extracted with EtOAc (10 mL x
3). The organic layers were combined, dried over MgSO4 and concentrated in vacuo to obtain
white-cream colored solids. No further purification steps were taken.
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KAT120413-1 100% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.81-7.79
(d, 1H, J= 6Hz), 7.65-7.62 (d, 1H, J= 9Hz), 7.56-7.48 (q, 2H, J= 8Hz),
7.32-7.30 (d, 1H, J= 6Hz), 7.21-7.18 (d, 1H, J=9 Hz), 7.09-7.04 (t, 2H,
J= 7.5Hz), 5.25 (s, 2H), 3.85 (s, 3H), 2.2 (s, 3H13CDEPT-135 NMR δ Negative (-): CH2: 52.8 Positive
(+): CH3, CH: 136.2, 131.2, 130.7, 121.0, 119.7, 117.6, 56.3, 11.5 ; MS (ESI+) calcd. m/z for
C19H17NO5 [(M)] 339.4, found [(M+H)+] 340.0.
KAT101013-2 82% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.947.91 (d, 2H, J= 9Hz), 7.82-7.80 (d, 1H, J= 6Hz), 7.53- 7.48 (t,
1H, J= 7.5Hz), 7.21-7.18 (d, 1H, J= 9Hz), 7.17 (s, 1H), 7.14 (s,
1H), 7.09-7.04 (t, 1H, J= 7.5Hz), 5.28 (s, 2H), 3.85 (s, 3H), 2.24 (s, 3H); 13C NMR δ 167.4, 161.9,
159.5, 157.7, 143.2, 137.0, 132.7, 131.8, 130.5, 124.0, 121.0, 116.2, 115.2, 113.1, 59.6, 56.3, 11.6;
13CDEPT-135

δ Negative (-): 132.7, 131.8, 130.5, 121.0, 115.2, 113.1, , 56.3, 11.6, Positive (+):

59.4; MS DUIS (+ve) calcd. m/z for C19H17NO5 [(M)] 339.4, found [(M+H)+] 340.0.
KAT101013-3 100% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.82-7.79
(d, 1H, J= 9Hz), 7.60 (s, 2H), 7.53-7.42 (m, 2H), 7.32-7.29 (d, 1H,
J= 9Hz), 7.21-7.18 (d, 1H, J= 9Hz), 7.08-7.03 (t, 1H, 7.5Hz), 5.26
(s, 2H), 3.84 (s, 3H), 2.24 (s, 3H).

13C NMR δ 167.5, 159.5, 158.3, 157.7, 142.5, 136.8, 132.7, 132.7,

130.5, 130.2, 122.6, 121.0, 120.5, 116.3, 115.5, 113.1, 59.5, 56.3, 11.6;

13CDEPT-135

NMR δ

Negative (-): CH2: 59.6, Positive (+): CH3, CH: 132.7, 130.5, 130.1, 122.6, 121.0, 120.5, 115.5, 113,
56.3, 11.5; MS DUIS (+ve) calcd. m/z for C19H17NO5 [(M)] 339.4, found [(M-H)-] 338.0.
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KAT101013-4 100% yield; 1H-NMR (300 MHz) (CDCl3) δ 12.24 (s,
1H), 7.83-7.79 (d, 1H, J= 9Hz), 7.53-7.48 (t, 1H, J= 7.5Hz), 7.096.99 (m, 3H), 5.15 (s, 2H), 3.85 (s, 3H), 3.51 (s, 2H), 2.51 (m, 2H,
DMSO residual peak overlaps), 2.22 (s, 3H); 13C NMR δ 173.29, 159.37, 157.64, 157.12, 142.76,
136.56, 132.60, 130.87, 130.46, 128.13, 120.99, 116.33, 115.23, 113.06, 59.37, 56.28, 11.58;
13CDEPT-135

NMR δ Negative (-): CH2: 59.25, 40.14, Positive (+): CH3, CH: 132.60, 130.87, 130.15,

120.85, 115.12, 113.05, 56.11, 11.55; MS DUIS (+ve) calcd. m/z for C20H19NO5 [(M)] 353.4, found
[(M-H)-] 352.4.
KAT100313-5 100% yield; 1H-NMR (300 MHz) (CDCl3) δ
12.09 (s, 1H), 7.82-7.79 (d, 1H, J= 9Hz), 7.53-7.47 (t, 1H, J=
9Hz), 7.21-7.16 (t, 3H, J= 7.5Hz), 7.09-7.04 (t, 1H, J= 7.5Hz),
6.98-6.95 (d, 2H, J= 9Hz), 5.13 (s, 2H), 3.85 (s, 3H), 2.79-2.74 (t, 2H, J= 7.5Hz), 2.51 (m, 2H, DMSO
residual peak overlaps), 2.21 (s, 3H); 13C NMR δ 174.2, 159.3, 157.6, 156.7, 142.8, 136.5, 133.9,
132.6, 130.5, 129.7, 121.0, 116.4, 115.3, 113.05, 59.3, 56.3, 36.0, 30.0, 11.6; 13CDEPT-135 NMR δ
Negative (-): CH2: 59.4, 36.3, 30.1, Positive (+): 132.6, 130.5, 129.7, 121.0, 115.3, 113.1, 56.3,
11.6; MS DUIS (+ve) calcd. m/z for C21H21NO5 [(M)] 367.4, found [(M-H)- 366.4.
JWB111913-1 79% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.65-7.63
(d, 1H, J= 6Hz), 7.56-7.42 (m, 4H), 7.33-7.30 (d, 1H, J= 9Hz), 7.127.07 (m, 2H), 5.28 (s, 2H), 3.83 (s, 3H), 2.21 (s, 3H) ; MS DUIS (-ve)
calcd. m/z for C19H17NO5 [(M)] 339.1, found [(M-H)-] 338.4.
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JWB111913-2 100% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.637.54 (m, 3H), 7.47-7.41 (m, 3H), 7.29 (d, 1H, J= 6Hz), 7.10-7.01
(d, 1H, J= 6Hz), 5.29 (s, 2H), 3.83 (s, 3H), 2.25 (s, 3H); MS DUIS
(-ve) calcd. m/z for C19H17NO5 [(M)] 339.1, found [(M-H)-] 338.4.
JWB111913-3 100% yield; 1H-NMR (300 MHz) (CDCl3) δ 7.947.91 (d, 2H, J= 9Hz), 7.56-7.54 (d, 1H, J= 6Hz), 7.48-7.42 (t, 2H,
J= 9Hz), 7.17-7.14 (d, 2H, J= 9Hz), 7.12-7.10 (d, 1H, J= 6Hz),
5.31 (s, 2H), 3.83 (s, 3H), 2.26 (s, 3H); MS DUIS (+ve) calcd. m/z for C19H17NO5 [(M)] 339.1, found
[(M+H)+] 340.4.
JWB111913-4 100% yield; 1H-NMR (300 MHz) (CDCl3) δ
7.56-7.53 (d, 1H, J= 9Hz), 7.47-7.42 (t, 2H, J= 7.5Hz), 7.227.19 (d, 2H, J= 9Hz), 7.12-7.09 (d, 1H, J= 9Hz), 7.02-6.99 (d,
2H, J= 9Hz), 5.18 (s, 2H), 3.83 (s, 3H), 2.51 (m, 2H, DMSO residual peak overlaps), 2.23 (s, 3H); δ
MS DUIS (+ve) calcd. m/z for C20H19NO5 [(M)] 353.1, found [(M+H)+] 354.4.
JWB111913-5 100% yield; 1H-NMR (300 MHz) (CDCl3) δ
7.66-7.63 (d, 2H, J= 9Hz), 7.58 (s, 1H) 7.40-7.34 (t, 1H, J=
9Hz), 7.20-7.17 (d, 1H, 9Hz), 7.03-7.00 (d, 2H, J= 9Hz),
6.97-6.94 (d, 2H, J= 9Hz), 5.06 (s, 2H), 3.89 (s, 3H), 2.972.86 (m, 2H), 2.70-2.65 (m, 2H), 2.29 (s, 3H); δ MS DUIS (-ve) calcd. m/z for C21H21NO5 [(M)] 367.4,
found [(M-H)-] 366.4.
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3.3 Determining the Binding Between VDR and Coactivator in the Presence
of Oxazole-Substituted GW0742 Analogs
The binding data obtained for both the ortho- and meta- methoxy GW0742 oxazole
analogs (o-OCH3 and m-OCH3) are summarized in Table 12 and 13. This includes methyl esters as
Table 12. Modulation of VDR-Coactivator binding in the presence of ortho-methoxy
phenyl oxazole-based GW0742 analogs.
Compound
KAT092013-1
KAT092313-2
KAT092413-3
KAT092513-4
KAT092513-5
KAT120413-1
KAT101013-2
KAT101013-3
KAT100313-4
KAT101013-5

Recruitment of SRC2-3 VDR
Interaction EC50 (μM)
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive

Inhibition of SRC2-3 VDR
Interaction IC50 (μM)
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive

The maximum concentration used for this assay was 300 μM of each compound.

Table 13. Modulation of VDR-Coactivator binding in the presence of metamethoxy phenyl oxazole-based GW0742 analogs.
Compound
JWB091313-1
JWB091313-2
JWB091313-3
JWB091313-4
JWB091313-5
JWB111913-1
JWB111913-2
JWB111913-3
JWB111913-4
JWB111913-5

Recruitment of SRC2-3
VDR Interaction EC50 (μM)
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive

Inhibition of SRC2-3 VDR
Interaction IC50 (μM)
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive

The maximum concentration used for this assay was 300 μM of each compound.

well as carboxylic acids. Surprisingly, all compounds did not bind to VDR and initiate or inhibit the
interaction with coregulator peptide SRC2-3. Insufficient solubility was ruled out by the solubility
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assay reported later in this section. Changing the fluorophore attached to SRC2-3 to Texas Red
did confirm the absence of activity. An alternative commercially available assay (PolarscreenTM
VDR Competitor Assay) employing a fluorescent VDR ligand (Fluormone TM VDR Red) was
purchased from Invitrogen but unfortunately we were unable to run this assay with our Tecan
M1000 reader for unknown reasons. Currently, a coumarin-based probe is being developed in
our laboratory to enable the identification of direct ligand inhibitors of VDR. Regardless of the FP
results, the compounds were further tested for their ability to modulate transcription with
respect to VDR and PPARδ in addition to cytotoxicity in cells.

3.4 Modulation of VDR and other NR-Mediated Transcription by OxazoleSubstituted GW0742 Analogs
Upon ligand binding, nuclear receptors undergo a conformational change that can induce
recruitment of specific coactivators. In addition to the traditional two plasmid transcription
assay, a two-hybrid assay was used to study the ligand-dependent interaction between VDR and
coactivator SRC1 (Figure 46). The assay employs three plasmids. A fusion of SRC1 and a GAL4
DNA binding domain, a fusion between VDR LBD and VP16 plasmid and luciferase reporter

A

B

SRC1
GAL4
DBD
4xUAS

VDRVP16
LBD

VDRVP16
LBD
N

SRC1

Pol II

Light

GAL4
DBD
4xUAS

Luciferase gene

N
H

No Transcription
Luciferase gene

Figure 46. Cartoon describing luminescence-based 2-hybrid transcription assay. A)
Activated VDR transcribes the luciferase gene and produces light. B) In the presence of an
inhibitor, VDR is unable to transcribe the luciferase gene and produce light.
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plasmid with a 4xUAS repeat. A VDR agonist would induce the binding between VDR LBD and
SRC1 thus bringing the VP16 activation domain and GAL4 DNA domain together inducing the
transcription of the luciferase gene.

Scheme 6. Bioluminescent reaction that occurs when the luciferase enzyme is activated.

To determine if GW0742 oxazole analogs can inhibit the luciferase enzyme thus producing
a false response in the transcription assay, a luciferase binding assay was conducted using Cell
Titer-Glo™. This reagent, typically used for cell viability assays, contains already the luciferase
enzyme that produces light through a series of reactions (Scheme 6). Important for the light
reaction to occur are substrates luciferin, APT, and Mg2+. Because Cell Titer-Glo is missing ATP, it
must be added to the reaction in addition to the compounds.

3.4.1 Experimental Procedure
Luminescence-Based VDR-Mediated Transcription Assay Protocol: For complete details see
Part 1 of this chapter. In addition to VDR and PPARδ transcription assays, PPARα, PPARγ, retinoid
X receptor (RXRα), estrogen (ER, α and β isoforms) and thyroid (TR, α and β isoforms) receptor
were evaluated for inhibitory activity with four different oxazole GW0742 analogs. For each
competitive pan NR transcription assays, 2 mL of untreated DMEM containing 1.5 μg of NR
plasmid, 16 μg luciferase reporter gene, LipofectamineTM LTX (75 μl), and PLUSTM reagent (25 μl)
was added to a flask of HEK293T cells. Inhibition was determined in the presence of the following
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agonists: GW7647 (30 nM, PPARα), Rosiglitazone (300 nM, PPARγ), Bexarotene (200 nM, RXRα),
estradiol (10 nM, ERα/β) and Triiodothyronine (100 nM, TRα/β). For the VDR two-hybrid assay,
2 mL of untreated DMEM containing 5.0 μg of VP16-VDR-LBD plasmid, 4.0 μg of SRC1-GAL4
plasmid, 16 μg of a luciferase reporter plasmid, LipofectamineTM LTX (75 μl), and PLUSTM reagent
(25 μl) were added. Due to cell sensitivity to DMSO concentrations greater than or equal to 1%,
30 mM rather than 10 mM stock solutions were made allowing for only a 100 nL transfer of
compound into each well containing 20 µL of solution during the two hybrid assay.
Inhibition of Luciferase using Cell Titer Glo Assay Protocol: In a 384-well white optical bottom
plates (Nunc, #142762), 20 μL of Cell Titer-Glo™ (Promega, Madison, WI) was added to each well.
30 mM stock solutions of synthesized compounds made in DMSO were serially diluted (1:3) in
96-well plates. Four 14 μL aliquots of each compound concentration was transferred to opaque
384-well plates for storage. 100 nl of each compound was transferred to the 384-well white
optical bottom plate using the Tecan Freedom EVO liquid handling system (V&P Scientific). The
plate was incubated for 45 minutes at 37oC. After incubation, 20 μL of a 1 μM ATP solution diluted
in water was added to each well. Controls used were DMSO, DMSO and ATP, and ATP Cell TiterGlo™. Luminescence readings were performed on a Tecan Infinite M1000 plate reader.
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3.4.2 Results and Discussion
The transcriptional activity of oxazole analogs are summarized in Tables 14 and 15. None
of the analogs activate VDR-mediated transcription up to a concentration of 150 µM.
Table 14. Modulation of VDR and PPARδ transcription in the presence of orthomethoxy phenyl oxazole GW0742 analogs.
VDR
VDR
PPARδ
Cytotoxicity
Transcription
Transcription
Transcription
EC50
Compound
LD50 (µM)c
IC50 (µM)a
(µM)b
EC50 (µM)a
KAT092013-1
KAT092313-2
KAT092413-3
KAT092513-4
KAT092513-5
KAT120413-1
KAT101013-2
KAT101013-3
KAT100313-4
KAT101013-5

Inactive
Inactive
Inactive
Inactive
Inactive
>100
Inactive
Inactive
Inactive
Inactive

3.25 ± 1.4
4.85 ± 2.2
2.50 ± 1.2
3.82 ± 1.3
10.1 ± 1.7
Inactive
Inactive
Inactive
Inactive
>80

Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
8.7 ± 6.4 (16%)
0.88 ± 0.47 (22%)
11.0 ± 10.2 (48%)
4.6 ± 3.1 (30%)

Non-toxic
66.2 ± 5.4
Non-toxic
Non-toxic
50.6 ± 5.9
Non-toxic
Non-toxic
Non-toxic
Non-toxic
Non-toxic

a

Transcription assay using a CMV-VDR plasmid and a luciferase reporter plasmid under control of a 24hydroxylase promoter with GW0742-based oxazole analogs. bTranscription assay using a GALx4 PPARδ
plasmid and a luciferase reporter plasmid under control of GALx4 promoter. Percent partial agonistic
activity is shown in parenthesis. bCell- TiterGlo (Promega). The maximum concentration used was
100μM.

Interestingly, the o-OCH3 based esters were able to inhibit VDR-mediated transcription but not
activate PPARδ-mediated transcription. On the contrary, PPARδ-mediated transcription was
activated by most of the o-OCH3 derived acids without inhibiting VDR-mediated transcription.
The most potent VDR antagonist in this series was KAT092413-3 with an EC50 values of 2.5 µM
that completely lacked the ability to activated PPARδ-mediated transcription like the parent
compound GW0742.
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Table 15. Modulation of VDR and PPARδ transcription in the presence of metamethoxy phenyl oxazole GW0742 analogs.
VDR
VDR
PPARδ
Cytotoxicity
Transcription
Transcription
Transcription
EC50
Compound
LD50 (µM)c
IC50 (µM)a
(µM)b
EC50 (µM)a
JWB091313-1
JWB091313-2
JWB091313-3
JWB091313-4
JWB091313-5
JWB111913-1
JWB111913-2
JWB111913-3
JWB111913-4
JWB111913-5

Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive

6.75 ± 2.1
5.56 ± 1.9
5.67 ± 1.4
0.66 ± 0.30
2.88 ± 0.97
40.4 ± 13.4
33.2 ± 15.2
>100
3.60 ± 1.4
3.35 ± 1.5

Inactive
Inactive
Inactive
Inactive
1.09 ± 0.58 (7.7%)
Inactive
Inactive
2.62 ± 1.8 (2.1%)
1.80 ± 0.79 (8.5%)
1.39 ± 0.44 (13.7%)

48.0 ± 9.3
95.8 ± 14.7
>100
90.8 ± 12.0
>33
Non-toxic
Non-toxic
Non-toxic
Non-toxic
Non-toxic

a

Transcription assay using a CMV-VDR plasmid and a luciferase reporter plasmid under control of a 24hydroxylase promoter with GW0742-based oxazole analogs. bTranscription assay using a GALx4 PPARδ
plasmid and a luciferase reporter plasmid under control of GALx4 promoter. Percent partial agonistic
activity is shown in parenthesis. bCell- TiterGlo (Promega). The maximum concentration used was
100μM.

The series of m-OCH3 analogs showed similar trends than the o-OCH3 analogs, however the
following differences were observed. Most of the m-OCH3 esters showed a certain degrees of
toxicity, whereas only two of the o-OCH3 were slightly toxic. The m-OCH3 esters and acids were
able to inhibit VDR transcription, whereas one ester JWB091313-5 and some acids were able to
activate PPARδ-mediated transcription. The most potent VDR antagonist was JWB091313-4 with
an IC50 value of 660 nM. The compounds that activated PPARδ-mediated transcription exhibited
partial agonism as low as 2.2% in respect to agonist GW0742. In general, this partial agonism was
weaker for the m-OCH3 and for the o-OCH3 analogs.
Specificity towards a certain VDR-coactivator interaction was introduced with the twohybrid assay. The results of the ester and acid analogs for this protein-protein inhibition assay
are summarized (Table 16).
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The results of the protein-protein interaction assays were similar to the VDR transcription assay
confirming the interaction between VDR and coactivators as an essential interaction meditating
VDR transcription. The average activities of both assays differed up to three-folds but higher
standard deviations in the two hybrid assay resulted in non-significant differences between both
IC50 values in most cases.
Table 16. Modulation of VDR transcription in the presence of ortho and methamethoxy phenyl oxazole GW0742 analogs using a 2-hybrid cell assay.
2-Hybrid VDR
2-Hybrid VDR
Transcription
Transcription
Compound
Compound
IC50 (µM)
IC50 (µM)
KAT092013-1
KAT092313-2
KAT092413-3
KAT092513-4
KAT092513-5
KAT120413-1
KAT101013-2
KAT101013-3
KAT100313-4
KAT101013-5

20.2 ± 13.5
17.9 ± 7.92
7.33 ± 3.84
11.13 ± 4.9
13.6 ± 5.2
>80
>80
>100
>80
>100

JWB091313-1
JWB091313-2
JWB091313-3
JWB091313-4
JWB091313-5
JWB111913-1
JWB111913-2
JWB111913-3
JWB111913-4
JWB111913-5

15.4 ± 11.6
17.1 ± 5.2
8.89 ± 2.5
13.9 ± 11.5
6.7 ± 3.4
>33
33.14 ± 13.1
>80
27.7 ± 17.3
26.7 ± 15.8

2-Hybrid transcription assay using a CMV-VDR plasmid and a luciferase reporter plasmid under
control of a 24-hydroxylase promoter with GW0742-based oxazole analogs. The maximum
concentration used was 150μM.

The two most promising compounds from each oxazole series were chosen for further
investigation towards other nuclear receptors. These included PPARs α, γ, and δ, the RXRα, TRα
and β, and the estrogen receptors α and β (ERα and β). The results are summarized in Table 17.
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Table 17. Inhibition of transcription with an array of nuclear receptors in the presence
of KAT092413-3, KAT092513-4, JWB091313-3, and JWB091313-4 to determine
selectivity.
Compound

PPARα
IC50
(μM)a

PPARγ
IC50
(μM)b

PPARδ
IC50
(μM)c

RXRα
IC50
(μM)d

TRα
IC50
(μM)e

TRβ IC50
(μM)e

ERα
IC50
(μM)f

Erβ
IC50
(μM)f

KAT092413-3

6.6 ±
2.9

7.6 ±
3.4

10.9 ±
3.9

11.1 ±
4.6

10.1 ±
3.3

9.8 ±
2.9

5.2 ±
1.5

23.6 ±
17.2

KAT092513-4

8.0 ±
6.6

6.3 ±
3.1

6.6 ± 2.9

4.4 ±
3.1

8.4 ±
2.7

7.6 ±
4.4

4.1 ±
1.7

10.0 ±
6.4

JWB091313-3

3.5 ±
2.1

7.6 ±
3.4

10.9 ±
4.1

4.6 ±
2.6

5.4 ±
2.5

8.8 ±
3.0

4.7 ±
1.1

5.9 ±
2.8

1.9 ±
6.7 ±
11.3 ±
2.0 ±
4.2 ±
0.97 ±
1.7 ±
7.4 ±
1.3
3.0
6.8
1.7
2.2
0.82
0.96
6.3
a
GW7647 (30nM), bRosiglitazone (300nM), cGW0742 (50nM), dBexarotene (200nM), eT3 (10nM) and
f
Estradiol (10nM). The maximum concentration used was 100μM.

JWB091313-4

Interestingly, all four compounds inhibited the transcription mediated by all nuclear receptors
investigated. Minor selectivity was observed for each compound. For instance KAT092413-3 were
more effective towards ERα than ERβ, however selectivity between TR and PPAR isoforms was
marginal. Still, VDR-mediated transcription was inhibited at low concentration with an IC50 of 2.5
μM. In addition, JWB091313-4 exhibited not only selectivity between ER isoforms but also was
very selective towards PPARα in respect to PPARγ and PPARδ. Nevertheless the IC50 for VDR (0.6
μM) was still lower than that of PPARs with 1.9 μM. Triggered by the PAN activity by the four
compounds chosen, possible inhibition of the luciferase enzyme was investigated by adding ATP
and compounds to the Cell Titer GloTM assay from Promega. None of the four compounds
inhibited the formation of light as illustrated for JWB091313-3 and JWB091313-4 in Figure 47.
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Figure 47. Dose response curve showing no inhibition of the
luciferase enzyme by GW0742 oxazole derivatives

3.5 Determining Physiochemical Properties of Oxazole-based GW0742 Analogs
3.5.1 Solubility Assay
Drug solubility is defined as the amount of substance that dissolves in a given volume of
solvent at a specific temperature.161 In drug discovery, it is a physiochemical characteristic of a
molecule that influences its success as a lead compound. For instance, the bioavailability of
poorly soluble drugs is highly susceptible to food intake, active transport, and efflux. 162 In
addition, compounds with poor solubility carry a higher risk of failure during discovery and
development since it may compromise the success of biochemical and cell-based assays, induce
aggregation, and complicate formulation for in vivo studies.148 Experimentally, solubility can be
measured either thermodynamically or kinetically. Thermodynamic solubility is defined by the
addition of excess solid drug directly to an aqueous solution under constant agitation until
equilibrium is established. This assay can take several days for completion due to and slow
equilibration. Crystallinity plays an important factor for this assay thus variability in production
of solids will change its solubility. As parallel synthesis and combinatorial chemistry have
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increasingly become the most dominant methods of compound synthesis in the discovery stage
of pharmaceuticals, there is an increasing probability that the physical form of the compounds is
amorphous due to impurities and solvent residues. The non-crystalline materials will always be
more soluble than their pure counterpart.163 Therefore, early discovery stages adopted kinetic
solubility as an alternative. For this process, compounds diluted in an organic solvent (i.e. DMSO)
are added to an aqueous solution until precipitation is observed or the concentration of the
dissolved compounds becomes constant.164 The benefits of this method are that it is rapid and
requires only a small amounts of test compounds thus making it suitable for high throughput. In
general, there are two main approaches to determine kinetic solubility. The first one is done by
removing the precipitate by filtration or centrifugation followed by the determination of
compound concentrations by UV absorption or mass spectrometry. The second approach
detects the formation of precipitate by monitoring the scattering of light by particles using UV
absorbance or directly by detecting the light scattering by nephelometric turbidity detection.165
Within this section, we report the use of a miniaturized kinetic-based HTS assay for the
determination of solubility of GW0742 oxazole derivatives developed by Dr. Megan Pawlak in our
lab. Compounds tested included the ester and acid forms of the ortho and meta-methoxy
GW0742 oxazoles.

Experimental Procedure
Reagents and Instrumentation: All materials were used as they were received, with no further
purification. Five bioactive small molecules: 4,5-diphenylimidazole (Alfa Aesar), β-estradiol (Alfa
Aesar), diethylstilbestrol (Spectrum Chemicals), 3-phenylazo-2,6-diaminopyridine (Alfa Aesar)
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were used as standards. Each of the standards were made into a 10 mM solution in DMSO (Acros,
Spectroscopic Grade 99.9+%).

The buffer was prepared in 18 MΩ water with 90 mM

ethanolamine (Alfa Aesar, ACS grade 99+%), 90 mM KH2PO4 (J.T. Baker), 90 mM potassium
acetate (Fisher Biotech), and 30 mM NaCl (Fisher) and adjusted to pH 7.4 with HCl (Mallinckrodt).
HPLC grade acetonitrile (Columbus Chemical Industries) was used to make a 20% by
volume solution in buffer for the preparation of the calibration plate. The calibration solutions
(0-300 µM, 50µL each) were read in a 384-well UV plate (Greiner Bio-One, #781801), which was
also used for the solubility assay absorbance readings. The incubation and filtration were
performed in a 384-well filter plate (Pall, #5071), which was sealed with an aluminum cover
(Corning, #6570) during incubation and mixing. The filtration of the plates was performed using
a Millipore MultiScreenHTS Vacuum Manifold (MSVMHTS00). All of the absorbance readings were
performed on an Infinite M1000 plate reader (Tecan).
Solubility Assay Protocol: Calibration plots were generated to obtain the relationship between
solute concentration and absorbance. Molecules were serially diluted in 96-well plates (Table
18) and then 50 μL was transferred to 384-well UV plate so that one compound was in each row.
Each concentration was plated in duplicate. The top of the plate was then covered with an
aluminum plate cover. The UV plate was then carefully placed in the bench-top sonicator so that
it floated on top of the water. It was sonicated for 1 minute and centrifuged at 1000 rpm for 3
minutes to ensure that all of the solution remained in the wells. The plate was then scanned for
absorbance with the Tecan plate reader from 230-800 nm at 5 nm increments with 10 flashes per
well.
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Once the calibration plates were read, a calibration plot for each compound of adjusted
absorbance vs. solute concentration at the maximum wavelength (λmax) was generated. This was
done by subtracting the average absorbance of the 0 µM (background) wells from the absorbance
of each of the other wells. Each of the calibration plots was labeled with the compound name
Table 18. Preparation of 96 well calibration plate for solubility assay.
Well Number

1

Volume Buffer 291 µL
Volume 10
mM DMSO
Stock
Volume
DMSO
Volumes
transferred
from wells 1
to 2, 2 to 3, 3
to 4, 4 to 5
Final
Concentration

2

3

4

5

6

83.3 µL

125 µL

125 µL

125 µL

95 µL

9 µL
5 µL

166.7
µL

125 µL

125 µL

125 µL

300 µM

200 µM

100 µM

50 µM

25 µM

0 µM
(blank)

and maximum wavelength. Finally, a best fit linear trend line through the origin of the plot with
the equation and r2 value to 4 decimal places was added to the plot.
After the calibration plots were generated at the wavelength of maximum absorbance for
each molecule, the solubility assay was performed. The wells in the 384-well filter plate were
pre-wetted with 20-40 µL of buffer. The buffer was left to sit in the wells for about 5 minutes
and subsequently removed by vacuum. An aluminum film cover was then adhered underneath
Table 19. Preparation of solution for solubility assay.
500 µM

Blank

47.5 µL buffer
2.5 µL of 10 mM stock DMSO solution

47.5 µL buffer
2.5 µL DMSO

110

the filter plate to prevent wicking out or evaporation of the solvents during the incubation period.
The solubility assay was then mixed in the filter plate according to Table 19 with four wells per
molecule. With an adhesive plate cover on top and underneath the filter plate, it was sonicated
for 1 minute, and shaken on a reciprocating plate shaker overnight.
The next morning, the solution was filtered into a collection plate (384-well polystyrene
plate). From the filtrate, 30 µL from each well from the collection plate was transferred into a
384-well UV plate using a multichannel pipette. Next, 20 µL of acetonitrile was added to each
well by pipette and shaken for 5 minutes on the plate shaker followed by centrifugation at 1000
rpm for 3 minutes. The absorbance was scanned from 230-800 nm at 5 nm increments with 10
flashes per well.

Equation 3)

𝑆𝑜𝑙𝑢𝑏𝑖𝑙𝑖𝑡𝑦 =

𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑎𝑡 𝜆𝑚𝑎𝑥 3
𝑆𝑙𝑜𝑝𝑒

(5)

Finally, the solubility was determined using Equation 3 with the slope from the calibration
plot for the molecule. At the maximum wavelength for each compound, the average absorbance
from the blank wells (no small molecule) was subtracted from the absorbance of the solution
after filtration (adjusted absorbance at λmax). The average of the solubility values were calculated
and the standard deviations were determined. Five small molecules (4,5-diphenylimidazole, βestradiol, diethylstilbestrol, 3-phenylazo-2,6-diaminopyridine) with known solubility values were
analyzed as standards on each solubility assay plate.
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3.5.2 Parallel Artificial Membrane Permeability Assay (PAMPA)
In addition to solubility, permeability is an important property of drug-like molecules and
is necessary to determine the extent of oral absorption, bio-distribution and consequently the
target tissue uptake.166 Unlike solubility, permeability cannot be manipulated by formulations
but rather is an inherent property of the molecule itself that can only be changed by adjustments
to its structure.
The absorption of orally administered substances is widely determined by their ability to
cross the gastrointestinal tract (GI-tract), its penetration of the blood brain barrier, and its
transport across cell membranes.167 This is governed by several different mechanisms of
permeation including passive diffusion, active uptake, paracellular transport, and efflux. It is
generally assumed that sufficiently lipophilic compounds are transported via passive diffusion,
while small hydrophilic compounds (<200 Da) are transported through the paracellular route if
not by active transport.168 However, active transport of small molecules is difficult to replicate
with in vitro assays. For this reason, the assessment of passive cellular absorption is the preferred
method.
Passive diffusion is a physiochemical process that is governed by physiochemical
properties like lipophilicity, molecular weight, pKa, polar surface area, ionization state and
hydrogen bond capacity.169 Drug lipophilicity is commonly used as a predictor for membrane
permeability because membranes are primarily lipophilic in nature.170 Molecular size can also
play a distinct role in the permeation process because larger molecules diffuse more slowly than
smaller molecules. Lipids within a membrane that contain hydrogen-bonding acceptor groups
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can associate with the hydrogen-bonding solutes. This hydrogen-bonding prevents the solutes
from penetrating the membrane and slows down the diffusion process. Directly related to the
hydrogen-bonding capacity is the polar surface area.170 Polar surface area is the molecular
surface area associated with hydrogen bonding acceptor atoms (i.e., oxygen and nitrogen) plus
the area of the hydrogen atoms. Finally, membranes are more permeable to non-ionized forms
of drug than the ionized species because of their greater lipid solubility and the charged nature
of the membranes.170
The Caco-2 cells monolayer permeation has long been widely and successfully used to
screen drug candidates. However, the Caco-2 method possessed many limitations including
expensive cell culture that could take weeks to obtain confluency with full cell differentiation,
low throughput, variable expression of transport and metabolizing proteins, and the
complication of multiple permeation mechanisms.167 Because of this, the Caco-2 method in
many cases has been replaced by a parallel artificial membrane permeability assay (PAMPA).
PAMPA is a high-throughput, inexpensive method that produces reproducible results without
requiring cell culture.170 Although, PAMPA methods are not completely predictive of in vivo
permeability, they can identify definitive trends in the ability of a molecule to permeate
membranes by passive diffusion.163
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PAMPA is typically performed in a 96-well plate with two parts, the donor plate and the
acceptor plate (Figure 48). The donor plate has a permeable membrane or filter along the bottom
which aligns with the wells in the acceptor plate. The artificial membrane, which is either
composed of lecithin, phosphatidylcholine, hexadecane, or porcine brain lipid extract, etc. in
organic solvents, is impregnated into the filter of the donor plate. Buffer and compound are
added to the donor wells while buffer is added to the acceptor wells. With the impregnated filter
in contact with both solutions, the assay plates are incubated for a set amount of time, and the

Figure 48. Illustration of PAMPA plates. A) 96-well filter plate pre-coated with an
artificial membrane with a matched 96-well receiver plate. B) Solutions of the
compounds in buffer are added to the filter plate on top of the artificial membrane
(donor plate), while buffer is added to the receiver plate (acceptor plate).11

concentration of compound that has passed through the membrane is determined usually by
absorbance spectroscopy, HPLC, or LC-MS. An illustration of the PAMPA method is shown in
Figure 49.
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Figure 49. Example of a PAMPA assay performed in a multi-well
plate.

The effective permeability determined by cell-based or PAMPA method is calculated using
Equation 4. Here, dCA/dt (mg/s·mL) is the increase of drug concentration in the acceptor well
over the incubation period. The term A (cm2) is the surface area of the membrane that is exposed
to the compound. VA (mL) is the volume of the solvent in the acceptor well. Finally, CA and CD
(mg/mL) are the initial drug concentration in the acceptor and donor wells, respectively. 170

Equation 4)

𝑃𝑒𝑓𝑓 =

𝑉𝑎
𝐴(𝐶𝐷 −𝐶𝐴

𝑑𝐶

( 𝐴)
) 𝑑𝑡

The PAMPA assay was used to evaluate oxazole-based GW0742 analogs for their ability
to cross a hydrophobic membrane at biological pH. By doing so, a correlation could be made
between their cellular bio-activity and their ability to cross the cell membrane. High, medium
and low permeable standards were chosen based on their in vivo permeability values found in
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the Biopharmaceutics Classification System (BCS) database. The logP values calculated for each
molecule was compared to the standard molecules to provide the degree of in vitro permeability.

Experimental Procedure
Reagents and Instrumentation: All materials were used as received with no further purification.
The following small molecules were used as standards: verapamil hydrochloride (Tocris
Bioscience), 10,11-dihydrocarbamazepine (Alfa Aesar), and ranitidine hydrochloride (Alfa Aesar).
Each of the small molecules were dissolved in DMSO to make 10 mM solutions (Acros,
Spectroscopic Grade 99.9+%).
The PAMPA assay was performed with the Millipore MultiScreen filter plates
(MAIPNTR10) and Millipore transport receiver plates (MATRNPS50) using a 5% by volume nhexadecane (Acros) in n-hexane (Fisher) solution to create the artificial layer. The absorbance
readings were completed with a Corning Costar 96 well UV plate (3635). 1x Phosphate buffered
saline (PBS) was prepared in 1L batches using 18 MΩ water with 3.23 mM K 2HPO4·7H2O (J.T.
Baker), 7.84 mM KH2PO4 (J.T. Baker), 5 mM KCl (Fisher), 150 mM NaCl (Fisher), and adjusted to
pH 7.2 with HCl (Mallinckrodt) and NaOH (Fisher). All of the absorbance readings were
performed on an Infinite M1000 plate reader (Tecan).
PAMPA Assay Protocol:
The artificial membrane was prepared by carefully pipetting 15 µL of the 5% (v/v)
hexadecane in hexane solution to each of the wells of the donor plate (assay plates as shown in
Figure 49). The plate was placed into a fume hood for 1 hour to ensure complete evaporation of
the hexane. After the hexane had evaporated, 300 µL of PBS with 5% (v/v) DMSO was added to
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each of the wells of the acceptor plate. The hexadecane treated donor plate was then placed on
top of the acceptor plate taking care that the underside of the membrane is completely in contact
with the solution in each of the acceptor wells. Each of the compounds solutions were prepared
in triplicate in a separate 96-well plate to 300 µM (4.5 µL of 10 mM compound solution in DMSO,
3 µL DMSO, and 95 µL buffer). Then, 150 µL of the compound solution was added to the donor
wells. For each plate, 10, 11-dihydrocarbamazepine (medium-high permeability), verapamil
(high permeability), and ranitidine (low permeability) were used as standard molecules for
reference.
The lid was placed on the plates and the entire plate sandwich was placed into a closed
container with a wet paper towel along the bottom to circumvent evaporation during the
incubation process. The container was then placed on a reciprocal shaker for agitation at about
100 rpm. The time at the beginning of the incubation was recorded, as this is a thermodynamicbased assay. The incubation was then allowed to continue for approximately eighteen hours.
The next day, the plates were removed from the incubation container and the incubation
end time was noted. The donor plate was removed and 50 µL of the acceptor solution was
transferred to the UV plate. Drug solutions at the theoretical equilibrium concentration (300 µM)
was also prepared and transferred to the UV plate. The absorbance of the solutions in the UV
plate was then scanned from 250-600 nm with 1 nm steps and a 5 nm bandwidth.

Equation 5)

𝑙𝑜𝑔𝑃 = 𝑙𝑜𝑔 {𝐶 × − ln (1 −

[𝐷𝑟𝑢𝑔]𝐴
[𝐷𝑟𝑢𝑔]𝐸
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𝑉𝐴 × 𝑉𝐷
)
𝐷 + 𝑉𝐴 )𝐴 × 𝑇

)} ; 𝑊ℎ𝑒𝑟𝑒 𝐶 = ((𝑉

The relative permeability (cm/s) of the small molecules was calculated with Equation 5,
where VD is the volume of the donor well in cm3 (150 µL), VA is the volume in the acceptor well
in cm3 (300 µL), A is the active surface area of the membrane in cm2 (0.283 cm2), T is the
incubation time of the assay in seconds, [Drug]A is the absorbance of the compound in the
acceptor well after the incubation period, and [Drug]E is the absorbance of the compound at the
concentration of the theoretical equilibrium (as if the donor and acceptor solutions were simply
combined).171 The equation is derived from Equation 4, described previously, in which the
change in concentration of the solute is time dependent.

3.5.3 Results and Discussion
The ester and acid forms of the GW0742 oxazole analogs developed in our lab were
evaluated for two physiochemical characteristics: aqueous solubility and permeability. The
solubility results as well as the measured maximum wavelength obtained for these compounds
are summarized in Table 20. Overall, the ester oxazole derivatives were less soluble than their
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acid counterparts. When compared to the standards, the esters possessed low solubility while
the acids had medium solubility in water.
Table 20. Solubility assay results. Table includes solubilites (μM) and maximum
wavelengths (nm) measured for each standard and compound.
Maximum Wavelength
Aqueous Solubility
Compound
(µM)
(nm)
4,5-diphenylimidazole
β-estradiol
Diethylstilbestrol
3-phenylazo-2,6-diaminopyridine
KAT092013-1
KAT092313-2
KAT092413-3
KAT092513-4
KAT092513-5
KAT120413-1
KAT101013-2
KAT101013-3
KAT100313-4
KAT101013-5
JWB091313-1
JWB091313-2
JWB091313-3
JWB091313-4
JWB091313-5
JWB111913-1
JWB111913-2
JWB111913-3
JWB111913-4
JWB111913-5

18.71 ± 0.028
47.61 ± 0.014
60.6 ± 0.003
221.28 ± 0.012
67.71 ± 0.011
22.52 ± 0.0068
15.87 ± 0.0122
22.18 ± 0.0006
22.54 ± 0.0045
146.46 ± 0.0289
170.99 ± 0.0578
152.30 ± 0.0164
161.72 ± 0.058
144.18 ± 0.0264
20.1 ± 0.011
8.67 ± 0.004
6.19 ± 0.006
16.31 ± 0.0018
15.58 ± 0.0203
97.88 ± 0.0264
186.06 ± 0.0356
166.58 ± 0.0293
150.30 ± 0.0350
84.40 ± 0.0043

286
290
290
425
274
262
274
274
274
272
304
272
272
272
282
282
266
280
282
284
280
274
276
274

Maximum compound concentration was 500 μM.

The relative permeability for GW0742 oxazole analogs are summarized in Table 21.
When compared to the standards, the ester form had medium permeability while the acids
were more comparable to Ranitidine with low permeability across a hydrophobic barrier.
Overall, the esters would be more drug-like.
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Table 21. PAMPA assay results
Compound

LogP (cm/s)

Verapamil (high)
10, 11-Dihydrocarbamazepine (medium- high)
Ranitidine (low)
KAT092013-1
KAT092313-2
KAT092413-3
KAT092513-4
KAT092513-5
KAT120413-1
KAT101013-2
KAT101013-3
KAT100313-4
KAT101013-5
JWB091313-1
JWB091313-2
JWB091313-3
JWB091313-4
JWB091313-5
JWB111913-1
JWB111913-2
JWB111913-3
JWB111913-4
JWB111913-5

-2.81 ± 0.003
-3.22 ± 0.002
-3.92 ± 0.009
-3.33 ± 0.001
-3.35 ± 0.013
-3.42 ± 0.002
-3.56 ± 0.002
-3.34 ± 0.001
-3.63 ± 0.003
-3.67 ± 0.001
-3.58 ± 0.0001
-3.72 ± 0.001
-3.59 ± 0.0005
-3.29 ± 0.002
-3.37 ± 0.002
-3.43 ± 0.0005
3.32 ± 0.001
-3.34 ± 0.002
-3.63 ± 0.001
-3.88 ± 0.0003
-3.77 ± 0.003
-3.88 ± 0.012
-3.92 ± 0.005

Permeabilities were measured using the parallel artificial membrane
permeation assay (PAMPA) at neutral pH (pH 7.4).

3.6 Conclusion
A good SAR could be established with the ortho- and meta-oxazole containing GW0742
analogs with an ester or acid moiety. Overall in the cell-based transcription assay, the o-OCH3
and m-OCH3 esters were more potent VDR inhibitors with reduced activation of PPARδ-mediated
transcription. m-OCH3 acids able to inhibit VDR transcription possessed partial PPARδ agonism
making them not selective, while o-OCH3 acids only showed partial agonism for PPARδ and no
inhibition of VDR. Although none of these analogs demonstrated VDR inhibition in the FP binding
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assay, we know that solubility did not play a role and that the VDR inhibitory effect seen in cells
was not due the molecules binding to the luciferase enzyme. A coumarin-derived probe is being
developed in our lab and will give insight into if these molecules bind in the LBP of VDR. Therefore
this project is ongoing and just like the thiazole analogs, subject to further rational design. This
project would also enormously benefit from a GW0742 analog VDR or PPARδ crystal structure,
which is currently underway in Prof. Silvaggi’s lab.
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CHAPTER 4: SYNTHESIS OF NATURAL VDR LIGAND METABOLITES AND
THEIR INTERACTION WITH THE VITAMIN D RECEPTOR
4.1 Introduction
4.1.1 Metabolism of 1,25(OH)2D3
The major enzyme responsible for the catabolic breakdown of 1,25(OH)2D3 is the
mitochondrial inner-membrane cytochrome p450 enzyme, CYP24A1.172,
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As previously

mentioned, 25(OH)D3 is formed in the liver and then shuttled to the kidney where the final
hormonal form of vitamin D3, 1,25(OH)2D3, is made through the actions of CYP27B1. Once
formed, 1,25(OH)2D3 targets VDR in many different tissues. Interestingly, expression of CYP24A1
in target tissues is regulated by 1,25(OH)2D3 through a classic endocrine negative feedback loop.
Major catabolism of 1,25(OH)2D3 occurs on the secosteroid’s aliphatic chain either forming C24oxidation pathway products or C23-hydroxylation path products (Figure 50).174 The C24 pathway
is comprised of five enzymatic steps beginning with the 24-hydroxylation of 1,25(OH)2D3 to yield
1,24,25(OH)3D3. This metabolite is oxidized to the ketone, 24-oxo-1,25(OH)2D3, and then
hydroxylation at C-23 to generate 24-oxo-1,23,25(OH)3D3.175, 176 This compound is metabolized
by oxidative cleavage of the carbon-carbon bond between C-23 and C-24 to produce 24,25,26,27tetranor-1,23(OH)2D3.177 The C23 alcohol is converted to calcitroic acid, a main excretory product
of 1,25(OH)2D3 in bile.178, 179 The 1,25(OH)2D3-induced C24 pathway has been observed in many
different cell lines including kidney, bone, intestine, skin and breast thus demonstrating this
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pathway can occur in many different tissues.180-182 The main role of C24 oxidation pathway is

Figure 50. Enzymatic pathways catalyzed by CYP24A1 with 1,25(OH)2D3 as a substrate. The
C24-oxidation pathway products are on the left and the C23-hydroyxlation products are on the
right.

most likely to regulate the 1,25(OH)2D3 biological signal inside target cells. This is supported by
cell-based experiments where CYP24A1 activity was blocked by ketoconazole, an antifungal
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derivative known to inhibit P450 activity. The result is a build-up of 1,25(OH)2D3 and extended
hormone action.183 In CYP24A1 deficient mice, hypercalcemia and hypervitaminosis D3 was
observed due to high serum levels of 1,25(OH)2D3 and their inability of clearance.184
Furthermore, when VDR-knockout mice were administered 1,25(OH)2D3, it was observed that the
induction of CYP24A1 expression is dependent on VDR and is required for the production of
calcitroic acid and 1,25R(OH)2D3-26,23S-lactone (final product of C23 hydroxylation pathway).185,
186

The C23 hydroxylation pathway consists of four enzymatic steps starting with the
formation of 1,23S,25(OH)3D3 from 1,25(OH)2D3.187

This is further converted to

1,23S,25,26(OH)4D3, then to 1,25R(OH)2D3-26,23S-lactol and finally 1,25R(OH)2D3-26,23Slactone.174 The biological activity of the C23 hydroxylation metabolites is unclear but it has been
speculated that 1,25R(OH)2D3-26,23S-lactone could act as a VDR antagonist thus suggesting the
lactone pathway proves a fail-safe mechanism to efficiently and rapidly diminish the vitamin D
signal.188, 189
The binding and transcriptional activity of calcitroic acid with VDR was investigated in our
lab. It was hypothesized that the final metabolite of the C24 pathway, a molecule that cannot be
further oxidized by CYP24A1 enzymes, would be more metabolically stable and may bind and
inhibit VDR-mediated transcription.

4.1.2 Lithocholic Acid Metabolism
Bile acids are the end products of hepatic cholesterol catabolism and acts as an emulsifier
for ingestion and intestinal absorption of hydrophobic nutrients like cholesterol, fatty acids and
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lipid-soluble vitamins like vitamin D. Primary bile acids are synthesized from cholesterol in the
liver through a series of enzymatic reactions catalyzed by cytochrome p450 enzymes such as
CYP7A1, CYP7B1 and/or CYP27A1 where CYP7A1 accounts for 50% or more of bile production in
humans.190 They are then secreted in bile as glycine or taurine conjugates where they assist in
lipid digestion and absorption. Most bile acids are reabsorbed in the intestine and recirculate to
the liver. Others are converted to secondary bile acids in the intestinal microflora, such as
deoxycholic acid (DCA) and lithocholic acid (LCA).191
Secondary bile acids, like LCA, are toxic in higher concentrations when absorbed and can
promote the development of liver disease and colorectal cancer. VDR has be found to act as a
bile acid sensor and is involved with bile acid metabolism by inducing a LCA detoxification
mechanism in the liver and intestine. The activation of VDR by either LCA or 1,25(OH)2D3 induces
expression of CYP3A4, the cytochrome p450 enzyme responsible for the removal of harmful
secondary bile acids. The conversion of cholesterol to bile acids is tightly regulated to maintain
homeostasis. Two receptors in particular, VDR and farnesoid X receptor (FXR), are part of this
feedback regulation (Figure 51).190 High concentrations of bile acids activate FXR resulting in
suppressed bile acid biosynthesis. Activated FXR also stimulates fibroblast growth factor (FGF)
19 (in humans) and 15 (in mice) transcription which signals through hepatocytes to suppress
CYP7A1 expression192. Interestingly, it has been observed that VDR-null mice have increased bile
acid levels and decreased expression of FGF15. This phenotype has also been observed in FXRnull mice. Furthermore, 1,25(OH)2D3 suppressed bile acid synthesis through a mechanism that
involved regulation of FGF15 by VDR.193, 194 This evidence shows that both FXR and VDR are
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Figure 51. Summary of the role VDR and FXR in bile acid metabolism.

required for FGF15 (19) expression and that VDR plays an important role in the regulation of bile
acids which may contribute to further protection against colorectal cancer.

4.1.3 VDR Ligand Metabolite Binding
In vivo studies conducted by DeLuca et al demonstrated that vitamin D deficient rats
administered high concentrations of LCA showed induction of the vitamin D dependent calcium
binding protein, calbindin-D9k. However this link between LCA and calcium homeostasis was
quickly dismissed when rats with normal vitamin D levels showed no effect from LCA. This could
be explained by the lower binding affinity LCA has compared to 1,25(OH)2D3.195 In 2014, Rochel
et al crystallographic studies revealed that two molecules of LCA bind to two distinct sites on the
VDR LBD of zebra fish (Figure 52).196 The first LCA molecule binds to the VDR ligand binding
pocket (LBP) with a reversed orientation compared to 1,25(OH)2D3. The binding requires VDR to
rearrange near helix 6 (H6) where LCA interacts mainly through hydrophobic interactions and
weaker H-bonds with residues through water molecules with zSer265, zArg302, zHis333, and
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zHis423 and direct contacts with zTyr175 and zSer306. These weaker interactions explain the
lower affinity of LCA for VDR and its ability to activate VDR-mediated transcription only at high
micromolar concentrations. The second LCA molecules is slightly exposed to water and is
anchored to VDR through its C3 hydroxyl group forming direct H-bonds with zSer263 (H3) and
zGln267 (H3). This site is of considerably lower affinity compared to the first site but importantly

Figure 52. zVDR LBD crystal structure bound to two LCA molecules. A) The overall structure
of VDR LBD receptor with two ligand binding sites. B) Comparison of the interactions
between VDR and LCA (pink) and VDR and 1,25(OH)2D3 (orange) in the first binding site. The
hydroxyl groups of LCA forming H-bonds are labeled in black. Specific interactions between
VDR and 1,25(OH)2D3 that are absent in LCA are labeled in orange. Specific interactions
between VDR and LCA that are absent for 1,25(OH)2D3 are labeled pink. Red spheres
represent water molecules.

stabilizes the active protein conformation.
In recent years, LCA has been investigated as an important biological VDR ligand because
of 1) its selectivity for VDR among other NRs and 2) its inability to induce hypercalcemia. Table
22 shows a list of compounds that have been investigated.197,

198

The results show that

esterification of the LCA side chain carboxyl group with methyl, ethyl, and benzyl moieties
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drastically decreases transactivation. However, esterification of the C3 hydroxyl group increases
VDR activity. LCA formate and LCA acetate activate VDR three times and thirty times the potency
of LCA, respectively. Structure-function analysis and docking models have even shown that LCA
acetate interacts with H3 and H4/5 residues in VDR LBP differently than 1,25(OH)2D3 suggesting

Table 22. Derivatives based on LCA structure

R
R1
OH
H
OH
CH3
OH
C2H5
OH
CH2C6H5
HCOO
H
CH3COO
H
C3H7COO
H
COOHC2H4COO
H
CH3COO
CH3
CH3CH2COO
H

Compound
LCA
LCA methyl ester
LCA ethyl ester
LCA benzyl ester
LCA formate
LCA acetate
LCA isobutyrate
LCA hemisuccinate
LCA acetate methyl ester
LCA propionate

.
differential cofactor recruitment and selective
physiological function.

Furthermore, LCA

propionate is as potent a VDR agonist as LCA acetate, while LCA isobutyrate and LCA
hemisuccinate showed a decrease in VDR activation compared to LCA.
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4.1.4 Proposed VDR Ligand Metabolites
Although many LCA derivatives have been investigated as VDR agonists, none have been
studied as VDR-coactivator inhibitors. Herein we report the first look at LCA phase 1 and phase 2
metabolites evaluated as VDR-coactivator inhibitors. Phase 1 metabolic reactions include
oxidation, hydrolysis and reduction reactions, while phase 2 are produced through conjugation

Figure 53. The phase 1 and phase 2 metabolites evaluated as VDR inhibitors.
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reaction with glucuronic acid, sulfate and glycine. Our goal was to identify new natural VDR
ligands. Figure 53 shows the phase 1 and phase 2 metabolites evaluated in our lab and their
biological activity.

4.2 Chemistry
4.2.1 Synthetic Strategy
LCA was the starting material used to synthesize LCA acetate and LCA sulfonate (Scheme
7). A base catalyzed esterification reaction using 4-dimethylaminopyridine and acetyl chloride

Scheme 7. Synthetic scheme for converting LCA to LCA acetate and LCA sulfonate. i) pyridine,
acetyl chloride and 4-DMAP at room temperature, 1 hour. ii) sulfuric acid, acetic anhydride,
and pyridine, 50-55oC, 30 minutes. iii) 25% ammonia water, 0oC, 15 minutes.

produced LCA acetate at a 95% yield.199 To obtain LCA sulfonate, sulfuric acid and acetic
anhydride in pyridine were used as oppose to the more “classical” method using pyridine sulfur
trioxide to make sulfonate steroids.200, 201 According to the literature, the “classical” method had
low conversion of the starting alcohol (in this case LCA), produced polymeric byproducts resulting
in difficulties during purification and low yields. The final product was converted into an
ammonium salt using 25% ammonia acetate at 0oC to receive a final yield of 97%. For the
synthesis of O-glucuronide I and II (Scheme 8), LCA methyl ester (LCME) was used as starting
material. A Koenigs-Knorr condensation reaction of LCME with acetobromo-α-D-glucuronic acid
methyl ester catalyzed by CdCO3 in dry benzene at reflux was performed to make LCME O130

Scheme 8. Synthetic scheme for converting LCME to LCA O-glucuronide I and II. i) Dry benzene,
CdCO3, acetobromo-α-D-glucuronic acid methyl ester, reflux, 5 hours, ii) MeOH, 1M NaOH,
room temperature, 4 hours followed by 5% HCl. iii) TBDMSCl, DMF, imidazole, room
temperature, iv) THF, 2M NaOH, 75oC, 24 hours followed by 2M HCl, v) pyridine, CDI, reflux, 3
hours, vi) a) NaH, tetrabutylammonium glucuronate, 50oC, 4-5 hours, b) acetic acid, vii) THF,
tetrabutylammonium
fluoride, 40oC, H2O.
202

glucuronide I.

The β-glycosidic linkage with LCA methyl ester at the C-3 position was confirmed

by 1HNMR with the appearance of a doublet at 4.69 ppm and the disappearance of the
brominated anomeric proton doublet 6.67ppm. Hydrolysis with sodium hydroxide afforded the
final product, LCA O-glucuronide I, at an overall yield of 61%. Figure 54 shows the proposed
mechanism for the Koenigs-Knorr glycosylation reaction. The acyl protected sugar molecule is
first activated through an SN1 removal of the bromine. The reaction then proceeds through a
process called neighboring group participation with the acetoxy substituent to form an
acyloxonium cation intermediate that is stabilized by both acetoxy oxygen atoms. The sugar is
now a good acceptor/electrophile for the donor/nucleophile, LCA, to attack at the anomeric
carbon and form the final LCA O-glucuronide I product.203-205
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Figure 54. Mechanism of the Koenigs-Knorr glycosylation reaction to produce LCA Oglucuronide I.

LCA O-glucuronide II was synthesized in four steps starting with the protection as tbutyldimethylsilylether (TBS). TBS was chosen as a protecting group because it is 104 more stable
to basic hydrolysis than trimethylsilyl (TMS).206 However, a t-butyldiphenylsilylether would have
allowed TLC monitoring omitting the use of a stain. Hydrolysis of LCME-TBS afforded the
corresponding carboxylic acid, LCA-TBS.

Next, glucuronic acid was converted into a

tetrabutylammonium salt (Scheme 9), which not only protected the free carboxyl group but also
rendered it soluble in organic solvents.207 In a one pot reaction, LCA-TBS was activated with 1,1’-

Scheme 9. Tetrabutylammonium salt formation of glucuronic acid.
i) MeOH, 40oC, 1 hour.

carbonyldi-imidazole followed by the addition of tetrabutylammonium glucoronate.

The

reaction was quenched with acetic acid to produce LCA-TBS O-glucuronide II. To avoid accidental
cleavage of the coupled sugar ring, deprotection of the TBS group was accomplished under
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neutral conditions with tetrabutylammonium fluoride as oppose to acidic conditions. 206 The
fluoride-based deprotection is driven by the formation of a Si-F bond which is about 30kcal/mol
stronger than a Si-O bond. This reaction was quenched with water to yield the final product, LCA
O-glucuronide II. The final product was purified by silica gel column to remove any unreacted
LCA and then recrystallized with EtOH to yield about 40 mg of product with an overall yield of
10%. Although this multistep synthesis produced little product, it was beneficial to have the
sugar as the donor and LCA as the acceptor molecule because it omitted unnecessary protection
and deprotection of the sugar hydroxyl groups.

4.2.2 Characterization
All phase 1 metabolites, lithocholic acid, lithocholic methyl ester and taurolithocholic acid
were purchase from Sigma-Aldrich and glycolithocholic acid was purchased from Santa Cruz
Biotechnology. Calcitroic acid was purchased from Toronto Research Chemicals. Synthesized
compounds were either purified via recrystallization or normal phase flash chromatography (SPI
Biotage, silica gel 230-400 mesh). Compound characterization was performed using a Shimadzu
2020 LC-MS (single quadrupole) instrument with compounds directly injected. NMR spectra
were recorded on a Bruker 300MHz instrument with samples diluted in either CDCl3 or DMSOD 6.
LCA Acetate: 95% yield; Lithocholic acid (0.5 g, 1.3 mmol), was
dissolved in dry pyridine (10mL) under N2 gas and cooled to 0oC.
4-dimethylaminopyridine (0.02 g, 0.13 mmol) and acetyl chloride
(1.1 mL, 16 mmol) were added to the solution. The reaction was
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stirred at room temperature and monitored by TLC using EtOAc-Hexanes-MeOH (4:1:1, v/v/v)
and cerium molybdate as a developing stain. After 1 hour, water (3 mL) was added and the
solution was evaporated under reduced pressure. DCM (15 mL) was used to dissolve the residue,
which was subsequently washed with saturated aqueous NaCl (20 mL) and water (15 mL). The
organic phase was dried over Na2SO4, then filtered and evaporated to dryness. The crude
product was co-evaporated with toluene (10 mL x2), ethanol (10 mL x2), acetonitrile (10 mL x 2)
and DCM (10 mL x 2) in order to remove traces of pyridine and purified by silica gel
chromatography with CH3OH-CH2Cl2 (0%-5% strong). 1H-NMR (300 MHz) (CDCl3) δ 4.75 (m, 1H,
H-3), 2.05 (s, 3H, -CH3, Ac), 0.95 (m, 6H, H-18/19, 21), 0.67 (s, 3H, H-18/19); 13C NMR δ 178.57,
170.72, 74.43, 56.51, 55.99, 42.75, 41.89, 40.42, 40.16, 35.79, 35.35, 35.03, 34.58, 32.25, 31.06,
29.69, 28.18, 26.32, 23.33, 20.83, 18.55, 18.28, 12.05; MS DUIS (-ve) calcd. m/z for C26H42O4 [(M)]
418.3, found [(M-1)-] 417.4.

LCA Sulfonate: 97% yield; Sulfuric acid (0.16 mL, 3 mmol)
and acetic anhydride (0.28 mL, 3 mmol) were mixed with
dry pyridine (5 mL) and after 5 minutes of stirring at 50-55oC
a solution of lithocholic acid in 2 mL of pyridine was added.
The mixture was stirred for 30minutes at the same conditions, cooled to 0oC, and 25% ammonia
water (0.74 mL) was added. After 15 minutes of stirring, the precipitate was filtered and the
filtrate was placed on a rotary evaporator for concentrating. The product isolated was not
purified further. 1H-NMR (300 MHz) (DMSO-D6) δ 3.96 (m, 1H, H-3), 0.88 (m, 6H, H-18/19, 21),
0.61 (s, 3H, H-18/19); 13C NMR δ 175.18, 75.98, 56.41, 55.93, 42.66, 35.77, 35.47, 35.24, 24.53,
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33.77, 31.21, 31.08, 28.16, 27.27, 26.52, 24.31, 23.65, 20.85, 18.59, 12.34;

13CDEPT-135

δ

Negative (-) CH2: 76.05, 56.42, 55.94, 42.06, 40.33, 35.82, 35.51, 24.31, 18.59, 12.34 Positive (+)
CH and CH3: 40.09, 35.29, 33.80, 31.21, 31.13, 28.16, 27.27, 26.53, 23.64, 20.85; MS DUIS (-ve)
calcd. m/z for C24H40O6S [(M)] 456.3, found [(M-1)-] 455.4.
LCME O-glucuronide I: 43% yield; To a solution of lithocholic
methyl ester (400 mg) in anhydrous benzene (16 mL) was
added cadmium carbonate (400 mg), acetobromo-α-Dglucuronic acid methyl ester (400 mg) and a quantity of
molecular sieves (400 mg). The mixture was stirred at reflux. After 1 hour and 3 hours, additional
quantities of acetobromo-α-D-glucuronic acid methyl ester (200 mg) and cadmium carbonate
(200 mg) were added and the mixture stirred for 7 hours and was monitored by TLC using hexaneEtOAc-AcOH (50:50:1, v/v/v) and cerium molybdate as the developing stain. The precipitate was
removed by filtration and washed with EtOAc. The filtrate and washings were combine and
evaporated to dryness under reduced pressure and the oily residue was recrystallized in MeOH
(5mL) to make white crystals.

1H-NMR

(300 MHz) (CDCl3) δ 5.28-5.24 (m,2H), 5.01-4.95 (t, 1H,

J= 9Hz), 4.69-4.66 (d, 1H, J= 9Hz, anomeric), 4.06-4.03 (d, 1H, J= 9Hz), 3.78 (s, 3H, Ac), 3.69 (s, 3H,
Ac), 3.62 (m, 1H, H-3), 2.07, 2.04 (s, 9H, COCH3), 0.92 (m, 6H, H-18/19, 21), 0.65 (s, 3H, H-18/19);
13C

NMR δ 174.76, 170.21, 169.35, 169.28, 167.32, 99.57, 80.56, 72.61, 72.20, 71.57, 69.50,

56.28, 55.89, 52.82, 51.46, 42.70, 42.17, 40.30, 40.09, 35.81, 35.35, 35.09, 34.63, 33.99, 31.05,
30.99, 28.16, 27.09, 27.01, 26.23, 24.16, 23.35, 20.83, 20.71, 20.63, 20.51, 18.25, 12.01; MS DUIS
(+ve) calcd. m/z for C38H58O12 [(M)] 706.4, found [(M+ 18 (NH4))+] 724.8.

135

LCA O-glucuronide I: 100% yield; To a solution of LCME Oglucuronide I (70 mg) in MeOH (8 mL) an aqueous solution
of 2M NaOH was added dropwise until the mixture was
basic.

The reaction was stirred at room temperature

overnight and monitored by TLC using hexanes-EtOAc-AcOH (50:50:1, v/v/v) and cerium
molybdate as the developing stain. After most of the solvent was removed by rotary evaporation,
the reaction product was diluted with water, neutralized with 3M HCl and then evaporated to
dryness. The residue was re-suspended in anhydrous EtOH (10 mL) and the insoluble material
was filtered off and washed with EtOH. The combined filtrate was evaporated and the residue
was recrystallized from MeOH resulting in white, flakey solid. 1H-NMR (300 MHz) (DMSO-D6) δ
4.34-4.31 (d, 1H, J= 9Hz, anomeric), 3.61-3.58 (d, 1H, J= 9Hz), 3.33-3.27 (2H, t, J= 9Hz), 3.20-3.14
(1H, t, J= 9Hz), 2.93 (m, 1H, H-3), 0.88 (m, 6H, H-18/19, 21), 0.61 (s, 3H, H-18/19); 13C NMR δ
175.30, 170.86, 101.33, 77.75, 76.55, 76.00, 73.65, 72.01, 56.45, 55.97, 51.65, 42.72, 41.86,
35.80, 35.29, 34.26, 31.13, 30.83, 28.17, 27.20, 26.85, 26.55, 24.31, 26.55, 24.31, 23.49, 20.86,
18.59, 12.32 ; MS DUIS (-ve) calcd. m/z for C30H48O9 [(M)] 552, found [(M-1)-] 551.
LCME-TBS: 84% yield; To a solution of LCME (3 g, 0.0077 mols)
and imidazole (3.74 g, 0.0231 mol, 3 equiv.) in dry DMF (28
mL) tert-butyldimethylsilyl chloride (3.48 g, 0.0231 mols, 3
equiv.) was added dropwise.

The mixture was stirred

overnight at room temperature and monitored by TLC using EtOAc-DCM- AcOH (5:95:1, v/v/v)
and cerium molybdate as the developing stain. Upon completion, the reaction was diluted with
water and extracted with DCM (25 mL x 3) and then dried using rotary evaporation. The resulting
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crude product was purified using silica gel chromatography using EtOAc-Hexanes with 1% AcOH
(1% -20% strong). A white solid was isolated. 1H-NMR (300 MHz) (CDCl3) δ 3.67 (s, 3H, Ac) 3.59
(m, 1H, H-3), 0.92 (m, 6H, H-18/19, 21), 0.90 (s, 9H, t-butyl-Si), 0.63 (s, 3H, H-18/19), 0.06 (s, 6H,
2CH3-Si);

13C

NMR δ 174.90, 135.15, 121.89, 72.85, 56.39, 55.93, 51.49, 42.70, 42.27, 40.20,

40.12, 36.90, 36.49, 35.84, 35.56, 35.36, 34.57, 31.57, 31.06, 31.00, 28.18, 27.28, 26.39, 25.97,
25.74, 24.20, 23.38, 20.79, 18.33, 18.24, 12.00; MS DUIS (+ve) calcd. m/z for C31H56O3Si [(M)] 504,
found [(M-TBDMS)]+ 373 and [(M+1+imidazole)+] 574.
LCA-TBS: 64% yield; LCME-TBS (3.25 g, 6.45 mmol) was
dissolved in THF (20 mL) and to it 2M NaOH was added until
it reached pH=10. The reaction was stirred at 75oC for 24
hours and monitored by TLC using EtOAc-Hexanes-AcOH
(3:2:1, v/v/v) and cerium molybdate as the developing stain. Once complete, most of the solvent
was removed by rotary evaporation. The reaction product was diluted with water and acidified
with 3M HCl to pH=3. The solid formed was collected and purified by silica gel chromatography
using EtOAc-Hexanes with 1% AcOH (1-20% strong). A white solid with low solubility in MeOH,
EtOH and CHCl3 was obtained. 1H-NMR (500 MHz) (DMSO-D6) δ 8.45 (s, 1H, COOH), 3.58 (m, 1H,
H-3), 0.88 (m, 6H, H-18/19, 21), 0.85 (s, 9H, t-butyl-Si), 0.61 (s, 3H, H-18/19), 0.02 (s, 6H, 2CH3Si); 13C NMR δ 175.14, 72.56, 56.45, 56.09, 42.80, 42.05, 37.11, 35.90, 35.49, 35.24, 34.62, 31.34,
31.24, 28.11, 27.26, 26.53, 26.28, 24.28, 23.62, 20.92, 18.65, 18.23, 12.36; MS DUIS (-ve) calcd.
m/z for C31H54O3Si [(M)] 490.3, found [(M-1)-] 489.4.
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Tetrabutylammonium Glucuronate: ~100% yield; Glucuronic acid (2.9
g) was suspended in methanol (25 mL) to which tetrabutylammonium
hydroxide 30-hydrate (12 g) was added. The mixture was stirred at
room temperature for 1 hour until a clear solution resulted. The solvent was removed in a rotary
evaporator at 40oC, thereby yielding a syrup.

Addition of acetone (100 mL) resulted in

precipitation of the tetrabutylammonium glucoronate. That salt was separated by filtration and
washed with acetone. The filtrate and washings, on further concentration in a rotary evaporator,
resulted in precipitation of more salt. A flakey, white solid was obtained. 1H-NMR (500 MHz)
(DMSO-D6) δ 5.75- 5.72 (d, 1H, J= 9Hz), 4.50-4.58 (d, 1H, J= 6Hz), 3.86-3.58 (m, 4H,OHs), 3.193.14 (m, 8H), 1.57 (m, 8H), 1.37-1.25 (m, 8H), 0.96-0.91 (t, 12H, J= 7.5Hz); MS DUIS (-ve) calcd.
m/z for C22H45NO7 [(M)] 435.2, found [(M-tetrabutylammonium)-] 193.
LCA-TBS-O-glucuronide II: >100% yield (crude); LCA-TBS
(1.0 g, 2.04 mmol) and 1,1’-carbonyliimidazole (0.66 g,
4.08 mmol, 2 equiv.) were dissolved in dry pyridine (40
mL). The mixture was stirred at reflux overnight and was
monitored by both TLC using EtOAc-Hexanes-AcOH (4:1:1, v/v/v) and cerium molybdate as a
developing stain and mass spectrometry. The development of a peak at 542 m/z in the positive
mode indicated the formation of LCA-TBS-imidazole coupled product. To the same reaction pot,
tetrabutylammonium glucuronate (2.22 g, 5.1 mmol, 2.5 equiv.), dry pyridine (10 mL), and
sodium hydride (15 mg, 0.04 mmol, 0.02 equiv.) were added and the reaction was stirred at 50oC
for 5 hours.
spectrometry.

The reaction was monitored by TLC (same conditions as above) and mass
The development of a peak at 666 m/z in the negative mode indicated the
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formation of LCA-TBS-O-glucuronide II product. The reaction was stopped by careful addition of
water. After the solution was made just acidic with acetic acid, the product was extracted with
EtOAc (25mL x 3). The EtOAc layer was dried over Na2SO4 and then evaporated to dryness with
a rotary evaporator. The final yellow oil was not purified and was directly used for the next
reaction. Crude sample: 1H-NMR (300 MHz) (DMSO-D6) δ 4.69-4.67 (d, 2H, J= 6Hz anomeric), 3.47
(m, 1H, H-3), 0.89 (m, 6H, H-18/19, 21), 0.83 (s, 9H, t-butyl-Si), 0.63 (s, 3H, H-18/19), 0.07 (s, 6H,
2CH3-Si); 13C NMR δ 178.36 (glucuronic acid COOH) and 175.73 (LCA COOR) MS DUIS (-ve) calcd.
m/z for C36H62O9Si [(M)] 667, found [(M-1)-] 666.
LCA O-glucuronide II: 10% yield; LCA-TBS-O-glucuronide
II (1.3 g, 2.0 mmol) was dissolved in a 1.0M THF solution
of tetrabutylammonium fluoride (1.66 mL, 3 equiv.). The
reaction was stirred at 40oC for 2 days and was monitored
by mass spectrometry with the disappearance of the startming material peak at 666 m/z in the
negative mode. When complete, the reaction was quenched with addition of water and washed
with EtOAc (3x). The EtOAc layer was dried over MgSO4 and dried by rotary evaporation. The
crude yellow oil re-suspended in EtOH and the insoluble solid was filtered and washed with EtOH.
The filtrate was collected and dried.

The residue was then purified using silica gel

chromatography with MeOH-EtOAc with 1%AcOH (0-60% strong) to remove the LCA impurity.
Fractions containing the product were dried and then recrystallized with EtOH to produce a
cream colored solid. 1H-NMR (300 MHz) (DMSO-D6) δ 5.23-3.77 (m, 5H, sugar-ring protons), 3.46
(m, 1H, H-3), 2.28-2.22 (m, 0.88 (m, 6H, H-18/19, 21), 0.62 (s, 3H, H-18/19);

13DEPT-135

δ

Negative (-) CH2: 56.48, 40.25, 36.78, 35.64, 31.11, 30.86, 28.14, 27.38, 26.64, 20.89, Positive (+)
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CH and CH3: 93.07, 89.76, 70.77, 70.34, 56.52, 42.01, 40.81, 40.53, 40.43, 40.25, 39.98, 39.70,
35.86, 35.21, 23.74, 19.02, 18.62, 12.34. MS DUIS (-ve) calcd. m/z for C30H48O9 [(M)] 552, found
[(M-1)-] 551.

4.3 Modulation of VDR-Coactivator Binding by VDR Ligand Metabolites
Table 23 summarizes the binding results for phase 1 metabolites of VDR ligands. All
compounds but LCA showed no induction of the VDR-SRC2-3 interaction. Surprisingly, LCA had
low agonistic binding at an estimated value greater than 150 μM although activity of LCA has
been reported in the range of 4-6 µM.208 Interestingly, the VDR-SRC2-3 binding was inhibited with
an IC50= 13.6 ± 4.6 μM. Ursodeoxycholic acid, cholic acid, and deoxycholic acid were inactive as
antagonist, while chenodeoxycholic acid and hyodeoxycholic acid exhibited low inhibition
affinities at values greater than 150 μM. The poor inhibition by these compounds could be
Table 23. Modulation of VDR-Coactivator binding in the presence of phase 1 VDR
ligand metabolites
Recruitment of SRC-2-3
Inhibition of SRC2-3 VDR
to VDR
Interaction
Compound
EC50 (µM)
IC50 (µM)
Ursodeoxycholic Acid
Lithocholic Acid
Cholic Acid
Deoxycholic Acid
Chenodeoxycholic Acid
Hyodeoxycholic Acid
Calcitroic Acid

Inactive
>150
Inactive
Inactive
Inactive
Inactive
Inactive

Inactive
13.6 ± 4.6
Inactive
Inactive
>150
>150
6.12 ± 2.1

The maximum concentration used for this assay was 450 μM of each compound.

contributed to the additional hydroxyl groups. VDR-LBD has a very hydrophobic pocket with
hydrogen bonding occurring at the outer ends of the pocket. Hydroxyl groups in this region might
promote unfavorable binding. Interestingly, calcitroic acid was the most potent inhibitory
metabolite with an IC50 value two times as potent as LCA. The comparable potency of these two
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compounds could be contributed to the absence of any hydroxyl groups on the B and C rings and
their ability to make favorable hydrogen bonds at each end of the molecules (C3 –OH and C25 –
COOH). As expected, LCA showed agonistic behavior in the same experiments at higher
concentrations, as seen in Figure 55, A. It can be speculated that the availability of two VDR
binding sites for LCA might be responsible for this behavior. However, we also observed a large
B
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Figure 55. A) LCA effect on the interactions between VDR and Alexa Fluor 647-labeled
SRC2-3 coactivator. B) LCA effect on VDR and Texas Red-labeled SRC2-3

increase in fluorescence polarization and fluorescence intensity using a Texas Red labeled SRC23 (Figure 55, B), which is an indication of aggregation between LCA and the fluorescent probe.
This affect has been observed with other compounds for example GW0742, where aggregates
between compound and probe and increases the fluorescence intensity and polarization in the
absence of VDR.150 LCA phase 2 metabolites were also investigated using the fluorescence
polarization-based binding assay (Table 24). None of the compounds were able to induce VDRcoactivator binding. However, changes to the C3 hydroxyl group versus modification to the C25
position still allowed for inhibition of VDR-coactivator interactions. As previously discussed, LCA
acetate is a known VDR agonist with potency 30 times greater than LCA but has never been
evaluated as a VDR antagonist. Although agonistic binding of LCA acetate was not observed in
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Table 24. Modulation of VDR-Coactivator binding in the presence of phase 2 VDR
ligand metabolites
Recruitment SRC2-3
Inhibition of SRC2-3 VDR
VDR Interaction
Interaction
Compound
EC50 (µM)
IC50 (µM)
Glyco-LCA
Tauro-LCA
LCA Acetate
LCA O-Glucuronide I
LCA O-Glucuronide II
LCA Sulfonate

Inactive
Inactive
Inactive
Inactive
Inactive
Inactive

this

40.1 ± 8.0
14.5 ± 4.3
11.02 ± 3.2
28.7 ± 8.8
2.90 ± 0.6
23.3 ± 4.3

The maximum concentration used for this assay was 450 μM of each compound

assay, LCA and LCA acetate have comparable inhibitory effects on the interactions between VDR
and coactivator. Tauro-LCA was about three times more potent than glycol-LCA and the
sulfonate was less inhibitory than acetate. When comparing the positioning of glucuronic acid
on LCA, LCA O-glucuronide II was 10 times more potent than LCA O-glucuronide I.
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4.4 Modulation of VDR-Mediated Transcription by VDR Ligand Metabolites
Table 25 summarizes the VDR transcription data obtained for LCA, its phase 1 metabolites
and calcitroic acid. Surprisingly, LCA was unable to activate VDR-mediated transcription in cells
although the reported activation was observed in the presence of overexpressed RXR. Thus, the
Table 25. Modulation of VDR transcription in the presence of phase 1 VDR ligand
metabolites
Compound

VDR Transcription
EC50 (µM)a

VDR Transcription
IC50 (µM)a

Cytotoxicity
LD50 (µM)b

Ursodeoxycholic Acid
Lithocholic Acid
Cholic Acid
Deoxycholic Acid
Chenodeoxycholic Acid
Hyodeoxycholic Acid
Calcitroic Acid

Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
2.56 ± 1.04 (16.2%)

66.3 ± 39.5
35.9 ± 4.4
>100
40.0 ± 2.24
61.3 ± 11.0
62.7 ± 26.9
3.20 ± 2.4

Non-toxic
>50
Non-toxic
>150
>150
Non-toxic
>100

RXR

a

Transcription assay using a CMV-VDR plasmid and a luciferase reporter plasmid under control of a 24hydroxylase promoter with LCA and its phase 1 metabolites as well as 1,25(OH)2D3 metabolite, calcitroic
acid. Efficacy, shown in parenthesis, is in respect to full activation with 1,25(OH)2D3. bCell- TiterGlo
(Promega). Maximum concentration used was 150 μM.

dimer is essential to mediate the agonistic activity of LCA. As expected from the FP-binding data,
all the other LCA phase 1 metabolites did not activate transcription. Calcitroic acid showed
exciting transcription data. As previously thought, metabolites derived from CYP24A1-mediated
catabolism like calcitroic acid would be inactive intermediates of vitamin D degradation and thus
serve no physiological function. However, our data demonstrates that calcitroic acid possesses
partial agonistic activity at 16.2%, although at higher concentration and to a lower degree than
1,25(OH)2D3. In addition, calcitroic acid was the only compound in this series to inhibit VDRmediated transcription at a low micromolar level with little toxic effects, which is consistent with
the FP-binding data from above. Most interestingly, as calcitrioic acid inhibits the binding of
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1,25(OH)2D3 it also acts a partial agonist at nearly the same concentration (Figure 56). Further
studies will be conducted to determine the physiological role of calcitroic acid especially in
Modulation of VDR-SRC2-3 Interactions
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Figure 56. Combined dose response curves showing partial
agonistic activity (pink) and competitive inhibition (in the
presence of 1,25(OH)2D3) (green) of calcitroic acid with VDR.

respect to calcium homeostasis. Only LCA had a moderately toxic effect on the cells.
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In the 2-hybrid assay (Table 26), LCA showed agonistic results that coincides with the

Inhibition of VDR-SRC2-3 Interactions
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Table 26. Modulation of VDR-SRC1 interaction in cells in the
presence of phase 1 VDR
Positve Control
50
ligand metabolites
2-Hybrid: VDR
2-Hybrid: VDR
0
Transcription
Transcription
-4
-2
0
2
4
Compound
log [Ligand]
(M)
IC50 (µM)
EC50 (µM)
Ursodeoxycholic
acid
Inactive
Inactive
Figure 57. Dose-response curve showing the partial agonistic
Lithocholicactivity
acid of LCA compared
2.63 ± 1.75
(35.2%)
40.0
± 8.24
to 1,25(OH)2D3.
Cholic acid
Inactive
Inactive
Deoxycholic acid
Inactive
57.36 ± 11.1
Chenodeoxycholic acid
Inactive
>60
Hyodeoxycholic acid
Inactive
66.6 ± 32.1
Calcitroic Acid
0.85 ± 0.33 (47.6%)
Inactive
Two-hydrid assay: HEK293T cells were transfected with a VP16-VDR-LBD, SRC1-GAL4, and luciferase
reporter plasmid vector with or without 1,25(OH)2D3 and LCA phase 1 metabolites or calcitroic acid.
Efficacy, shown in parenthesis, is in respect to full activation with 1,25(OH)2D3. Maximum concentration
used was 150 μM.

literature.198 It was able to recruit SRC1 coactivator and activate transcription with an IC50= 2.63
± 1.75 μM, however the effects was only 35.2% of that of 1,25(OH)2D3 (Figure 57).
LCA inhibited transcription at a moderate level that was comparable to the results found in the
transcription assay (Table 25). Again, calcitroic acid was a partial agonist but did not have any
inhibitory effect on the recruitment of SRC1. All other LCA phase 1 metabolites did not activate
transcription thus suggesting unfavorable interactions with VDR due to extra hydrogen bond
donor/acceptors in the ring system. Deoxycholic acid, chenodeoxycholic acid, and
hyodeoxycholic acid again showed moderate antagonistic effects on transcription.
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Table 27 summarizes the transcription data obtained for LCA phase II metabolites. All
compounds were non-toxic at a maximum concentration of 150 μM. Glyco-LCA, tauro-LCA, and
Table 27. Modulation of VDR transcription in the presence of phase 2 VDR ligand
metabolites
Compound

VDR Transcription
EC50 (µM)a

VDR Transcription
IC50 (µM)

Cytotoxicity
LD50 (µM)

Glyco-LCA
Tauro-LCA
LCA Acetate
LCA O-Glucuronide I
LCA O-Glucuronide II
LCA Sulfonate

Inactive
Inactive
17.6 ± 7.60
3.73 ± 2.1 (22.1%)
6.92 ± 3.9 (21.7%)
Inactive

>50
Inactive
44.3 ± 16.4
>150
>150
Inactive

Non-toxic
Non-toxic
Non-toxic
Non-toxic
Non-toxic
Non-toxic

a

Transcription assay using a CMV-VDR plasmid and a luciferase reporter plasmid under control of a 24hydroxylase promoter with LCA phase 2 metabolites. Percent partial agonistic activity is shown in
parenthesis. Efficacy, shown in parenthesis, is in respect to full activation with 1,25(OH)2D3. bCellTiterGlo (Promega). Maximum concentration used was 150 μM.

LCA sulfonate were unable to activate or inhibit transcription with glyco-LCA possessing very
moderate inhibitory effects. LCA acetate agonist activity was confirmed but also inhibited VDRmediated transcription at an IC50= 44.3 ± 16.4 μM. In addition, LCA O-glucuronide I and II
exhibited a potent partial agonist activity as seen in the dose-response curve in Figure 58.
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Figure 58. Dose-response curve showing the partial agonistic
effect LCA O-glucuronide I and LCA O-glucuronide II have on VDRmediated transcription.

In the 2-hydrid assay (Table 28), LCA acetate was able to recruit SRC1 and activate VDRmediated transcription reported. LCA O-glucuronide II but not LCA O-glucuronide I was also a
potent agonist with a partial agonistic effect of 30.7% compared to 1,25(OH) 2D3. Other phase 2
metabolites exhibited no activity.

Table 28. Modulation of VDR-SRC1 interaction in cells in the presence of phase 2 VDR
ligand metabolites.
2-Hybrid: VDR
2-Hybrid: VDR
Transcription
Transcription
COMPOUND
IC50 (µM)
EC50 (µM)
Glyco-LCA
Tauro-LCA
LCA Acetate
LCA O-Glucuronide I
LCA O-Glucuronide II
LCA Sulfonate

Inactive
Inactive
1.79 ± 1.16
>150
8.39 ± 4.60 (30.7%)
Inactive

>50
Inactive
>150
>150
>150
Inactive

Two-hydrid assay: HEK293T cells were transfected with a VP16-VDR-LBD, SRC1-GAL4, and luciferase
reporter plasmid vector with or without 1,25(OH)2D3 and LCA phase 2 metabolites. Percent partial
agonistic activity is shown in parenthesis. Efficacy, shown in parenthesis, is in respect to full activation
with 1,25(OH)2D3. Maximum concentration used was 150 μM.
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4.5 Semi-Quantitative Real Time PCR
Polymerase chain reaction (PCR) is an important
tool in molecular biology, medicine and forensics
sciences because it can amplify DNA from a selected
region of a genome by a billion-fold thus effectively
purifying the DNA from the remainder of the genome.209
The process relies on thermal cycling which consists of
repeated cycles of heating and cooling of the DNA in the
presence

of

reverse

and

forward

primers,

deoxynucleoside triphosphates (dNTPs) and polymerase
enzyme. The DNA is first heated to about 90oC to

Figure 59. SYBR green binding to
dsDNA to produce a fluorescent
signal.

denature it into single stranded DNA. After strand separation, cooling of the DNA allows for the
hybridization of the primers to the strand. This occurs usually between 50-60oC for a few seconds,
where it is typically 3-5oC below the melting temperature (Tm) of the primers being used. The
single stranded DNA is then ready for extension. Starting at the primers, the dNTPs are added to
the single strand with the help of DNA polymerase. The number of double stranded (dsDNA)
produced is exponential and dependent on the number of cycles. Once the desired amount of
dsDNA is produce, it can be quantified and identified using gel electrophoresis. In addition to
DNA, trace amounts of RNA can be analyzed in the same way by first transcribing them into DNA
with reverse transcriptase. The procedure for semi-quantitative real time polymerase chain
reaction (qRT-PCR) is very similar to classic PCR except for the ability to obtain real time analysis
through the incorporation of a fluorescent marker into the PCR product with every cycle. In our
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case, fluorescence was detected using a SYBRTM Green probe. It is a DNA binding dye that binds
to the minor groove of dsDNA and emits light (Figure 59). When only single stranded DNA is
present, the dye weakly binds and low fluorescence is observed therefore making the dye a
selective tool for detecting the PCR product being produced.
As previously mentioned, 1,25(OH)2D3 upregulates its own catabolic degradation through
the C24-oxidation and C23-hydroxylation pathways of CYP24A1 rendering it biologically unstable.
Because many VDR agonist contain the secosteroidal scaffold, they too experience metabolic
instability requiring them to be given in combined therapies with CYP inhibitors. Herein we
report the use of a qRT-PCR to investigate the effect VDR ligands, LCA O-Glucuronide I, LCA OGlucuronide II, LCA or calcitroic acid, would have on CYP24A1 gene regulation.

4.5.1 Experimental Procedure
Reagents and Instrumentation: The prostate cancer cell line, DU 145, was purchased (ATCC) and
in cultured in 75 cm2 flasks (CellStar). Cells were grown in DMEM/High Glucose (Hyclone,
#SH3024301) media to which non-essential amino acids (Hyclone, #SH30238.01), 10 mM HEPES
(Hyclone, #SH302237.01), 5 x 106 units of penicillin and streptomycin (Hyclone, #SV30010), and
10% of heat inactivated fetal bovine serum (Gibco, #10082147) were added. Cells were
harvested using 0.05% Trypsin (Hyclone, #SH3023601), which disrupts the cell monolayer and
proteolytically cleaves the bonds between the cells and flask. Cells were re-plated into 6 well
plates ( coated in matrigel (BD Bioscience, #354234) using DMEM/High Modified buffer without
phenol red (Hyclone, #SH30284.01) that contained all the above mentioned additives plus 10mM
sodium pyruvate and 2% percent charcoal treated FBS (Invitrogen, #12676-011) instead of HI FBS
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prior to dosing. Compounds were diluted to either 10 mM or 30 mM solutions with DMSO. The
cells were lysed using a QIAshredder (Qiagen) and total RNA was isolated using RNAeasy kit
(Qiagen). RNA concentration was determine by UV at 260nm using the Tecan Infinite M1000
plate reader.

A QuantiFast SYBR Green RT-PCR Kit (Qiagen) was used for the real time PCR

following manufacturer’s recommendations. Primers used in these studies are as follows:
GAPDH FP 5’-ACCACAGTCCATGCCATCAC-3’, GAPDH RP 5’-TCCACCACCCTGTTGCTGTA-3’;
CYP24A1 FP 5’-CTTTGCTTCCTTTTCCCAGAAT-3’; CYP24A1 RP 5’- CGCCGTAGATGTCACCAGTC-3’;
Real-time rt-PCR was carried out on a Mastercycler (Eppendorf).
Semi-Quantitative RT-PCR Protocol: 80-90% confluent DU145 cells were harvested using 0.05%
Trypsin and transferred to 6 well plates coated in matrigel. Cells were cultured in DMEM media
without phenol red and incubated at 37oC overnight to allow the cells to settle and adhere to the
plate. The next day, either DMSO (0.03%), test compound (7.5 μM, LCA O-glucuronide I, LCA Oglucuronide II, Calcitroic acid, LCA) or 1,25(OH)2D3 (20 nM) were added to the 6-well plate and
incubated at 37 °C for 18 hours. Cells were harvested following the RNAeasy Mini Handbook
“Protocol for the Purification of Total RNA from Animal Cells using Spin Technology”.210 After 18
hours, cells were first harvested with 0.05% Trypsin and added to media to be counted using a
hemocytometer. The cell suspension was then spun down for 2 minutes at 1000 rpm to form a
pellet. Media was removed and the cell pellet was resuspended in RTL buffer and vortexed for 5
seconds each. RTL buffer and cell mixture was added to a QIAshredder spin column and spun for
2 minutes at 10,000 rpm. One volume of 70% ethanol was added to the homogenized lysate and
mixed well by pipetting. Afterwards, the solution transferred to an RNAeasy spin column and
spun for 15s at 10,000 rpm. At this point, all RNA is attached to the spin column and washed
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several times with different buffers provided by the RNAeasy Qaigen kit. All flow throughs were
discarded. Once thoroughly washed and dried, the RNA is collected by adding 30-50 μL RNasefree water to the spin column and collecting it in a 1.5 mL tube by spinning for 1 minute at 10,000
rpm. Total RNA concentration was determined by UV at 260nm. Once isolated, RNA was diluted
accordingly and a QuantiFast SYBR Green RT-PCR Kit (Qiagen) was used for the real time PCR
following the “QuantifastTM SYBRTM Green RT-PCR Handbook”. The cycling conditions used for
Quantifast SYBR Green was 10 minutes at 50oC (reverse transcriptase), 5 minutes at 95oC (PCR
initial activation step), 10s at 95

oC

(denaturation), and 30s at 60

oC

(combined

annealing/extension) for 50 cycles. The forward and reverse primers used were the house
keeping gene, GAPDH and the gene of interest, CYP24A1. We used the ∆∆Ct method to measure
the fold change in gene expression of target genes. Standard errors of mean were calculated from
two biological independent experiments performed in triplicates.
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4.5.2 Results and Discussion
The expression levels of VDR target gene, CYP24A1, was determined in DU145 cells
treated with 7.5μM of LCA O-glucuronide I and II, LCA and calcitroic acid as seen in Figure 60. As
expected, a strong induction of CYP24A1 by 1,25(OH)2D3 (20nM) was observed. Cells treated with

Figure 60. CYP24A1 regulation by LCA phase 2
metabolites, LCA, and calcitroic acid (7.5μM) in DU145
compared to 1,25(OH)2D3 and DMSO after 18hrs.
Standard errors of mean were calculated from two
biological independent experiments performed in
triplicate.

the two synthetically made LCA phase 2 metabolites, LCA O-Glucuronide I and II did not induce
the expression of CYP24A1 gene. However, LCA and the 1,25(OH)2D3 catabolic metabolite,
calcitroic acid, induced the induction of transcription but not to the extent of 1,25(OH)2D3 ,
supporting the agonistic effect seen for both of these compounds in the transcription assay.
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4.6 Conclusion
Overall, LCA-based phase 2 metabolites and LCA itself but not phase 1 metabolites were
able to competitively inhibit the recruitment of Alexa Fluor 647-labeled SRC2-3 to VDR-LBD.
Importantly, calcitroic acid was identified as partial VDR agonist. Unfortunately, aggregation
between LCA analogs and Texas Red omitted the application of different coregulator peptides,
which were only available as Texas-Red conjugates. All but LCA showed minor activation of
binding in the absence of LG190187 and LCA O-glucuronide II was the most potent molecule
among LCA phase 1 and phase 2 metabolites with an IC50 five time more potent than LCA.
Judging from the results of the 2-hybrid assay, none of the metabolites were novel VDR
inhibitors. However, the lower efficacy compared to 1,25(OH)2D3 was observed for LCA Oglucuronide I and II and calcitroic acid in the transcription assay means that it could be used to
restrict full activation of VDR-mediated transcription. Further studies are necessary to evaluate
these partial agonist in respect to calcium homeostasis and metabolic stability.
The qRT-PCR study revealed that LCA and calcitroic acid but not LCA O-Glucuronide I and
II up-regulate CYP24A1 and produce 24-hydroxylase. Interestingly, because expression was
conducted in DU145 cells, a prostate cancer cell line, it can be postulated that these molecules
may promote anti-proliferation and differentiation of cancer cells. This is evidenced in the
literature by other analogs, such as P450 enzyme inhibitors that deactivate 24-hydroxylase thus
increasing the concentration of 1,25(OH)2D3 induced anti-proliferation.211, 212
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CHAPTER 5: IDENTIFICATION OF VDR ANTAGONISTS AMONG
NUCLEAR RECEPTOR LIGANDS USING VIRTUAL SCREENING
5.1 Introduction
NRs are one of the most important drug targets today.213 Over the last decades thousands
of small molecules have been synthesized to improve the activity of NR ligands identified by HTS
or rational drug design. Although the activity of NR ligands is very important in terms of dosage
and suppression of side effects, the selectivity of ligands towards a particular NR is crucial for
specific pharmacological effects. Usually NR ligands are investigated in respect to their NR
isoform-selectivity. For instance, ER ligands are evaluated for their selectivity towards ERα and
ER, which are distributed tissue-selectively in the human body.214 Once a promising ligand has
been identified, further analysis in respect to other closely related NRs is conducted based on
phylogenetic distance or NR sequence similarity.215, 216 Schapira et al. introduced an alternative
concept of NR similarity based on the likelihood that two NRs share a common ligand. 217
Therefore, sixteen NR crystal structures and 78 NR ligands were used in a computational
approach to determine the cross-reactivity of NR ligands. Herein, we present an alternative
approach by using a large library of NR ligands and only one receptor, VDR. Among 14330
compounds, we identified four new VDR antagonists that were originally developed as ligands
for other nuclear receptor. Thus, virtual screening represents a useful tool to identify those NRs
that are likely to interact with a new NR ligand.

5.2 Experimental Procedure
5.2.1 Virtual Screens
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A library of nuclear receptor ligands were assembled using “the Binding Database”. The
database included 14330 compound structures and their nuclear receptor binding data (EC50,
IC50, or KD). Weakly active ligands that had estimated binding data (e.g. >5000 μM) or inactive
compounds (e.g. no binding observed) were assigned a zero activity. Compounds that were not
tested were assigned an empty field. The database only included compounds that were at least
tested with one nuclear receptor. For racemic compounds only one stereoisomer was used for
the screen. All compounds were minimized and the ionization state of functional groups was
adjusted to pH 7. Molecule conformations were generated from a single 3D conformer by
applying a collection of preferred torsion angles to the rotatable bond during the virtual screen.
The crystal structure of VDR bound to 1,25(OH)2D3 (PDB ID 1DB1)218 was prepare for docking
using the MOE structure preparation function to repair any structural defects in the pdb file. In
addition, a protonation 3D function was used to optimize the hydrogen bond network and
hydrogen positions. Finally unbound water molecules were removed. The virtual screen was
carried out by selecting VDR-bound 1,25(OH)2D3 as binding site and a triangle matcher for the
placement of compounds. The triangle matcher function generated poses by superposition of
ligand atom triplets and triplets of receptor site points. The receptor site points are alpha sphere
centers which represent locations of tight packing. At each iteration, a random triplet of ligand
atoms and a random triplet of alpha sphere centers were used to determine the pose. The poses
were scored using affinity London dG scoring that estimated the free energy of binding (ΔG) from
each given pose given in kJ/mol. Compound conformations that do not satisfy the
pharmacophore model 1 or 2 depicted in Figure 4 were eliminated.
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5.2.2 Fluorescence Polarization Assay with VDR-SRC2-3
Reagents and Instrumentation: LG190178 was synthesized using a published procedure.153 The
peptide SRC2-3 (CLQEKHRILHKLLQNGNSPA),219 was purchased and labeled with the cysteinereactive fluorophore (Alexa Fluor 647 maleimide) in a 50:50 DMF/PBS mixture. After purification
by high performance liquid chromatography, the corresponding labeled peptide was dissolved in
DMSO and stored at -20ºC. The VDR-LBDmt DNA was kindly provided by D. Moras218 and cloned
into the pMAL-c2X vector (New England Biolabs). A detailed expression and purification protocol
for VDR was reported previously.219
Fluorescence Polarization Assay Protocol: Agonistic and antagonistic activity was studied using
a FP assay. This assay was conducted in 384-well black polystyrene plates (Corning) using a buffer
(25 mM PIPES (pH 6.75) 50 mM NaCl, 0.01% NP-40, 2% DMSO), VDR-LBD protein (0.1 μM),
LG190178 (3 μM), and Alexa Fluor 647-labeled SRC2-3. Small molecule transfer into a 20 μL assay
solution was accomplished using a stainless steel pin tool (V&P Scientific), delivering 100 nL of
the serially diluted compound solution. Fluorescence polarization was detected after 1 hour at
excitation and emission wavelengths of 650 nm and 665 nm, respectively. Three independent
experiments were conducted in quadruplicate. The data were analyzed using nonlinear
regression with a variable slope (GraphPadPrism).
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5.3 Results
A library of 14330 NR ligands were compiled using “The Binding Database.org”. 220 The
sets of NR ligands were downloaded individually and merged as a virtual small molecule library
using MOE (molecular operating environment). The number of ligands downloaded per NR is
given in Figure 61. The NRs with the largest ligand databases are the peroxisome proliferator-

Figure 61. Number of NR ligands deposited with “The
Binding Database”.

activated receptor (PPAR)γ, PPARδ, PPARα, the progesterone receptor (PR), the androgen
receptor (AR), the ERα, the ER, and the glucocorticoid receptor (GR) with more than a thousand
ligands each. Overall, 30 NRs are represented by their ligands in “The Binding Database” with a
total of 14330 unique NR ligands. Many of these ligands were investigated in regards to multiple
NR binding and some of them exhibited a significant potency to more than one NR.
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The analysis to determine global selectivity of ligand among nuclear receptors is restricted
by the fact that limited data are available. We were surprised that for the majority of ligands only
one NR was evaluated. 4006 ligands out of 14330, thus a quarter of the ligands, were investigated
with only two different NRs as illustrate in Figure 62. Most of NR ligands tested with two NRs

Figure 62. Number of NR ligands that bind to
multiple NRs.

were able to bind two NR isoforms with different affinity, such as α and , which applies to the
liver X receptor (LXR), ER, and TR. Ligands that were developed for NRs having three isoforms
such as PPAR, estrogen related receptor (ERR), RXR, and retinoic acid receptor (RAR) represent
almost half of the NR library members (Figure 61). However, only a fraction of these ligands
(1853) were evaluated with more than two NRs (Figure 62). Some examples of ligands that bind
multiple NRs, although with different affinity, are depicted in Figure 63. Compound 1 (Figure 63,
A) was developed by Ligand Pharmaceuticals as RXRα antagonist.221 Although the selectivity in
respect to RARs is very high, there is a moderate selectivity toward other RXR subtypes. In
addition, a synergistic activation of transcription was observed when cotransfected with PPARγ
in the presence of selective PPARγ ligand. Guggulsterone (Figure 63, B) was predominately
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evaluated with steroid hormone receptors.222 The compound has a strong affinity for the

Figure 63. NR ligands that were evaluated towards multiple nuclear receptors.

mineralocorticoid receptor (MR) and the pregnane X receptor (PXR).223 Compound 2 (Figure 63,
C) is a very potent GR antagonist, which still has a significant activity towards PR and AR.224 Finally,
GW0742 (Figure 63, D) was developed by GlaxoSmithKline as highly a selective agonist for the
PPARδ.225 The evaluation of GW0742, in respect to NR-mediated inhibition of transcription,
identified this compound as antagonist for AR and VDR.152
Nevertheless, the exhaustive characterization of NR ligands is limited by the sheer
number of different NRs resulting in a cost and time-intensive analysis for research labs and the
pharmaceutical industry. Therefore, a prediction of NR-selectivity of new ligands using
computational approaches might enable a selection of a smaller pool of NRs to be considered for
evaluation. In addition, this approach might also identify groups of NRs that bind similar ligands,
thus introducing a new relationship between NRs that is different from phylogenetic distance or
NR sequence similarity. In order to test this hypothesis, we used the library of NR ligands and
carried out two virtual screens applying the first crystal structure of liganded VDR.218 For each
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screen, we applied a different pharmacophore model to filter all molecule conformations. The
two different pharmacophore models are depicted in Figure 65.
The virtual screen 1 was carried out with a pharmacophore model that specifies three electron
donor/acceptor elements depicted as purple spheres (Figure 64, A). These three elements
represent the spatial configuration of three hydroxyl groups of the most active endogenous VDR
ligand 1,25-dihydroxy vitamin D3 (1,25(OH)2D3).226 1,25(OH)2D3 is a metabolic product of vitamin
D3 formed from 25(OH)D3 by 1α-hydroxylase.227 The binding affinity of 1,25(OH)2D3 is 0.1-1 nM,
whereas 25(OH)D3 binds with a moderate affinity of 1420 nM towards VDR.228 The virtual screen
A

B

Figure 64. Two different pharmacophore models for VDR ligands. Pharmacophore models
were established using MOE.

of 14330 compounds using model A (Figure 64) identified 64 compounds. 32 of the 64
compounds had a significant calculate free energy of VDR binding of more than -6.0 kJ/mol.
Nordihydroguaiaretic acid (NDGA) was the only non-VDR ligand identified with a calculate ΔG of
-11.1 kJ/mol (Figure 65, B). NDGA is a bioactive compound that inhibits lipoxygenases, functions
as an antioxidant, and has shown promising anti-cancer activities.229 The compound has also
been reported to weakly interact with the androgen receptor by binding to a new BF3 binding
site.230
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Herein, we confirmed the activity NDGA towards VDR using a fluorescence polarization
assay. In the presence of 1,25(OH)2D3, NDGA was able to inhibit the interaction between VDR
and coactivator peptide SRC2-3 with an IC50 values of 15.8 ± 2.1 μM. In the absence of

Figure 65. Nordihydroguaiaretic acid is inhibiting the interaction between
VDR and coactivator peptide SRC2-3.

1,25(OH)2D3, NDGA was not able to promote the recruitment of coactivator towards VDR (Figure
65, A). Because of the fact that the interactions between VDR and coactivators are essential for
VDR-mediated transcription we identified NDGA as novel VDR antagonist.
Virtual screen 2 was carried out using a less stringent pharmacophore model depicted in Figure
64, B bearing two acceptor/donor groups representative of VDR ligand 25(OH)D 3. Among the
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14330 molecules, 397 compounds were identified and 162 compounds exhibited a free energy
of binding of more than -6.0 kJ/mol (Figure 66). Among the hit compounds of virtual screen 2,

Figure 66. Number and affiliation of NR ligands identified by virtual
screen 2 using the pharmacophore model depicted in Figure 4, B.

the majority of molecules were developed as ligands for VDR. Ligands developed for LxRα/,
TRα/, and ERα/ ligands were among the most frequent ligands that potentially interact with
VDR. We picked one TRα ligand (3) and one ERα ligand (H6036) in order to confirm the activity in

Figure 67. Interaction between virtual screen hit compounds (♦H6036,  compound 3,
▲triiodothyronine) and VDR. A) Hit compound inhibition of the interaction between SRC2-3
and VDR in the presence of VDR agonist LG190178; B) Association of VDR-LBD and SRC2-3 in
the presence of hit compounds; C) Structure and generation of NR ligands.

regard to VDR (Figure 67). Fortunately, both compounds (1 and H6036), identified by virtual
162

screen 2, were able to inhibit the interaction between VDR and SRC2-3 with IC50 values of 44.5 ±
6.1 μM and 20.0 ± 3.4 μM, respectively (Figure 67, A). The original docking score for these
compounds was -7.9 kJ/mol (3) and -9.1 kJ/mol (H6036). The thyroid receptor ligand
triiodothyronine did not score during the virtual screen 2 because it did not satisfy the
pharmacophore model. However, we observed that triiodothyronine did inhibit the interaction
between VDRSRC2-3, although at higher concentrations. In the absence of VDR ligand LG190178
no recruitment of SRC2-3 to VDR was observed in the presence of any of these ligands (Figure
67, B).

5.4 Discussion
We showed that databases such as the “Binding database” can function as starting point
for virtual screening. During the compilation of this focused library we were surprised by the
small number of developed NR ligands that have been evaluated with other NRs. The main reason
for this lack of investigation is the size of the NR superfamily in addition to the existing agonism
and antagonism that would make an exhaustive evaluation with a panel of NRs very time
intensive and costly. An alternative approach to predict NR selectivity might be realized by virtual
screening. Using the first published VDR crystal structure and pharmacophore models
representing the essential features of VDR ligands, we showed that among NR ligands those with
higher affinities for VDR can be identified by virtual screening. The essential features of VDR
ligand 1,25(OH)2D3 are three hydroxyl functions that interact with VDR via hydrogen bonding. In
addition, this ligand induces a large hydrophobic effect due to the non-polar vitamin D3 scaffold.
Using a pharmacophore model based on 1,25(OH)2D3 that defines the spatial orientation of three
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OH groups as filter, we were able to identify compounds that interact with VDR with 100%
accuracy during the first virtual screen using a cutoff of -6 kJ/mol for the calculated free energy
of binding. 31 out of the 32 hit compounds were VDR ligands such as agonists 2MD 231 or
antagonist 4232. Both compounds have been shown to bind VDR, however 2MD promoted the
recruitment of coactivators, whereas antagonist 4 inhibited the interaction between VDR and
coactivator. Thus, our virtual screen 1 was very efficient to identify VDR ligands but did not
differentiate between VDR agonists and antagonists.
Our virtual screen 2 applied a less stringent pharmacophore model based on VDR ligand
25(OH)D3, which is at least 1000-fold less potent than 1,25(OH)D3. As expected, we identified
more and different NR ligands that are likely to interact with VDR. In total we found 162
compounds with a calculated free energy of VDR binding of more than -6.0 kJ/mol. 54% of these
ligand were developed for VDR. The next biggest group included ER ligands (26%) with different
affinities for the ERα and ER, followed by TR ligands (7%) and LxR ligands (7%). Thus, there is a
relationship between VDR, TR and ER that is beyond the phylogenetic distance or NR sequence
similarity. We picked two compounds that were commercially available or in case of 3 easy to
synthesize. Fortunately, both compounds inhibited the interaction between VDR and coactivator
peptide SRC2-3 although at different concentrations. We were very pleased that the calculated
free energy of binding correlated with the IC50 values observed for the new VDR antagonists.
NDGA exhibited the highest VDR affinity and largest free energy of VDR binding followed by
H6036 and 3, respectively. Interestingly, triiodothyronine was not among the hit compounds
because it failed to satisfy the pharmacophore used for virtual screen 2. Nevertheless, we
confirmed triiodothyronine as a weak VDR antagonist highlighting the fact that other
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pharmacophore models exist to identify VDR ligands. One approach to develop a new
pharmacophore for this kind of virtual screening could include the application of a VDR crystal
structure bound to a VDR ligand with a low calculated free energy of VDR binding for the virtual
screen 1 but a relative high reported affinity for VDR. Another approach could include the
optimization of our current pharmacophore model by changing the volume of the
donor/acceptor elements or by adding additional pharmacophore elements.
Overall, the development of NR-specific pharmacophore models is important because it
can assist in the choice of NRs that should be evaluated in order to determine NR-selectivity of
novel NR ligands. Although this approach can drastically decrease the cost and time to determine
NR-selectivity of new ligands it is not a full substitute for an exhaustive investigation of a
comprehensive panel of NRs in respect to agonism and antagonism. In addition, NR-specific
pharmacophore models can be used to identify new NR ligands. We demonstrate the utility of
this approach using a library of NR ligands to identify new VDR antagonists. The application of
larger virtual compound libraries such as the “Zinc Library” might result in the identification of
even more compounds that interact with VDR. Overall it can be concluded that virtual screening
can support both the identification of new NR ligands as well as the identification of NRs that are
likely to interact with new NR ligands in order to accelerate the determination of NR selectivity.
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PART II. THE DEVELOPMENT OF A UNIVERSAL GTPase ASSAY
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CHAPTER 1: INTRODUCTION
GTPases act as molecular switches in which their “on” and “off” functions are triggered
by the binding and hydrolysis of GTP.233, 234 Their highly conserved function allows GTPases to
play an important role in regulation of cellular processes ranging from cell growth and
differentiation to vesicular and nuclear transport. As depicted in Figure 68, activation of GTPases
requires the dissociation of protein bound guanosine diphosphate (GDP) an intrinsically slow
process that is accelerated with the help of guanine nucleotide-exchange factors (GEFs). The
switch-ON process involves the exchange of GDP for guanosine triphosphate (GTP), which in
theory is a reversible reaction. The switch-off process involves hydrolysis of GTP to GDP, which
is an irreversible reaction. This additional slow process is accelerated by GTPase-activating
proteins (GAPs).
Several proteins belong to the GTPase superfamily including small Ras-related proteins
=
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Figure 68. The basic “on” and “off” switch cycle of GTPases.

with many subfamilies (Rho, Rab, Arf and Ran), heterotrimeric G proteins with α, β and γ subunits,
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and large proteins such as dynamin, which is responsible for endocytosis in eukaryotic cells.234
With growing research in this area, many members of the GTPase family have been linked to
diseases like cancer, diabetic renal disease, and neurological diseases such as Parkinson’s
disease.235, 236 Especially Ras GTPases (HRas, KRas, and NRas), which control cell proliferation,
differentiation, cellular growth and apoptosis, have been implicated in a large number of cancers
and hyperproliferative diseases.237, 238 Ras GTPase-mediated regulation is disrupted by specific
gene mutations coding these proteins, specifically at codon 12, 13, and 61. The single point
mutation promotes oncogenesis and promotes GTP binding and activation of Ras. The presence
of mutations in cancer does vary between different types of tumors with predominate isoforms
in particular cancers. For instance, K-Ras has been shown to be the most frequently mutated
GTPase in cancers with 90% of pancreatic tumors harboring this mutation.237
Due to their relationship to many diseases, numerous GTPase targeting drugs have been
developed. One third of all drugs targeting proteins are either interacting with kinases (22% of
drugs) or GTPases (15% of drugs). The growing interest in GTPase targeting drugs has promoted
the development of assays that can efficiently test these compounds in a high throughput and
inexpensive way. Although many commercially available kinase/GTPase assays are on the
market, they do not necessarily directly monitor the conversion of NTP to NDP. Activity-based
assays are advantageous because of their sensitivity and ability to directly detect changes in the
biochemical activity of the enzyme. However, many of these activity-based assays utilize
antibodies to detect the phosphorylated peptide produced. This makes them specific but not
universal. Monitoring the formation of GDP is universal because it is the most basic function of
GTPases irrespectively which substrate is phosphorylated. The available assays a variety of
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detections including proximity-based scintillation, fluorescence polarization, UV, and
fluorescence resonance energy transfer (FRET).
AviMed Pharmaceuticals, LLC, is a local company founded by Dr. Daniel Sem with interest
in developing a universal kinase/GTPase assay kit that is affordable and commercially available

Figure 69. The dithio-coupled reaction using Ellman’s reagent to detect the enzymatic
activity of kinases or GTPases.

for industry and research labs to test potential drug candidates. Dr. Sem is the inventor of two
kinase/GTPase assay patents describing the assay to be used in for these kits.239, 240 The assay
designed relies on the fact that a beta thiol substituted ATP (GTP for GTPases) can be
enzymatically hydrolyzed and produce ADP (GDP). The exposure of the thiol makes it nucleophilic
and reactive towards thiol-sensitive fluorescent or calorimetric reagents such as Ellman’s
reagent.241 The assay is illustrated in the Figure 69. Enzymatic reaction rates can be measured
in the presence or absence of inhibitors as a way to identify and screen potential kinase (GTPase)
targeting drug candidates. Herein, we report the synthesis of assay reagents and the preliminary
development of a universal, inexpensive, sensitive GTPase assay kit that directly detects the
GTPβ-S hydrolysis product, GDPβ-Se.
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CHAPTER 2: THE SYNTHESIS OF GTPase ASSAY REAGENTS: GTPβ-S AND
GTPβ-Se
2.1 Chemistry
2.1.1 Synthetic Strategy
The overall synthetic scheme used in our lab to make GTPβ-S and GTPβ-Se was adopted
from the literature and is shown in Scheme 10.242 Essentially, it’s a two-step one pot reaction to
convert GDP to GTP without the use of enzymes. First, (2-cyanoethyl) phosphate barium salt (2.1)
was converted into its triethylammonium salt (2.2) using the ion-change resin Dowex and
triethylamine (TEA).

The reaction with imidazole in the presence of 2,2’-dithiopyridine,

Scheme 10. General synthetic scheme for GTPβ-X analogs. i) a) H2O, Dowex (50Wx8, 200400mesh), rt, 1 hour b) TEA, EtOH; ii) a) imidazole, 2,2’-DTDP, Ph3P, TEA, DMF, rt, 6-8 hours, b)
LiClO4, dry ACN ; iii) MgCl
rt, 24generated
hours; iv) DBU,
DMF, 50oC, 2-5
hours.1a. GTPβ-S or GTPβ2, DMF,
triphenylphosphine
and TEA
in DMF
the DTT,
phosphorylating
agent,

Se were synthesized by coupling of 1a with GDPβ-S or GDPβ-Se in the presence of MgCl2 followed
by β-elimination of the cyanoethyl (CE) group using 1,8-diazabicycloundec-7-ene (DBU). Due to a
possible conjugate addition of acrylonitrile with the nucleotide, dithiothreitol (DTT) was added
to scavenge formed acrylonitrile during the reaction. In addition, either an open flask capped
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with anhydrous calcium chloride to protect the reaction from moisture, or a weak vacuum
applied to the sealed reaction can aided in the removal of acrylonitrile.
The syntheses of GDPβ-S and GDPβ-Se are summarized in Scheme 11 and 12, respectively.
First, guanosine 5’-monophosphate disodium salt (2.4) was transformed to the TEA salt (GMP-

Scheme 11. Synthesis for GDPβ-S. i) a) H2O, Dowex (50Wx8, 200-400mesh), rt, 1
hour, b) TEA, EtOH; ii) a) imidazole, 2,2’-DTDP, Ph3P, TEA, DMF, rt, 6-8 hours, b)
NaClO4, dry acetone; iii) a) DMF, ZnCl2, thiosphophate TEA+ salt, rt, 30 minutes, b)
EDTA, NaHCO3, H2O.

TEA+) following the same ion-exchange procedure reported previously. Activation yielded
guanosine monophosphate phosphorimidazolide (GMP-Im), which was coupled with
thiophosphate to yield guanosine 5’-O-(2-thiodiphosphate) (GDPβ-S).

Scheme 12. Synthesis of GDPβ-Se. i) a) dry pyridine, CH3CN, rt, 30
minutes, b) TEA, MeOH, rt, 3 hours; ii) DMF, ZnCl2, rt, 20 minutes b) EDTA,
NaHCO3, H2O, pH= 7.5, room temperature, 3 hours.
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Elemental selenium and tris(trimethylsilyl)phosphite (2.5) were mixed and transformed
with TEA to synthesize triethylammonium selenophosphate (2.6).243 Inert and dry conditions
were essential to suppress the formation of Se-Se bonds.

31P-NMR

confirmed the formation of

triethylammonium selenophosphate, which due to its instability, was immediately coupled with
GMP-Im in the presence of ZnCl2 to yield the final product, guanosine 5’-O-(2-selenodiphosphate)
(GDPβ-Se).

All diphosphate and triphosphate nucleotides were purified by ion-exchange

chromatography on DEAE-Sephadex A-25 (HCO3-) column. Briefly, the crude product was loaded
on the column and washed with excess water to remove metal salt/EDTA complexes.
Subsequently, the nucleotide was eluted using a linear gradient of triethylammonium
bicarbonate (TEAB, pH= 8.0).

2.1.2 Characterization
All starting reagents were purchased from either Sigma-Aldrich or Fisher Scientific.
Synthesized nucleotides were purified using a fast protein liquid chromatography system (FPLC,
GE Healthcare AktaPurifier UPC 10, #28406268). 5 mL proteus FPLC columns were purchased
from NuSep (#Nu-FliQ1-25) and loaded manually. GTPβ-Se reaction was monitored by HPLC
using a Agilent Tech. Series 1220 Infinity LC with a Supelcosil LC-18-T HPLC column (Sigma,
#58971, 4.6 x 250mm, flow rate 1mL/min) with a linear gradient 1-25% of methanol in 0.05M
ammonium acetate buffer (pH=5.9) in 15 minutes, UV-detection at 260 nm.

Compound

characterization was performed using a Shimadzu 2020 LC-MS (single quadrupole) instrument
with compounds directly injected. NMR spectra were recorded on a Bruker 300MHz instrument
with samples diluted in D2O.
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General Procedure for Converting to TEA Salt using Dowex: 5 g of starting salt (i.e. Ba2+, Na+)
was suspended in water (100mL) and mixed with a calculated amount of Dowex 50W x 8 (200400mesh) resin in H+ form (see calculation below) in a beaker covered with parafilm. The mixture
was agitated on a reciprocal shaker for 1 hour. The suspension was then filtered and the eluate
was collected in a round bottom flask containing a solution of trimethylamine (3.2mL) in absolute
ethanol (100mL). The solvents were mostly evaporated by rotary evaporation and then further
dried in vacuum over P4O10 to obtain the final TEA salt.
Ion Exchange Capacity Calculation with Dowex 50Wx8 200-400 mesh H+ form:
In general, the capacity of an ion exchange resin can be expressed as the quantity of ions that
can be taken up by a specific volume of resin. This can be expressed in quantity/unit volume such
as milli-equivalents/milliliter (meq/mL). Equivalents refers to the equivalent weight (EW) of the
substance expressed in grams (or meq in milligrams), which is the molecular weight (MW) divided
by valence.244 For example: (2-cyanoethyl) phosphate barium salt dihydrate
Ba2+ MW= 137.3 g/mol and is divalent
Dowex 50Wx8 200-400 mesh H+ form total exchange capacity= 1.7 meq/mL245
137.3𝑔
÷ 2 = 68.65 𝐸𝑊
𝑚𝑜𝑙
116.7 𝑔 𝐵𝑎2+ 𝑠𝑎𝑙𝑡
1.7 × 68.65 𝐸𝑊 =
𝐿 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛
Grams of Ba2+ in 5g of (2-cyanoethyl) phosphate barium salt dehydrate:

15.5𝑚𝑚𝑜𝑙 ×

137.3𝑔
= 2.1𝑔
𝑚𝑜𝑙
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2.1𝑔 116.7𝑔𝐵𝑎2+
=
𝑋𝐿
1𝐿 𝑟𝑒𝑠𝑖𝑛
X= 17mL of resin needed to exchange ions with TEA+
General Purification Procedure with FPLC: Synthesized nucleotides were purified by ion
exchange chromatography on DEAE-sephadex A-25 (HCO3- form) column. Resin was soaked in
water for 1 day at room temperature before being loaded to a 5 mL proteus FPLC column. The
reaction mixture was loaded to the column and washed through with excess water to remove
metal (II) salt/EDTA complex. Nucleotides were eluted slowly over 7 hours (flow rate of 2.5
mL/min) using a linear gradient (0-100%) of triethylammonium bicarbonate (TEAB) buffer in 18
MΩ water (0.7M, pH=8.5). Afterwards, fractions were collected and buffer was evaporated
under reduced pressure. Several 15 mL portions of absolute ethanol were added to decompose
the TEAB and produce the TEA salts.
Triethylammonium Bicarbonate Buffer Recipe: To make TEAB at 1M, 120 mL of HPLC grade
triethylamine was diluted in 740 mL of 18 MΩ water. Dry ice was placed into a separate vessel
with a nozzle connected to a hose. The CO2 from the dry ice was bubbled
into the triethylamine solution for 2-3 hours and stopped once the
solution reached a pH=8.5. The buffer was filtered using HVLP 0.45μM
filter paper.
1a: 82% yield; (2-cyanoethyl) phosphate barium salt dihydrate (5g, 15.5mmol) converted to the
TEA salt using 20 mL of Dowex 50W x 8 (200-400mesh) resin in H+ form (see general procedure
above). About 3.91 g (92% yield) of (2-cyanoethyl) phosphate TEA salt was obtained. Thereafter,
(2-cyanoethyl) phosphate TEA salt (2.9 g, 11.9 mmols) was mixed with imidazole (10 equiv., 8.07
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g, 0.119 mols), 2,2’dithiodipyridine (3 equiv., 7.85 g, 35.6 mmol), DMF (25 mL), trimethylamine
(3 equiv., 3.6 mL, 35.6 mmol), and triphenylphosphine (3 equiv., 9.34 g, 35.6 mmol) and the
mixture was stirred for 6-8 hours. The product was precipitated from the reaction mixture with
a solution of anhydrous LiClO4 (4 equiv., 5.05 g, 47.5 mmol) in dry acetonitrile (187.5 mL). After
cooling to 4oC, the precipitate was filtered off, washed repeatedly with cold, dry acetonitrile, and
dried in vacuum over P4O10. The resulting product, 1a, was stored at 4oC in a closed vessel for
several months. 1H-NMR (300 MHz) (D2O) δ 7.84 (s, 1H), 7.22 (s, 1H), 7.03 (s, 1H), 3.95-3.88 (q,
2H, J= 7Hz), 2.68-2.65 (t, 2H, J= 6Hz), 1.96 (s, 1H); 31P NMR (121 MHz) δ -8.56 (s, 1P); MS DUIS (ve) calcd. m/z for C6H7N3O2P- [(M-H+)-] 200.2, found [(M-H+)-] 200.2.
Guanosine monophosphate phosphorimidazolides (GMPIm): 75% yield; Guanosine 5’monophosphate (GMP)
disodium salt (5 g, 12.3 mmol) was converted to the TEA salt
using 14.4mL of Dowex 50W x 8 (200-400 mesh) resin in H+ form (see general procedure above).
About 4.78 g (84% yield) of GMP TEA salt was obtained. Thereafter, GMP TEA salt (1 equiv., 4.78
g, 10 mmol), imidazole (10 equiv. 7.0 g, 0.103 mols), and 2,2’dithiodipyridine (3 equiv., 6.82 g, 31
mmol), were mixed in 30mL of DMF. Trimethylamine (3 equiv., 4.33 mL, 31.0 mmol) and
triphenylphosphine (3 equiv., 8.13 g, 31.0 mmol) were added and the mixture was stirred for 68 hours. The reaction was monitored by 31P-NMR to confirm the disappearance of GMP at 3.76
ppm. The product was precipitated from the reaction mixture with anhydrous NaClO 4 (4 equiv.,
4.9 g, 40.0 mmol) solution in dry acetone. To ensure the acetone was completely dry, it was
distilled over MgSO4 and stored with 4Å molecular sieves at 4oC. After cooling the mixture to
4oC, the precipitate was filtered, washed repeatedly with cold, dry acetone and the solvent was
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removed under reduced pressure. 1H-NMR (300 MHz) (D2O) δ 7.79 (s, 1H), 7.71 (s, 1H) 7.02 (s,
1H), 6.82 (s, 1H), 5.74-5.72 (d, 1H, J= 6Hz), ~4.70-4.66 (overlapped with water, m, 1H), 4.32-4.29
(t, 1H, J= 3Hz), 4.14 (s, 1H), 4.00-3.98 (m, 2H), 2.91 (s, 1H); 31P NMR (121 MHz) δ -7.96 (s, 1P); MS
DUIS (-ve) calcd. m/z for C13H15N7O7P- [(M-H+)-] 412.2, found [(M-H+)-] 412.2.
Guanosine 5’-O-(2-thiodiphosphate) (GDPβ-S): 99% yield;
GMP-Im (1 equiv., 0.435 g, 1.0 mmol), thiophosphate TEA salt
(converted sodium thiophosphate tribasic hydrate to TEA salt
using general procedure, 2 equiv., 0.431 g, 2.0 mmol), and anhydrous ZnCl 2 (8 equiv., 1.09 g, 8.0
mmol) were dissolved in DMF (10 mL) and stirred at room temperature. After 30 minutes, the
reaction was quenched by the addition of a solution of EDTA (8 equiv., 2.34 g, 8.0 mmol) and
NaHCO3 (18 equiv., 1.51 g, 18 mmol) in water. The resulting product was purified on DEAEsephadex and isolated as a TEA salt according to the general procedure. 1H-NMR (300 MHz) (D2O)
δ 8.03 (s, 1H), 5.83-5.81 (d, 1H, J= 6Hz), 3.25-1.13 (TEA residues);

31P

NMR (121 MHz) δ 31.1

(broad s, 1P), -11.7 (d, 1P, J= 31.5Hz) (; MS DUIS (-ve) calcd. m/z for C10H14N5O10P2S - [(M-H+)-]
458.0, found [(M-H+)-] 458.2.
Guanosine 5’-O-(2-thiotriphosphate) (GTPβ-S): 10%
yield; GDPβ-S TEA salt (1 equiv., 167 mg, 0.30 mmol)
was suspended in 3 mL of DMF. Then, 1a (3 equiv.,
186 mg, 0.90 mmol) and anhydrous MgCl2 (8 equiv., 228 mg, 2.4 mmol) were added to the
suspension. The mixture was stirred at room temperature for 24 hours. Next, the product was
subjected to cyanoethyl group removal (one-pot reaction) with the addition of more DMF (3 mL),
1.1 mL of DBU and DTT (3 equiv., 138 mg 0.9 mmol). The reaction was carried out at 50 oC in
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either an open flask protected from moisture (capped with drying tube packed with anhydrous
calcium chloride) or a sealed flask with a rubber septum pierced with a needle attached to a weak
pressure vacuum. The deprotection reaction went for 5 hours and was stopped by the addition
of 1% acetic acid to pH=7, diluted with water and washed 3 times with ethyl acetate. Finally, the
product was purified on DEAE-Sephadex and isolated as a TEA salt.

31P

NMR (121 MHz) δ 28.1

(broad s, 1P), -6.70 (dd, 1P, J= 6Hz, J= 28Hz), -12.1 (d, 1P, J= 28Hz); MS DUIS (-ve) calcd. m/z for
C10H15N5O13P3S - [(M-H+)-] 537.9, found [(M-H+)-] 538.0.
Triethylammonium Selenophosphate: 98% yield; *Note: This procedure should
be performed under a fume hood, including all evaporations of solvents. Prior to
the reaction, pyridine was distilled over CaH2 to ensure complete removal of
water. A suspension of selenium (160 mg, 2 mmol) in dry pyridine (1 mL) was added dropwise
through a syringe into a septum-sealed and nitrogen-bubbled solution of tris(trimethylsilyl)
phosphite (600 μL, 1.8 mmol) in dry CH3CN (10 mL). The resulting solution was held at room
temperature for 30 minutes, and then was evaporated to dryness.

Next, a solution of

trimethylamine (250 μL, 1.8 mmol) in dry MeOH (10 mL) was added and the mixture was stirred
at room temperature for 3 hours. During this time, the initially colorless solution turned yellow
with black particulates (elemental Se falling out of solution). The reaction was then filtered and
the solvent removed under reduced pressure. The residue was re-dissolved in MeOH and dried
under reduced pressure two times. The product isolated was a semi-solid yellow residue and
confirmed by 31P NMR. It was immediately used for the following coupling to make GDPβ-Se.
31PNMR

(121 MHz) δ 26.8 (s, 1P)
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Guanosine 5’-O-(2-selenodiphosphate) (GDPβ-Se): 98%
yield; To a suspension of GMP-Im (250 mg, 0.42 mmol) and
selenophosphate TEA salt (prepared from 600 μL
tris(triemthylsilyl)phosphite) in 5 mL of dry DMF, anhydrous ZnCl2 (580 mg, 4.20 mmol) was
added and the mixture was vigorously shaken until all reagents dissolved (2-3 minutes). The
resulting solution was stirred for 20 minutes at room temperature (during this time a
precipitation of small red, slowly turning black, solid, presumably selenium, was observed). The
reaction was quenched by diluting a solution of disodium EDTA (1.6 g, 4.20 mmol) and NaHCO3
(800 mg) in 300 mL of water. The pH was checked and, if necessary, adjusted with a small portion
of NaHCO3 to pH=7.5. The mixture was stirred at room temperature for 1-2 hours and the
precipitated selenium was filtered off using 0.45 μm PVDF syringe filters. The product was
isolated on DEAE Sephadex according to the general procedure. *Note: Sephadex resin is
irreversibly stained a bright red-orange but still remains useable for other purifications. 31P NMR
(121 MHz) δ 15.53 (d, 1P, J= 37Hz), -12.37 (d, 1P, J= 37Hz); MS DUIS (-ve) calcd. m/z for
C10H15N5O13P2Se - [(M-H+)-] 505.9, found [(M-H+)-] 506.0 in addition to selenium isotope peaks.
Guanosine

5’-O-(2-selenotriphosphate)

(GTPβ-Se):

30% yield; GDPβ-Se TEA salt (1 equiv., 167 mg, 0.30
mmol) was suspended in 3 mL of DMF. Then, 1a (3
equiv., 186 mg, 0.90 mmol) and anhydrous MgCl2 (8 equiv., 228 mg, 2.4 mmol) were added to
the suspension. The mixture was stirred at room temperature for 24 hours. The coupling reaction
was monitored by HPLC with a linear gradient 1-25% of methanol in 0.05M ammonium acetate
buffer (pH=5.9) over 15minutes and UV-detection at 260 nm. Next, the product was subjected to
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cyanoethyl group removal (one-pot reaction) with the addition of more DMF (3 mL), 1.1mL of
DBU and DTT (3 equiv., 138 mg 0.9 mmol). The reaction was carried out at 50oC in either an open
flask protected from moisture (capped with drying tube packed with anhydrous calcium chloride)
or a sealed flask with a rubber septum pierced with a needle attached to a weak pressure
vacuum. The deprotection reaction was monitored by HPLC with the same parameters as the
coupling reaction. After 2 hours, the reaction was stopped by the addition of 1% acetic acid to
pH=7, diluted with water and washed 3 times with ethyl acetate. Finally, the product was purified
on DEAE-Sephadex and isolated as a TEA salt.

31PNMR

(121 MHz) δ 16.7 (broad s, 1P), -8.54 (d,

1P, J= 31.5Hz), -12.68 (d, 1P, J= 31.5Hz); MS DUIS (-ve) calcd. m/z for C10H15N5O13P3Se - [(M-H+)-]
585.9, found [(M-H+)-] 586.0.

2.2 Preliminary GTPase Assay Development
For this assay, we wanted a rapid, sensitive and selective fluorescent probe to detect the
hydrolysis of GTPβ-S or Se independent of the GTPases. A panel of sulfur-sensitive fluorophores were

tested but the most promising probe was Thiofluor 623 (Figure 70). In 2008, Bouffard et al at

Figure 70. The “turn-on” reaction that occurs when Thiorfluor 623 is cleaved with a thiol like
GDPβ-S.

Harvard University developed this Thiofluor probe to address the many drawbacks associated
with already commercially available thiol-detecting chromophores and fluorophores.246
Thiofluor 623 is a “turn-on” probe whose structure is based on a classical donor-π-acceptor
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design.

The probe will undergo a nucleophilic substitution with nucleophilic compounds

liberating the aniline based fluorescence compound (Figure 71). This increases the push-pull
character of the dye and results in a higher quantum yield and large bathochromic shifts in the
absorption and emission spectra. Arenesulfonamides are stable towards oxygen and nitrogen
nucleophiles but react with thiols in contrary to arene-sulfonate-based probes.247 Furthermore,
the long triethyleneglycol methyl ether chain substituted on the nitrogen allows for a wide pH
range in which this probe can be used and increases its water solubility. Figure 71 shows that
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Figure 71. Thiofluor 623 excitation and emission spectra; A) Excitation spectra at 630 nm
emission B) Emission spectra at 560 nm excitation.

Thiofluor 623 has an Exmax of 560 nm and Emmax at 630 nm.
Within this section, we report the use of Thiofluor 623 to determine the limit of detection
with Glutathione (GSH), GDPβ-S and GDPβ-Se over a range of different concentrations and time.
The optimizations resulted in the detection of GTPβ-Se in the presence of H-Ras. The activity of
H-Ras was determined using a calorimetric assay that detects inorganic phosphate liberated
when H-Ras hydrolyzes GTP to GDP.
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2.2.1 Experimental Methods
Optimization of Assay Conditions:
Reagents and Instrumentation: The buffer was prepared from phosphate buffered saline, pH 7.4
(Hyclone, #SH30256.01) and 0.001% Tween.

Thiofluor 623 was purchased from Cayman

Chemical Company (#13083). The reagents tested were L-Glutathione reduced (GSH) (SigmaAldrich #G4251), GDPβ-S and GDPβ-Se (both synthesized in our lab). All fluorescence readings
were performed with Tecan Infinite M1000 plate reader. Small volume transfers were performed
on the Tecan Freedom EVO liquid handling system with a 100 nL pin tool transfer (V&P Scientific).
Serial dilutions were done in 96-well polypropylene plates (Corning, #3365) and assays were
conducted in 384-well black polystyrene microplates (Nunc, #262260).
Probe Determination Assay Protocol: Solid Thiofluor 623 was diluted in DMF at 10 mM. 10 mM
stock solutions of GSH, GDPβ-S and GDPβ-Se in water were serially diluted in the prepared PBS
buffer (2.5 μM-0.00488 μM).

Determining H-Ras Functionality using a GTPase Calorimetric Assay248:
Reagents and Instrumentation: The assay buffer was prepared by adding 50 mM Tris (Acros
Organics, #201-064-4) , 5 μg/mL BSA (Thermo Scientific, #23209), 0.01% (v/v) Tween 20 (Fisher
Scientific, #BP337), 5 mM DTT (Gold Biotechnology, #DTT100) to 18 MΩ water. The final buffer
was pH to 7.5 and filtered to remove any particulates. A 12.5 mM MgCl2 (Fisher Scientific, #AB0359) solution was prepared in 18MΩ water. A 30 mM stock solution of guanosine 5’triphosphate sodium salt hydrate (Sigma, #G8877) was prepared in 18MΩ water. The 25 μM
stock GTPase protein, H-Ras, was a gift from Prof. Evgueni Kovriguine (Marquette University).
The calorimetric dye, Biomol GreenTM (Enzo Life Sciences, #BML-AK111), reacts with inorganic
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phosphate to produce a product that absorbs light at 620 nm. Controls used were buffer
(negative control) and KH2PO4 (J. T. Baker Chemical Company, #3246, positive control) Serial
dilutions were done in 96-well polypropylene plates (Corning, #3365) while reactions were
performed in clear, 384-well UV plates (Greiner Bio-One, #781801). Each concentration was
done in triplicate. All UV readings were performed with a Tecan Infinite M1000 plate reader.
GTP Hydrolysis Assay Protocol: GTP was serially diluted (1:2) to produce concentrations ranging
from 30 mM to 0.001524 mM. H-Ras was diluted to 80 nM in buffer. In a clear, 384 well UV plate
each well contained 6.75 μL H-Ras (final concentration 40 nM), 6.75μL of GTP (final
concentrations ranging from 15 mM-0.000762 mM) and 1.5 μL of MgCl2 to equal a total volume
of 15 μL. The plate was incubated for 1 hour at 37oC. After 1 hour, 25 μL of Biomol GreenTM was
added to each well and the plate was incubated for an additional 30 minutes at 37 oC. Absorbance
was read at 620 nm to determine if phosphate was in fact hydrolyzed from GTP by the GTPase
actions of H-Ras.

H-Ras Hydrolysis of GTPβ-Se Monitored with Fluorescence:
Reagents and Instrumentation: Buffer was made by adding 50mM Tris (Acros Organics, #201064-4), 0.03% (v/v) Tween 20 (Fisher Scientific, #BP337), 80 mM NaCl (Fisher Scientific, #S640), 8
mM MgCl2 (Fisher Scientific, #AB-0359), 1 mM EDTA (Fisher Scientific, #S80007) to 18MΩ water.
The buffer was pH to 7.4 with HCl and filtered to remove any particulates. 10 mM stock solutions
of GDPβ-Se, GTPβ-Se and GSH (Sigma-Aldrich #G4251) were diluted in 18MΩ water. The probe,
Thiofluor 623, was diluted in the buffer to 1 μM and GTPase protein, H-Ras, at 40 nM
concentration. All fluorescence readings were performed on a Tecan Infinite M1000 plate reader
with excitation read at 570 nm and emission at 630 nm. The gain was set manually at 100 and
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10 nm bandwidth was used. Serial dilutions were done in 96-well polypropylene plates (Corning,
#3365) and assays were conducted in 384- well black polystyrene microplates (Nunc, #262260).
H-Ras Activation using Thiofluor 623 Assay Protocol: First, to check if GDPβ-Se and GTPβ-Se had
different fluorescence intensities without the presence of H-Ras they were serially diluted (1:2)
in 96 well plates to obtain concentrations ranging from 10 mM-0.000508 mM. 10 μL of each
concentration of compound was transferred to a 384 well black plate. To each well 10 μL of a 20
μM Thiofluor 623 solution (diluted in buffer) was added. Therefore, the resulting plate had the
final concentrations of compound ranging from 5 mM- 0.000254 mM and 10 μM Thiofluor 623.
To determine if H-Ras hydrolyzes GTPβ-Se to GDPβ-Se, another experiment was set up where
GTPβ-Se was serially diluted (1:2) to in 96 well plates and 10 μL was transferred to 384 well black
plates just like before. To the 20 μM Thiofluor 623 solution, H-Ras protein was added to yield a
final concentration of 80 nM. To each well, 10 μL of the probe/protein solution was added.
Therefore, the final concentrations in each well were: 5 mM- 0.000254 mM GTPβ-Se, 40nM HRas and 10 μM Thiofluor 623. For both experiments, the plate was incubated at room
temperature and fluorescence was read at 10, 20, 30, 40, 50, 90 and 120 minutes.
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2.2.2 Results and Discussion
Initial experiments were conducted to determine the best assay conditions to monitor
the formation of GDPβ-S or GDPβ-Se by fluorescence. Thiofluor 623 was incubated with GSH
over a range of concentrations over 60 minutes (Figure 72, A). After 40 minutes, it was evident
that the fluorescence intensity reached its maximum before starting to decrease at 60 minutes.
In addition, the fluorescence signal was high at about 25,000 units. When GDPβ-S was used, the
fluorescence intensity was much lower even after 30 minutes (Figure 72, B). This indicated that
a large amount of the GDPβ-S would be necessary to obtain a significant window of detection.
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concentrations at 30 minutes.

With these results, it was concluded that GDPβ-S may not be a good substrate for the assay being
developed. Therefore, GDPβ-Se was investigated as a possible GTPase substrate because of the
higher nucleophilicity of the larger selenium atom. GDPβ-Se gave higher fluorescence when
compared to GDPβ-S (Figure 73, A and B). A concentration of 1mM of GDPβ-Se appeared to be
necessary to observe a significant window of detection. The initial assay development was
conducted with the GTPase, H-Ras. Prior to its use, the functionality was evaluated using a
calorimetric assay developed at UWM by Sweeney et al.248 GTP was serially diluted and
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incubated with H-Ras. The production of inorganic phosphate (Pi) was detected by its reaction
with Biomol GreenTM, a dye that absorbs UV light at 620nm (Figure 74). The H-Ras protein was
capable of hydrolyzing GTP to GDP with a concentration of less than 1.0 mM GTP was necessary
to create a workable signal.
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Figure 74. Dose response curve representing the hydrolysis of
GTP to GDP with H-Ras using the calorimetric assay.

GDPβ-Se and GTPβ-Se were first compared without H-Ras present in Figure 76, A. As
observed before, GDPβ-Se reacted with Thiofluor 623 showing an increased fluorescence with
increasing concentration over 90 minutes (figure 75, A). However, GTPβ-Se with a “capped”
selenium atom did not induce fluorescence (Figure 75, A). Thus, thiofluor 623 was capable of

Figure 75. A) A comparison of GTPβ-Se and GDPβ-Se and their ability to turn “on” the probe,
Thiofluor 623. B) The activation of H-Ras with the binding of GTPβ-Se using Thiofluor 623 to
detect the production GDPβ-Se.

detecting GDPβ-Se in the presence of GTPβ-Se.
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With H-Ras present, GTPβ-Se was not

Figure 76. A comparison of GTPβ-S and GTPβ-Se in activating H-Ras using a calorimetric
assay. A) GTPβ-S and B) GTPβ-Se.

enzymatically converted into GDPβ-Se and therefore no fluorescence was observed even in the
presence of increasing amounts of GTPβ-Se substrate (Figure 75, B). One hypothesis is that HRas is not able to convert GTPβ-Se to GDPβ-Se. Therefore, the Biomol GreenTM –based
calorimetric assay was used in the presence of GTPβ-Se and GTPβ-S and H-Ras (Figure 76, A and
B).

Initially, H-Ras appeared to be capable of hydrolyzing both substrates, however the

absorbance was higher than the control concentration of phosphate. When the reactions were
carried out in the absence of H-Ras a similar curve was obtained, thus the substrates GTPβ-Se
and GTPβ-S reacted with Biomol GreenTM to increase the absorbance at 620 nm. Another
possibility is that traces of seleno- and thio-phosphate or compound 1a might react with Biomol
GreenTM. We are currently in the process to purify the final products with HLPC and scan the
absorbance spectra from 250-800 nm to identify if the GTP analogs change the absorbance
spectra of the molybdate-malachite green complex.

2.2.3 Conclusion
The synthesis of GDPβ-S/Se and GTPβ-S/Se was successfully executed. In addition, an
appropriate probe, Thiofluor 623, was identified for the detection of GDPβ-S and GDPβ-Se.
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Interestingly, H-Ras was not able to convert the heavy atom analogs of GTP, which prompted us
to investigate other GTPases with our assay system. In addition, we will continue the search for
a fluorescence probe that will work for the GDP/GTPβ-S system. The Biomol GreenTM –based
assay did identify phosphate species in the purified end products or reacted with the GTP analogs
itself. . Overall, a significant progress has been made to develop a universal GTPase assay, which
encourages us to continue this work in the future with AviMed Pharmaceuticals, LLC.
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APPENDIX A: VDR BINDING AND TRANSCRIPTION DATA FOR GW0742
ANALOGS
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Table 29. Evaluation of mono-substituted GW0742 analogs

H
o-CH3
m-CH3
p-CH3
o-Cl
m-Cl
p-Cl
o-F
m-F
p- F
o-CF3
m-CF3

VDR-SRC2-3
interaction IC50
(μM)a
16.95± 1.64
43.88± 8.54
47.45± 6.61
37.52± 6.12
32.27± 3.19
24.10± 3.39
29.72± 2.28
35.53± 4.46
42.68± 5.14
45.61± 3.87
32.27± 5.28
24.5± 2.27

VDR
transcription
IC50 (μM)b
41.5± 11.9
19.2 ± 5.6
38.2± 8.6
42.0± 11.1
28.9± 5.0
19.4 ± 8.5
17.5± 5.7
40.0± 8.5
28.3± 7.1
16.8± 4.64
31.5± 9.1
19.0± 6.01

p-CF3

22.92± 2.08

16.0 ± 3.6

o-OCH3
m-OCH3
m-OCF3
p-OCF3
m- CN
p-CN
p- N(CH3)2
p-NHCH3
p- COOCH2CH3
m-methylsulfinyl
p-methanesulfonamide
p-NHCOCH3
m-CONH(CH2)3N(CH3)2
p-CONH(CH2)2N(CH3)2
p-(4-methylpiperazinyl)
methanone
p-piperazinyl
Morpholino-methanone

45.18± 5.65
48.82± 6.56
13.86± 1.0
15.63± 0.94
>100
>100
>100
12.22± 1.93
19.52± 1.20
>100
>100
40.11± 9.26
30.28± 4.5
52.03± 12.79

31.4± 8.1
26.3± 6.9
24.5± 8.6
27.9± 7.4
25.1± 10.0
>50
24.5 ± 6.1
16.0 ± 7.1
17.6± 10.9
>100
Inactive
inactive
inactive
>100

>100

inactive

>100
>100

inactive
>100

Entry

R

NCGC00319174-01
NCGC00319046-01
NCGC00319053-01
NCGC00319065-01
NCGC00319061-01
NCGC00319050-01
NCGC00319056-01
NCGC00319063-01
NCGC00319048-01
NCGC00319055-01
NCGC00319064-01
NCGC00319049-01
NCGC00241455-04
(GW501516)
NCGC00319047-01
NCGC00319052-01
NCGC00319051-01
NCGC00319058-01
NCGC00319036-01
NCGC00319057-01
NCGC00319069-01
NCGC00319067-01
NCGC00319066-01
NCGC00319054-01
NCGC00319070-01
NCGC00319071-01
NCGC00319151-01
NCGC00319150-01
NCGC00319169-01
NCGC00319072-01
NCGC00319068-01
a

VDR-LBD concentration used was 0.1µM. Inhibition of VDR-SRC2-3 interaction in the presence of
LG190178 (0.75 µM). The maximum concentration used for this assay was 300 μM of each
compound; bTranscription assay using a CMV-VDR plasmid and a luciferase reporter plasmid under
control of a 24-hydroxylase promoter with GW0742 analogs. cCell-TiterGlo (Promega) The maximum
concentration used for transcription and toxcitiy assay was 100 μM of each compound. Data were
analyzed using a nonlinear regression with a variable slope (GraphPad Prism).
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Table 30. Evaluation of poly-substituted GW0742 analogs
Entry

R

R1

R2

R3

R4

VDR-SRC2-3
interaction
IC50 μMa

VDR
transcription
IC50 (μM)b

NCGC00092344-05
(GW0742)
NCGC00319082-01
NCGC00319145-01
NCGC00319172-01
NCGC00344925-01
NCGC00344922-01
NCGC00344921-01
NCGC00319077-01
NCGC00319159-01
NCGC00319154-01
NCGC00319171-01
NCGC00319147-01
NCGC00319168-01
NCGC00344924-01
NCGC00319153-01
NCGC00319148-01
NCGC00319143-01
NCGC00344923-01
NCGC00319075-01
NCGC00319142-01
NCGC00344926-01
NCGC00344927-01
NCGC00319146-01
NCGC00344928-01
NCGC00344929-01
NCGC00344930-01

H

F

CF3

H

H

9.32 ± 1.14

20.7 ± 4.5

H
CF3
Cl
H
H
H
H
H
H
H
F
H
H
H
CF3
H
H
H
Cl
H
H
H
Cl
Cl
Cl

CF3
H
H
Cl
Cl
F
OCH3
F
CH3
CF3
F
F
Cl
CN
H
CF3
F
Cl
H
Cl
CF3
Cl
H
Cl
H

H
H
H
H
H
H
H
H
H
H
H
F
H
H
H
H
H
H
H
F
Cl
Cl
H
H
Cl

H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
Cl
H
H

9.02 ± 0.982
16.4 ± 2.78
9.71 ± 2.24
15.6 ±2 9.1
10.3 ± 1.07
17.2 ± 3.7
>100
68.6 ± 12.24
39.42 ± 4.45
17.0 ± 1.64
51.55 ± 9.74
19.57 ± 3.06
10.2 ± 2.11
53.5 ± 16.0
34.02± 6.59
6.9 ± 0.99
22.90 ± 4.2
5.55 ± 1.17
17.4 ± 2.06
15.6 ± 2.01
11.2 ± 3.24
6.29 ± 0.79
40.3 ± 8.07
15.6 ± 2.01
14.5 ±2.21

15.0± 4.7
28.5± 5.2
9.9± 3.2
22.6 ± 7.1
22.1 ± 4.3
27.3 ± 5.1
>50
>50
22.3± 6.1
14.8± 6.3
36.9± 13.0
8.7 ± 4.4
>50
23.7± 4.7
35.4± 12.2
21.4± 4.2
>50
6.5± 3.1
39.4± 11.0
28.7 ± 8.2
32.6 ± 16.4
22.2± 9.6
33.0 ± 7.2
14.3 ± 5.7
>50

NCGC00319170-01

H

F

CF3
CF3
CF3
CF3
OCF3
OCF3
OCH3
OCH3
OCH2CF3
F
F
F
F
F
Cl
Cl
Cl
Cl
CN
H
H
H
H
H
H
Benzylmorpholi
ne

H

H

68.8 ± 13.0

>50

a

VDR-LBD concentration used was 0.1µM. Inhibition of VDR-SRC2-3 interaction in the presence of LG190178
(0.75 µM). The maximum concentration used for this assay was 300 μM of each compound; bTranscription
assay using a CMV-VDR plasmid and a luciferase reporter plasmid under control of a 24-hydroxylase
promoter with GW0742 analogs. cCell-TiterGlo (Promega) The maximum concentration used for transcription
and toxcitiy assay was 100 μM of each compound. Data were analyzed using a nonlinear regression with a
variable slope (GraphPad Prism).
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Table 31. Evaluation of heteroaromatic-substituted GW0742 analogs
entry

R

VDR-SRC2-3
interaction
IC50 μM

VDR
transcription
IC50 (μM)

NCGC00319037-01
NCGC00319078-01
NCGC00319073-01
NCGC00319074-01
NCGC00319040-01
NCGC00319076-01
NCGC00319038-01
NCGC00319039-01
NCGC00319155-01
NCGC00319173-01
NCGC00319059-01
NCGC00319162-01
NCGC00319164-01
NCGC00319149-01
NCGC00319160-01
NCGC00319166-01
NCGC00319163-01
NCGC00319167-01
NCGC00319165-01
NCGC00319144-01
NCGC00319157-01
NCGC00319156-01
NCGC00319152-01
NCGC00319158-01
NCGC00344920-01
NCGC00344919-01
NCGC00344918-01

3,5-dimethylisoxazol-4-yl
1H-indazol-4-yl
4-pyridine
2-(benzofuran-2-yl)
2,3-dihydrobenz[1,4]dioxin-6-yl
Naphthalene-1-yl
Benzo[1,3]dioxol-5-yl
Benzo[1,2,5]oxadiazol-5-yl
Furan-2-yl
Pyridin-3-yl
Benzothiophen-2-yl
Piperazin-1-yl
Pyrimidin-yl
1H-indazol-6-yl
Benzothiazol-6-yl
Isoquinolin-4-yl
6-fluoropyridin-3-yl
1-methyl-1H-indazol-6-yl
6-(trifluoromethyl)pyridin-3-yl
1-methyl-1H-indol-6-yl
1H-indol-5-yl
1H-pyrazol-4-yl
2-fluoropyridin-4-yl
1H-indazol-5-yl
Benzothiophen-5-yl
1H-indol-4-yl
1H-indol-2-yl

>100
50.2 ± 7.49
43.9 ± 8.54
52.8 ± 8.65
40.9 ± 5.67
20.2 ± 1.89
65.8 ± 15.54
20.7 ± 1.18
>100
>100
47.7 ± 8.29
>100
>100
57.9 ± 8.69
53.0 ± 7.35
53.5 ± 7.45
>100
57.1 ± 11.04
>100
20.9 ± 3.58
15.1 ± 11.8
>100
>100
51.1 ± 5.55
20.4 ± 1.96
28.9 ± 4.69
22.6 ± 3.83

>60
>20
inactive
>50
>50
26.3±0 8.3
42.5± 19.4
>50
>50
>100
>100
>50
inactive
inactive
32.0± 14.5
21.6± 6.05
>50
>50
>80
>50
>50
inactive
>100
inactive
>50
Inactive
30.1 ± 10.2

a

VDR-LBD concentration used was 0.1µM. Inhibition of VDR-SRC2-3 interaction in the presence of
LG190178 (0.75 µM). The maximum concentration used for this assay was 300 μM of each compound;
b
Transcription assay using a CMV-VDR plasmid and a luciferase reporter plasmid under control of a 24hydroxylase promoter with GW0742 analogs. cCell-TiterGlo (Promega) The maximum concentration used
for transcription and toxcitiy assay was 100 μM of each compound. Data were analyzed using a
nonlinear regression with a variable slope (GraphPad Prism).
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Table 32. Evaluation of tetrazole-substituted GW0742 analogs
Compound ID

R1

R2

R3

R4

NCGC00264097-01
NCGC00344870-01
NCGC00344869-01
NCGC00344871-01

H
Cl
H
H

CF3
H
Cl
Cl

F
Cl
H
Cl

H
H
CF3
H

a

VDR-SRC2-3
Interaction
IC50 μMa
4.25 ± 0.692
4.55 ± 0.738
11.85± 4.54
2.66± 0.487

VDR
Transcription
IC50 (μM)b
7.11± 1.74
11.8 ± 6.5
19.9 ± 1.06
9.03 ± 2.3

VDR-LBD concentration used was 0.1µM. Inhibition of VDR-SRC2-3 interaction in the presence of
LG190178 (0.75 µM). The maximum concentration used for this assay was 300 μM of each
compound; bTranscription assay using a CMV-VDR plasmid and a luciferase reporter plasmid under
control of a 24-hydroxylase promoter with GW0742 analogs. cCell-TiterGlo (Promega) The maximum
concentration used for transcription and toxcitiy assay was 100 μM of each compound. Data were
analyzed using a nonlinear regression with a variable slope (GraphPad Prism).
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Table 33. Evaluation of linker-substituted GW0742 analogs.
entry

R1

R2

Y

R

X

NCGC00264098-01
NCGC00264099-01
NCGC00263796-01
NCGC00264094-01
NCGC00264104-01
NCGC00264093-01
KAT-031513
NCGC00264101-01
NCGC00264103-01
NCGC00264102-01
KAT-050713

H
F
F
F
F
F
H
F
F
F
CH2OH

CF3
CF3
CF3
CF3
CF3
CF3
CF3
CF3
CF3
CF3
H

S
S
S
O
O
O
O
N
N
N
O

CH3
H
H
CH3
H
H
H
CH3
H
H
H

CH2
-O
O
CH2
S
CH2
O
O
CH2
CH2

a

VDR-SRC2-3
interaction
(IC50) μM
16.0 ± 1.22
34.9 ± 3.75
17.2 ± 1.52
19.8 ± 1.66
33.3 ± 3.71
15.0 ± 1.18
>100
62.4±8.52
>100
>100
>100

VDR
transcription
IC50 (μM)
3.62 ± 0.99
15.9 ± 6.46
13.33 ± 4.7
6.33 ± 3.18
6.40 ± 4.91
5.5 ± 2.0
>33
11.78± 6.32
21.0 ± 7.5
22.3± 7.1
Inactive

VDR-LBD concentration used was 0.1µM. Inhibition of VDR-SRC2-3 interaction in the presence
of LG190178 (0.75 µM). The maximum concentration used for this assay was 300 μM of each
compound; bTranscription assay using a CMV-VDR plasmid and a luciferase reporter plasmid
under control of a 24-hydroxylase promoter with GW0742 analogs. cCell-TiterGlo (Promega) The
maximum concentration used for transcription and toxcitiy assay was 100 μM of each
compound. Data were analyzed using a nonlinear regression with a variable slope (GraphPad
Prism).

213

APPENDIX B: SOLUBILITY ASSAY WITH GW0742 OXAZOLE ANALOGS:
CALIBRATION CURVES
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Undergraduate Chemistry Teaching Assistant
January 2009- May 2010
Illinois State University
General Chemistry (Majors and non-majors), Organic Chemistry, and Analytical
Chemistry
MENTORSHIP
 Angela Zivkovic, Undergraduate research student
2011-2012
Research: “Synthesis of Novel Non-secosteroidal Vitamin D Receptor Agonist”
 Rajwana Jahan, Graduate student teaching assistant
Fall 2012
 Nicholas Nassif, Undergraduate research student
2012-2013
Research: “Expression and Purification of the Vitamin D Receptor Ligand Binding
Domain for the Identification of Vitamin D Receptor-Coactivator Inhibitors”
 Praveen Ghosh, Undergraduate student teaching assistant
Spring 2013
 Quint Owen, Graduate student teaching assistant
Fall 2013
 Jon Bogart, Undergraduate research student
2013-2014
Research: “The Synthesis and Evaluation of Potential Non-secosteroidal VDRCoactivator Inhibitors”
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Surajadeen Omolabake, Graduate student teaching assistant
Spring 2014
Luis Sanchez, Undergraduate research student
2014-2015
Research: “Development and Synthesis of Potential Non-secosteroidal VDRCoactivator Inhibitors”
Charlie Stangl, Undergraduate research student
Spring 2015-Current
Research: “Synthesis of Hydrazine Derivatives as Potential Vitamin D Receptor
Modulators”

PUBLICATIONS
PUBLISHED
1. Guthrie, M. L.; Sidhu, P. S.; Hill, E. K.; Horan, T. C.; Nandhikonda, P.; Teske, K. A.; Yuan, N.
Y.; Sidorko, M.; Kodali, R.; Cook, J. M.; Han, L.; Silvaggi, N. R.; Bikle, D. D.; Moore, R. G.;
Singh, R. S.; Arnold, L. A., Anti-tumor Activity of 3-Indoylmethanamines 31B and
PS121912. Anticancer Research 2105, 35.
2. Sidhu, P. S.; Teske, K.; Feleke, B.; Yuan, N. Y.; Guthrie, M. L.; Fernstrum, G. B.; Vyas, N.
D.; Han, L.; Preston, J.; Bogart, J. W.; Silvaggi, N. R.; Cook, J. M.; Singh, R. K.; Bikle, D. D.;
Arnold, L. A., Anticancer Activity of VDR-coregulator inhibitor PS121912. Cancer
Chemother Pharmacol 2014.
3. Teske, K.; Nanhikonda, P.; Bogart, J. W.; Feleke, B.; Sidhu, P.; Yuan, N. Y.; Preston, J.;
Goy, R.; Han, L.; Silvaggi, N. R.; Singh, R. K.; Bikle, D. D.; Cook, J. M.; Arnold, L. A.,
Identification of VDR Antagonists Among Nuclear Receptor Ligands Using Virtual
Screening. Nuclear Receptor Research 2014, 1, 1-8.
4. Teske, K.; Nandhikonda, P.; Bogart, J. W.; Feleke, B.; Sidhu, P.; Yuan, N.; Preston, J.; Goy,
R.; Arnold, L. A., Modulation of Transcription Mediated by the Vitamin D Receptor and
the Peroxisome Proliferator-Activated Receptor δ. Biomolecular Research &
Therapeutics 2014, 3 (1).
5. Sidhu, P. S.; Nassif, N.; McCallum, M. M.; Teske, K.; Feleke, B. D.; Yuan, N. Y.;
Nandhikonda, P.; Cook, J. M.; Singh, R. K.; Bikle, D. D.; Arnold, L. A., Development of
Novel Vitamin D Receptor-Coactivator Inhibitors. ACS Medicinal Chemistry Letters 2014,
5 (2), 199-204.
6. Nandhikonda, P.; Yasgar, A.; Baranowski, A.; Sidhu, P. S.; McCallum, M. M.; Pawlak, A. J.;
Teske, K.; Feleke, B.; Yuan, N. Y.; Kevin, C.; Bikle, D. D.; Ayers, S. D.; Webb, P.; Rai, G.;
Simeonov, A.; Jadhav, A.; Maloney, D.; Arnold, L. A., Peroxisome Proliferation- Activated
Receptor δ Agonist GW0742 Interacts Weakly with Multiple Nuclear Receptors,
Including the Vitamin D Receptor. Biochemistry 2013, 52, 4193-4203.
SUBMITTED
7. Teske, K. A.; Yu, O.; Arnold, L. A., Arnold “Vitamin and Hormones: Chapter 7. Inhibitors for
the Vitamin D Receptor–Coregulator Interaction (published by the end of the year).
8. Min, J.; Arnold, L. A.; Attia, R. R.; Connelly, M.; Teske, K.; Shelat, A.; Guy, R. K. Inhibitors
of the Interaction of PPARγ and SMRT. Submitted to JBC.
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PRESENTATIONS
1. Teske, K. A.; Bogart, J. W.; Sanchez, L.; Arnold, L. A. Synthesis of Natural VDR Ligand
Metabolites and Their Interaction with the Vitamin D Receptor. 250th American
Chemical Society National Conference, Boston, MA, 2015
2. Teske, K. A.; Bogart, J. W.; Sanchez, L.; Bantukallu, G.; Simeonov, A.; Jadhav, A.; Yasgar,
A.; Maloney, D.; Arnold, L. A., Development of Selective Non-Secosteroid Vitamin D
Receptor Inhibitors, 248th American Chemical Society National Conference, San
Francisco, CA, 2014
3. Teske, K. A.; Bogart, J. W.; Sanchez, L.; Arnold, L. A., Identification of New Vitamin D
Receptor-Coregulator Inhibitors Among Nuclear Receptor Ligands, 248th American
Chemical Society National Conference, San Francisco, 2014
4. Teske, K. A.; Yasgar, A; Bantukallu, G.; Bogart, J.; Simeonov, A.; Jadhav, A.; Maloney, D.;
Arnold, L. A., Further Investigation of the First Non-Secosteroid Antagonist for the
Vitamin D Receptor, Awards Day, University of Wisconsin- Milwaukee, 2014
5. Teske, K. A.; Yasgar, A; Bantukallu, G.; Bogart, J.; Simeonov, A.; Jadhav, A.; Maloney, D.;
Arnold, L. A., Further Investigation of the First Non-Secosteroid Antagonist for the
Vitamin D Receptor, The 4th Yao Yuan Biotech/Pharma International Symposium,
University of Illinois-Chicago, 2014
6. Min, J.; Attia, R. N.; Arnold, L. A.; Teske, K.; Connelly, M.; Lemieux, G.; Ashrafi, K.; Shelat,
A.; Guy, R. K., Discovery of Small Molecule Inhibitors of the Interaction between PPARγ
and SMRT, 105th Annual Meeting of the American Association for Cancer Research, San
Diego, CA, 2014.
7. Teske, K. A.; Yasgar, A; Bantukallu, G.; Bogart, J.; Simeonov, A.; Jadhav, A.; Maloney, D.;
Nassif, N. D.; Arnold, L. A., Identification of the First Non-Secosteroid Antagonist for the
Vitamin D Receptor, Awards Day, University of Wisconsin- Milwaukee, 2013
8. Teske, K. A.; Yasgar, A; Bantukallu, G.; Bogart, J.; Simeonov, A.; Jadhav, A.; Maloney, D.;
Nassif, N. D.; Arnold, L. A., Identification of the First Non-Secosteroid Antagonist for the
Vitamin D Receptor, 245th American Chemical Society National Conference, New
Orleans, 2013
9. Teske. K. A.; Zivkovic, A.; Arnold, L.A., Rational Development of Reversible Inhibitors of
the Vitamin D Receptor-Coregulator Interactions, Awards Day, University of WisconsinMilwaukee, 2012
10. Teske. K. A.; Zivkovic, A.; Arnold, L.A., Rational Development of Reversible Inhibitors of
the Vitamin D Receptor-Coregulator Interactions, 243rd American Chemical Society
National Conference, San Diego, 2012
11. Teske, K.; Webb, J. W.; and Shaw, III, C. F., Studies of Ligand Exchange and OxidationReduction Reactions of Gold(I) and Gold(III) Cyanides with Cysteine, Undergraduate
Students Awards Day, Illinois State University, 2010
12. Teske, K.; Webb, J. W.; and Shaw, III, C. F., Studies of Ligand Exchange and OxidationReduction Reactions of Gold(I) and Gold(III) Cyanides with Cysteine, 2nd Annual Georgian
Bay International Conference on Bioinorganic Chemistry (CanBic), 2009
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13. Teske, K.; Webb, J. W.; and Shaw, III, C. F., Studies of Ligand Exchange and OxidationReduction Reactions of Gold(I) and Gold(III) Cyanides with Cysteine, Undergraduate
Students Awards Day, Illinois State University, 2009
14. Shaw, III, C. F.; Yangyuoru, P. M.; Manthey, A.; O’Neill, J.; Teske, K. A.; Minser, J., Mixed
Cyano-Thilato-Complexes of Gold (III) and Gold (I): Relevance to Chrysotherapy
Metabolites, 40th Central Regional Meeting of the American Chemical Society, Columbus,
Ohio, 2008
15. Teske, K.; Webb, J. W.; and Shaw, III, C. F., Studies of Ligand Exchange and OxidationReduction Reactions of Gold(I) and Gold(III) Cyanides with Cysteine, Undergraduate
Students Awards Day, Illinois State University, 2008
AFFILIATIONS
American Chemical Society
Member 2010- Present
Graduate Student Council
June 2014-May 2015
Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee
New Graduate Student Mentor
December 2012-May 2014
Department of Chemistry and Biochemistry, University of Wisconsin- Milwaukee
Society for Applied Spectroscopy
August 2012-May 2013
University of Wisconsin-Milwaukee Student Chapter
AWARDS
Student Travel Award; Awarded by the Chemistry and Biochemistry Graduate Student Council
at the University of Wisconsin- Milwaukee (May 2015)
Dr. and Mrs. George Sosnovsky Award for Excellence in Graduate Research; University of
Wisconsin-Milwaukee (April 2015)
Chancellor’s Graduate Fellowship; University of Wisconsin- Milwaukee (2010-2014)
MEDI-Chem Travel Award; Awarded by the National American Chemical Society MEDI- Chem
Division (August 2014)
Mentoring Travel Award; Awarded by University of Wisconsin- Milwaukee New Graduate
Student Mentor Program (August 2014)
Graduate School Research Poster Award; University of Wisconsin- Milwaukee (April 2014)
Graduate Student Travel Award; Awarded by the Graduate School at the University of
Wisconsin – Milwaukee (April 2014)
Student Travel Award; Awarded by the Milwaukee, WI section of the American Chemical
Society (April 2013)
Graduate Student Travel Award; Awarded by the Graduate School at the University of
Wisconsin – Milwaukee (April 2013)
Mentoring Travel Award; Awarded by University of Wisconsin- Milwaukee New Graduate
Student Mentor Program (April 2013)
The Gloria Moczynski Student Teacher Award; Awarded by the University of Wisconsin
Milwaukee Department of Chemistry and Biochemistry (April 2013)
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Student Travel Award; Awarded by the Graduate School at the University of Wisconsin –
Milwaukee (April 2012)
The American Chemical Society Undergraduate Award in Inorganic Chemistry; Awarded by
The American Chemical Society nominated by Illinois State University Department of Chemistry
and Biochemistry (May 2010)
The Shulman Scholarship for Outstanding Achievements in Chemistry; Awarded by Illinois
State University Department of Chemistry and Biochemistry (August 2009)
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